Imaging nociceptive signaling in peripheral CGRP terminal fibres by Baillie, Landon
  
 
Imaging nociceptive signaling in peripheral CGRP terminal fibres 
 
 
 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
In Partial Fulfillment of the Requirements 
For the Degree of Doctor of Philosophy 
In the Department of Physiology 
University of Saskatchewan 
Saskatoon 
 
By 
 
Landon D. Baillie 
 
 
 
 
 
© Copyright Landon D. Baillie, June 2015. All rights reserved. 
 
 i 
Permission to Use 
In presenting this thesis/dissertation in partial fulfilment of the requirements for a Postgraduate 
degree from the University of Saskatchewan, I agree that the Libraries of this University may 
make it freely available for inspection.  I further agree that permission for copying of this 
thesis/dissertation in any manner, in whole or in part, for scholarly purposes may be granted by 
the professor or professors who supervised my thesis/dissertation work or, in their absence, by 
the Head of the Department or the Dean of the College in which my thesis work was done.  It is 
understood that any copying or publication or use of this thesis/dissertation or parts thereof for 
financial gain shall not be allowed without my written permission.  It is also understood that due 
recognition shall be given to me and to the University of Saskatchewan in any scholarly use 
which may be made of any material in my thesis. 
 
Requests for permission to copy or to make other use of material in this thesis in whole or part 
should be addressed to: 
 Head of the Department of Physiology 
 University of Saskatchewan 
 Saskatoon, Saskatchewan  S7N5E5 
! ii!
ABSTRACT 
   
In this dissertation I introduce a simple experimental approach for studying afferent pain 
fibre physiology. I developed an en bloc dural-skull preparation that pairs electrophysiological 
stimulations, pharmacological manipulations, and the UV photolysis of caged compounds in and 
around selectively identified individual C-fibre nociceptors with microfluorometric imaging of 
Ca2+ responses. This allows the observation of physiological functioning in individual 
nociceptive fibre free nerve endings. I show high-resolution functional imaging of single action 
potential-evoked fluorescent transients, as well as sub- and supra-threshold calcium signaling 
events within individual nociceptive fibre terminations. 
 Utilizing the dural-skull preparation I was able to identify a peripheral mechanism of 
action in the terminals of CGRP nociceptive fibres for an effective migraine therapeutic, the 
selective 5-HT1 receptor agonist, sumatriptan. I found sumatriptan to cause an approximately 
40% reduction in the amplitude of action potential-evoked Ca2+ transients in the peripheral 
terminals of CGRP nociceptive fibres that was mediated selectively through the inhibition of N-
type Ca2+ channels. Observations from this study support a peripheral site of action for 
sumatriptan in inhibiting the activity of dural pain fibres and adds to our understanding of the 
mechanisms that underlie the clinical effectiveness of 5-HT1 receptor agonists such as 
sumatriptan. 
 While µ-opioid receptor agonists remain the most powerful analgesics for the treatment 
of severe pain, their mechanism of action in peripheral primary afferent pain fibres remain to be 
established. Further exploiting the dural-skull preparation I found activation of µ-opioid 
receptors in individual CGRP terminals had a dual modulatory effect; inhibition of N-type Ca2+ 
channel signaling and a frequency dependent, BKCa channel-mediated, suppression of action 
potential firing.  These results establish possible anti-nociceptive mechanisms of µ-opioid 
receptor activation in the peripheral terminals of CGRP nociceptive fibres and identify new 
pathways to target for peripherally mediated analgesia. 
 The development and subsequent testing of the dural-skull preparation in this dissertation 
displays its utility and opens up a new window for studying nociceptive fibre physiology and 
pathophysiology. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Nociceptive signaling 
Pain is described as the subjective, unpleasant sensory and emotional experiences 
associated with actual or potential tissue damage (Kandel, 2013).  The ability to sense noxious 
stimuli is essential to the survival and well being of many organisms and leads to appropriate 
protective behaviours to avoid or retract from conditions that may be life threatening (Basbaum 
et al., 2009).   
 The sensation of pain commonly begins with nociception, the process by which intense 
thermal, mechanical or chemical stimuli is sensed by a subset of peripheral sensory nerve fibres 
known as nociceptors (Gold and Gebhart, 2010) . Nociceptors are pseudounipolar neurons whose 
cell bodies reside in the dorsal root ganglion or trigeminal ganglion. From the cell body both 
peripheral and central terminals emanate from a common axonal stalk, one extending out to the 
periphery, the other entering into the dorsal horn of the spinal cord or brainstem (Figure1.1B) 
(Basbaum et al., 2009). 
 The peripheral terminals of nociceptors contain a variety of transducing channels that 
convert mechanical, chemical and thermal stimuli into electrical activity and thus action 
potentials in the nociceptors that travel back to the central nervous system (CNS) (Figure 1.1A) 
(Woolf and Ma, 2007). 
 Nociceptive signals are transmitted at a central synapse in the spinal cord or hind brain 
through the release of a variety of excitatory neurotransmitters such as glutamate, calcitonin 
gene-related peptide (CGRP) or substance P that have the potential to excite second order 
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nociceptive projection neurons (Grace et al., 2014). The majority of primary-secondary 
nociceptive synapses occur within the superficial laminae of the spinal dorsal horn (Kuner, 
2010). Nociceptive signaling can be modulated at the central synapse in the spinal cord via 
activation of γ-aminobutyric acid containing (gabaergic) and glycinergic inhibitory interneurons 
(Takazawa and MacDermott, 2010). 
 The majority of secondary projection neurons travel up the spinothalamic tract of the 
spinal cord and project to supra-spinal sites, primarily the thalamus, where this nociceptive 
information is then relayed to numerous cortical and subcortical regions via third order neurons 
allowing for encoding and perception of the painful experience (Grace et al., 2014). Aside from 
the spinothalamic tract, secondary projection neurons also ascend to the reticular formation and 
thalamus via the spinoretricular tract and the periaqueductal gray and mesencephalic reticular 
formation via the spinomesencephalic tract (Kandel, 2013).  
Primary-secondary nociceptive signaling in the spinal cord can be modulated by 
activation of descending pathways originating primarily in the periaqueductal gray of the 
midbrain (Heinricher et al., 2009). Neurons in the periaqueductal gray receiving nociceptive 
information from the spinomesencephalic tract project to and activate noradrenergic and 
serotonergic neurons in the locus ceruleus and nucleus raphe magnus of the brainstem (Kandel, 
2013). These neurons from the locus ceruleus and nucleus raphe magnus descend to the dorsal 
horn of the spinal cord where they synapse on and activate endogenous opioid containing 
interneurons (Heinricher et al., 2009). The release of endogenous opioids results in activation of 
opioid receptors on primary nociceptors and secondary projection neurons in the spinal cord. 
Opioid receptor activation in the primary nociceptors leads to the inhibition of a variety of Ca2+ 
channels and a subsequent decrease in synaptic release and in the secondary projection neurons 
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activates K+ channels causing hyperpolarization, leading to a decrease in excitation and/or 
propagation of action potentials (Stein C and Zollner C, 2009). 
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Figure 1.1. Overview of nociceptive signaling pathways. 
A) Highlights the transduction channels in the peripheral terminals of nociceptors responsible for 
sensing noxious stimuli. B) Nociceptors from the periphery travel back to the CNS and enter the 
dorsal horn of the spinal cord and synapse on secondary projection neurons or interneurons. The 
cell bodies of nociceptors are located outside the spinal cord in the dorsal root ganglion or 
outside the brainstem in the trigeminal ganglion.  C) Highlights the areas involved in the 
conscious sensation of pain and the areas of the brain that have descending outputs to the spinal 
cord to modulate incoming nociceptive signals. D) The developmental pathways of the two main 
subpopulations of C-nociceptors; peptidergic and non-peptidergic. PFC; prefrontal cortex, CeA; 
central nucleus of the amygdala, ACC; anterior cingulate cortex, S1; somatosensory cortex, IC; 
insular cortex, LC; locus ceruleus, PAG; periaqueductal gray, RVM; rostral ventromedial 
medulla. Adapted from (Grace et al., 2014; Marmigere and Ernfors, 2007) 
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1.2 Primary afferent nociceptors 
There are two main classes of nociceptors, unmyelinated slow conducting C nociceptors 
(C fibres) and lightly myelinated more rapidly conducting Aδ nociceptors (Aδ fibres).  Aδ 
nociceptors usually have medium to large sized cell bodies (>45 µm in diameter) and are capable 
of sensing noxious mechanical stimuli and a subset of them are also capable of transmitting 
noxious thermal stimuli; whereas the majority of C nociceptors have small to medium sized cell 
bodies (<45 µm in diameter) and are polymodal making them capable of sensing noxious 
thermal, mechanical and chemical stimuli (Julius and Basbaum, 2001). An additional class of C 
nociceptors exist known as silent nociceptors, which are polymodal nociceptors that only 
become responsive to noxious thermal and mechanical stimuli after sensitization from 
inflammatory mediators but in the absence of inflammatory mediators remain unresponsive 
(Dubin and Patapoutian, 2010).  
1.2.1 Subpopulations of C fibres 
C-fibres constitute the majority of nociceptors found throughout the body and are 
commonly broken down into two subpopulations, on the basis of cell content of receptor 
expression, peptidergic and non-peptidergic.  Peptidergic nociceptors are characterized by the 
presence of one or both of the neuropeptides calcitonin gene-related peptide (CGRP) and 
substance P and are further defined by the presence of the nerve growth factor receptor, 
tropomyosin receptor kinase A (TrkA) (Gold and Gebhart, 2010).  Non-peptidergic nociceptors 
are characterized by the expression of Ret, the tyrosine kinase receptor that is the signaling 
component for the neurotrophic factors of the glial-derived family (Franck et al., 2011); the 
presence of purinergic P2X3 receptors and the ability to bind and be labeled by an isolectin 
known as IB4 (Julius and Basbaum, 2001).  Peptidergic and non-peptidergic subpopulations are 
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often further sub-divided based on their primary stimulus response or the absence or presence of 
certain ion channels such as transient receptor potential V1 (TRPV1) or tetrodotoxin (TTX)-
resistant Na+ channels (Handwerker, 2010).  
1.2.2 Development 
The two populations of C nociceptors differentiate during peri/postnatal development and 
depend on genetic mechanisms (Abdel Samad et al., 2010).  Runt-related transcription factor 1 
(Runx1), plays a pivotal role in determining the two subpopulations of C fibres. Initially all 
nociceptors express TrkA and Runx1 during development and require nerve growth factor (NGF) 
for survival during embryonic life (Snider and McMahon, 1998). In non-peptidergic nociceptors 
Runx1 expression remains, TrkA expression is switched off and Ret expression on, whereas in 
the peptidergic nociceptors Runx1 expression switches off and TrkA expression is retained and 
occasionally Ret may also be expressed (Abdel Samad et al., 2010) (Figure 1.1D).  
1.2.3 Transduction 
The transduction of mechanical, chemical and thermal stimuli in nociceptors is initiated 
by the generation of depolarizing generator potentials created through the activation of unique 
protein molecules or receptors found in the peripheral terminals of C-fibres (Figure 1.2A+B, 
Table 1) (Gold and Gebhart, 2010).  When these receptors encounter the appropriate specific 
stimulus (e.g., high heat, extreme cold, chemicals, or excessive pressure) of sufficient intensity, 
the receptor molecule undergoes a conformational change that transduces the noxious signal into 
an electrical current (generator potential) by triggering the opening of depolarizing cationic ion 
channels, sodium/calcium (Na+/Ca2+) or the closing of outward potassium channels (K+) (Babos 
et al., 2013). If the generator potential is of sufficient magnitude or spread, nearby voltage gated 
Na+ channels become activated, initiating an action potential in the nociceptor. 
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Table 1. Primary afferent transducers 
 
     Mechanical Thermal Chemical 
ASIC1  TRAAK/TREK-1  ASIC 1-4 
ASIC2  Nav1.8  TRAAK/TREK 
ASIC3  TRPA1  TRPV1 
Cav3.2  TRPM8  TRPA1 
TRPV1  TRPV3  TRPM8 
TRPV4  TRPV4  P2X1-6 
TRPA1  TRPV1  5-HT3 
TRAAK  TRPV2  nAch 
TREK1/2    GluR-1, NR1-2 
P2X3    GABA 
 
 
Table 1. List of mechanical, thermal and chemical transducing channels found in primary 
afferent nociceptors. Adapted from Gold and Gebhart 2010. 
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1.2.4 Transduction channels 
 A wide variety of ion channels have now been discovered that can directly or indirectly 
transduce thermal, mechanical and chemical stimuli (Table 1) (Gold and Gebhart, 2010). The 
transient receptor potential (TRP) superfamily of channels appears to be of particular importance 
(Figure 1.2A).  The eight subfamilies of TRP channels share a few common features including 
consisting of six transmembrane segments, a varying degree of sequence homology and 
permeability to cations but despite their similarities display a diversity of cation selectivity and 
varying mechanisms of activation (Venkatachalam and Montell, 2007). Since the cloning of the 
first discovered TRP channel involved in pain, the capsaicin receptor (TRPV1) (Caterina et al., 
1997), a wide range of TRP channels have been found to be expressed in nociceptors including 
TRPV2, TRPV3, TRPV4, TRPM8, and TRPA1 and have been found to transduce a variety of 
noxious stimuli (Wang and Woolf, 2005).  
 Of all the TRP channels identified, the initially discovered TRPV1 channel has been the 
most studied. TRPV1 is found to be highly expressed in nociceptors and is considered to be a 
polymodal receptor capable of being activated by voltage and noxious thermal and chemical 
stimuli (Oh, 2006) and has been found to be involved in mechanical hyperalgesia (Honore et al., 
2005). Chemical activators of TRPV1 channels include capsaicin, (the main pungent ingredient 
in hot peppers), and related vanilloids, protons and endocannabinoids such as anandamide (Wang 
and Woolf, 2005). Being a polymodal receptor TRPV1 is also activated by noxious levels of heat 
with temperatures >42oC acting directly on the channel gating to open the TRPV1 channel 
resulting in a nonselective cation current (Cesare and McNaughton, 1996; Reichling and Levine, 
1997). 
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 The method by which noxious thermal and chemical stimuli initiate the opening of the 
TRPV1 channel resulting in a cation influx have recently been determined. Temperatures above 
42oC result in the pore undergoing a structural change resulting in the influx of cations (Grandl et 
al., 2010) whereas activation by vanilloids such as capsaicin is restricted to a small cytosolic 
segment spanning transmembrane 2-4 of the receptor (Jordt and Julius, 2002) and activation by 
protons is restricted to an extracellular domain (Jordt et al., 2000).  
 The TRPV1 channel is permeable to various monovalent cations including Na+, K+, 
cesium (Cs+) and Ca2+ (Oh et al., 1996), but it has an approximate 10-fold preference for Ca2+ 
(Chung et al., 2008). Classically the cation, primarily Ca2+, influx through TRPV1 is believed to 
cause generator potentials in the nociceptive terminal, depolarizing voltage gated Na+ channels 
followed by the generation of action potentials. More recently it has also been proposed that 
action potential generation by TRPV1 activation could occur via an anion efflux mechanism 
through the Ca2+ activated chloride (Cl-) channel anoctamin 1 (Takayama et al., 2015). 
 Similarly to TRPV1, other nociceptive channels in Table 1 transduce noxious stimuli into 
an electrical current (generator potential) primarily by triggering the opening of depolarizing 
cationic ion channels (Na+ and Ca2+) or the closing of outward potassium channels (Babos et al., 
2013). 
1.2.5 Transmission 
 Three voltage gated Na+ channels, Nav1.7, Nav1.8 and Nav1.9, are primarily expressed in 
C nociceptors and are believed to be responsible for initiating and propagating an action potential 
in response to a sufficient generator potential (Dib-Hajj et al., 2013). Nav1.7 has been the focus 
of intense research in the pain field due to the discovery of genetic mutations in this channel that 
can result in a loss of function in the channel and the inability to sense pain, or a gain-of-function 
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mutation leading to pain hypersensitivity (Cox et al., 2006; Fertleman et al., 2006).  Nav1.7 is 
found in high density near nociceptive endings where it plays the crucial role of amplifying small 
subthreshold depolarizations (generator potentials) acting as a threshold channel that regulates 
nociceptor excitability (Figure. 1.2B) (Dib-Hajj et al., 2013).  Nav1.9 plays a similar role to 1.7 
by acting as a threshold channel (Huang et al., 2014) whereas Nav1.8 is thought to carry the 
main Na+ current of the propagating action potential as it travels back to the CNS (Renganathan 
et al., 2001).  
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1.3 Current methods for studying nociception 
To study nociceptive signaling, identify novel pain targets, and characterize the analgesic 
potential of new compounds, a variety of cellular and behavioural experimental methods, 
primarily in rodents, have been developed. While the methods highlighted below have been vital 
to the current understanding of nociception and development of analgesic targets, the 
development of novel methods, particularly those that will allow study of the elusive tiny pain-
sensing terminals, will be important in moving pain research forward and allowing progress to 
continue.  
1.3.1 Behavioural 
 One of the largest obstacles in studying nociception in animals is the absence of verbal 
communication, which limits experimenters to only the study of physical signs of pain by 
observing “pain-like” behaviours (Xie, 2011). The study of pain-like behaviours most commonly 
uses tests of simple phasic pain in animals and relies on escape behaviour/withdrawal reflexes or 
vocalization as an index of pain (Boyce-Rustay et al., 2010).  
 The behavioural tests of nociception are commonly split based on stimulus into three 
categories: tests using thermal stimuli, tests using mechanical stimuli, and finally tests using 
chemical stimuli. 
1.3.1.1 Thermal: 
The tail flick test was first described by (D'amour and Smith, 1941), and involves 
restraining a rodent, focusing a heat source from a radiant lamp on the rodents tail and measuring 
the time from the onset of the stimulus to when the animal feels discomfort and reacts by 
withdrawing its tail from the heat with a brief vigorous movement (tail flick) (Le Bars et al., 
2001). A modified version of the tail flick was later developed that involves immersing the distal 
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half of the tail into a heated water bath and again measuring the time latency for a tail flick or a 
complete body movement (Janssen et al., 1963). Note that this method can also be used to test 
reactivity to cold by using a chilled water bath (Xie, 2011). Since such a large portion of the tail 
is being exposed to the heat source during the bath version, time latencies are often shorter than 
the focused light method.  
The paw withdrawal test, first developed by (Hargreaves et al., 1988), aimed to 
behaviourally study hyperalgesia resulting from inflammation. This test involves taking a freely 
moving rodent on a glass surface and placing a focused infrared source under the plantar surface 
of a hindpaw when the rodent is not moving. A start button turns on the light source as well as a 
timer and when the paw is actively removed from the light source it ceases, as does the timer and 
the time latency from heat onset to withdrawal is recorded.  
 The hot plate test was first introduced by (Woolfe and Macdonald, 1944) and involves 
placing a rodent in a open ended acrylic cylinder with a metallic plate floor that is heated by a 
thermode or boiling liquid to 65oC. At the onset of placement a timer is started and then stopped 
once the rodent responds with a hind paw lick, flick or jump. A similar device was developed 
that uses a cooled metallic floor to test behavioural responses to noxious cold (Bennett and Xie, 
1988).  
1.3.1.2 Mechanical: 
Similar to thermal nociceptive stimuli, mechanical stimuli are commonly applied to the 
tail or paw. One of the first tests of mechanical nociception still used in laboratories was 
developed by Randal and Selitto (Randall and Selitto, 1957) and involves the application of 
increasing measurable force to the tail or hindpaw. This force is continuously increased until a 
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paw/tail withdrawal or vocalization is recorded and the weight of the force to obtain the 
nocifensive response (in grams) is recorded. 
 First developed over 100 years ago to test touch sensibility in man (Fruhstorfer et al., 
2001), Von Frey filaments are still used in laboratories today.  The Von Frey filament test 
involves manually applying a short calibrated monofilament to the hindpaw of a rodent. 
Increasingly stronger filaments are applied until a nocifensive paw withdrawal response is 
observed. An electronic version of Von Frey filaments is also used and involves using a single 
filament tip on a force transducer that measures the amount of force applied to a rodent’s paw 
when withdrawal is observed (Cunha et al., 2004).   
1.3.1.3 Chemical: 
 The use of chemical stimuli differs from mechanical and thermal stimuli in that the 
application of pain causing chemicals commonly induces a slow, long lasting nociceptive 
response that cannot be immediately removed. The most common chemical substance used for 
inducing acute chemical pain is capsaicin. Capsaicin is commonly injected into the plantar 
surface of the hind paw and licking, biting, and flinching behaviours are measured for 5 minutes 
following the application (Boyce-Rustay et al., 2010). Because capsaicin can elicit a long-lasting 
nociceptive response, it is commonly used in conjunction with measurement of mechanical and 
thermal stimuli (Le Bars et al., 2001). 
While the observation of pain-like behaviours in response to noxious stimuli allow for the 
rapid screening of newly developed compounds for analgesia, it allows little opportunity for the 
study of pain at the cellular level and the development of new analgesic targets.  
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1.3.2 Cellular 
 The vast majority of research into the cellular mechanisms of nociception, including the 
assessment of specific ion channels involved in chemical, mechanical, thermal transduction as 
well as action potential generation, are based on experiments using heterologous expression 
systems and in vitro preparations (Zimmermann et al., 2009). The advantages and disadvantages 
of these in vitro preparations are highlighted below. 
1.3.2.1 Cultured DRG/TRG 
 Since the inception of tissue culture in 1907 (Harrison, 1907) neuronal cell cultures from 
various animals have been widely and successfully exploited as a powerful tool to answer 
relevant questions of neurobiology and neurodevelopment, such as neurite/axon formation and 
elongation, synapse formation and synaptic properties, neurotrophic factor trafficking and 
signaling, neurotransmitter release, electrical signaling, and intracellular protein trafficking 
(Melli and Hoke, 2009). 
 The cell bodies of nociceptors exist within the dorsal root ganglion and trigeminal 
ganglion and can be cultured. The advantages to using in vitro primary DRG or TRG cultures in 
the study of nociception is that it allows one to study whether a given compound has a direct 
effect on a primary sensory neuron, the precise monitoring of the concentrations of a given 
compound the primary sensory neurons are exposed to and finally, the ability to study cellular 
mechanisms of excitation and neurotransmitter release that would be otherwise be difficult to 
study in vivo (Burkey et al., 2004). 
 Of course the use of cultured sensory neurons comes with its limitations; without the 
surrounding tissue it is difficult to ascertain the physiological functions of the peripheral sensory 
neuron from its cultured somata and culture conditions frequently offer additional variables that 
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can alter expression of proteins or transmitters that limit extrapolation of results to the in vivo 
conditions. To overcome altered protein or transmitter expression experimenters can use acutely 
dissociated TRG and DRG instead of primary cultured neurons, which involve using the 
dissociated DRG or TRG neurons the day they are removed from the animal as opposed to after 
exposure to culture conditions for days/weeks.  
 Although much of the understanding of nociceptive transduction has come from the use 
of cultured or dissociated DRG/TRG somata, there is a high probability that significant 
quantitative differences exist in the patterns of expression of ion channels and signaling systems 
between the somata and the peripheral processes of the nociceptor neuron, which have often 
been overlooked (Kostyuk and Kostyuk, 2009), highlighting the need for an in vitro preparation 
that looks specifically at the tiny peripheral terminals. 
1.3.2.2 Reprogrammed cells 
 A significant limitation of nociceptive research, particularly at the cellular level, is that it 
is almost exclusively performed in other types of mammals, the majority in rodents. Although it 
is possible that nociceptive transduction processes are homologous across different orders of 
mammals, there exists a likelihood that ion channel expression and signaling mechanisms vary.   
 The recently developed ability to differentiate human pluripotent stem cells and perform 
lineage reprogramming of human cells allows researchers to derive a wide range of neuronal 
subtypes, which has recently been applied to the development of human-derived nociceptors.  
In 2012, researchers were able to take human pluripotent stem cells and through small 
molecule pathway inhibition, convert these cells to neurons expressing canonical markers and 
functional properties of human nociceptors (Chambers et al., 2012) and earlier in 2015 two 
	   17	  
separate research groups were able to reprogram human fibroblasts into noxious stimulus- 
detecting (nociceptor) neurons (Blanchard et al., 2015; Wainger et al., 2015).  
  Although these techniques are thought to overcome the interspecies differences that may 
exist when studying nociception and reduce the use of animals necessary for culturing DRG or 
TRG’s, they still focus on the cell somata and the use of a variety of pathway 
activators/inhibitors as well as various culture conditions during the creation of these 
reprogrammed nociceptors may possibly leave these cells with less resemblance to human cells 
than researchers would hope for.  
1.3.2.3 In vitro corneal preparations 
 The cornea is one of the most densely innervated tissues in the body and is richly 
supplied by sensory and autonomic nerve fibres (Muller et al., 2003). The majority of sensory 
neurons in the cornea are axons whose cell bodies reside in the ophthalmic division of the 
trigeminal nerve and predominately sense pain (Al-Aqaba et al., 2010). Because of the high 
density of nociceptive terminals within the cornea, in vitro electrophysiology and Ca2+ imaging 
preparations for studying signaling in the terminals have been developed.  
  The nociceptor peripheral terminals in the cornea terminate in the most superficial layer 
of the corneal epithelium in most species. This arrangement has allowed researchers to create an 
in vitro preparation in which the ciliary nerve of the eye is electrically stimulated and a recording 
electrode is applied to the corneal surface with light suction to record antidromic signals arriving 
in the endings of the nerve terminals (Al-Aqaba et al., 2010). While this preparation has provided 
insight into impulse generation in nerve terminals, especially in response to cold stimulation 
(Carr and Brock, 2002; Carr et al., 2002; Carr et al., 2003; Madrid et al., 2006), it does not allow 
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for activation of the peripheral terminals themselves, leaving this preparation restricted to the 
study of efferent signaling in nociceptors. 
 A second in vitro corneal preparation involves using a large electrical stimulation across 
the entire eye, paired with Ca2+ imaging in the peripheral terminals (Gover et al., 2003; Gover et 
al., 2007). This preparation appears to be restricted to the observation of Ca2+ handling in the 
peripheral terminals only, since the large stimulation used does not appear to evoke single, rapid 
and repeatable Ca2+ transients as would be seen if single action potentials were elicited by the 
electrical stimulation.  
 Aside from the inability to directly activate single nociceptors at the peripheral terminals, 
the in vitro corneal preparations cannot be used to study nociceptive states such as neurogenic 
inflammation and peripheral sensitization due to the lack of immune cells and vasculature in the 
cornea (Niederkorn, 2005).   
1.3.2.4 Isolated skin-saphenous nerve preparation 
 An in vitro model that allows for the study of responses of primary sensory neurons in the 
rodent skin is the saphenous skin–nerve preparation.  This preparation involves dissecting the 
saphenous nerve and a large part of the hindpaw skin innervated by the saphenous nerve from a 
rodent and superfusing it with a physiological solution (Reeh, 1986).  This preparation enables 
extracellular recording of propagated action potentials downstream from the receptive fields of 
single sensory nerve endings in the skin in response to electrical, thermal, mechanical and 
chemical stimuli (Zimmermann et al., 2009).  
 While this preparation is one of few that activates peripheral terminals of nociceptors and 
observes axons as opposed to cell bodies, it does have its limitations. A major limitation of the 
preparation is that a lot of patience and time is required to find and record from single units; 
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teasing apart the saphenous nerve to not only record from a single primary afferent but to 
confirm that the afferent being recorded from is a nociceptor is tremendously difficult 
(Zimmermann et al., 2009).  
Although this preparation does activate the peripheral terminals, recordings are taken a 
large distance away from the stimulus allowing only for the study of the action potentials as a 
result of the stimulus at the terminals, the inability to directly study the physiological processes 
that are occurring at the terminals themselves and the impossibility of studying signaling within 
the terminals.  
The in vitro preparations that currently exist for studying nociception have been key in 
the current understanding of nociception and development of analgesic targets, but the 
development of novel methods, particularly those that more closely reflect in vivo conditions and 
allow the direct study of the elusive tiny pain-sensing terminals are necessary in moving pain 
research forward. 
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1.4 Calcitonin gene-related peptide 
 The bulk of this thesis focuses on CGRP-containing nociceptors due to their involvement 
in numerous nociceptive processes highlighted below. Calcitonin gene-related peptide (CGRP) is 
a vasodilator neuropeptide found in a subpopulation of peptidergic nociceptive neurons 
(Benarroch, 2011). Within these small nociceptors it exists in two isoforms (α and β) that 
although being of similar homology are produced by different genes with the α-isoform being 
found in much higher levels (Seybold, 2009). CGRP is located within the peripheral terminals of 
nociceptors, packaged in large dense core vesicles, where its release contributes to neurogenic 
inflammation (Benemei et al., 2009; Kilo et al., 1997; Richardson and Vasko, 2002). CGRP 
released at the central terminals within the dorsal horn of the spinal cord or trigeminal nucleus 
caudalis has two main functions, one acting back on nearby central terminals to facilitate 
neurotransmitter release (Kangrga et al., 1990; Kangrga and Randic, 1990) and secondly acting 
on spinal neurons to increase glutamate activation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid  (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors 
(Ebersberger et al., 2000; Seybold, 2009). 
1.4.1 CGRP receptor 
  Functioning CGRP receptors are composed of a G-protein coupled receptor, calcitonin-
like receptor (CLR) paired with a single transmembrane domain protein called receptor activity 
modifying protein type 1 (RAMP1) that traffics the CLR to the cell membrane surface and a 
receptor component protein (RCP) that determines which G-protein is coupled to the receptor 
(Figure 1.3) (Durham and Vause, 2010).  
 CGRP receptors are found in numerous pain-related locations and cell types throughout 
the body where their activation leads to pro-nociceptive effects. The CGRP receptor is localized 
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to vascular smooth muscle (Brain and Grant, 2004), central terminals of non-CGRP containing 
nociceptors (Eftekhari and Edvinsson, 2010; Natura et al., 2005), mast cells (Lennerz et al., 
2008), satellite glia and Schwann cells (Eftekhari et al., 2010), as well as in second order 
nociceptive neurons within the spinal cord and trigeminal nucleus caudalis (Eftekhari and 
Edvinsson, 2010). Release of CGRP and activation of its receptor are involved in a variety of 
nociceptive states including central sensitization, neurogenic inflammation and most importantly 
migraine (Benarroch 2011).    
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Figure 1.3. The functional CGRP receptor. 
The CGRP receptor consists of three subunits; the calcitonin-like receptor (CLR), the 
transmembrane domain protein called receptor activity modifying protein type 1 (RAMP1) and a 
receptor component protein (RCP). Adapted from (Recober et al., 2009) 
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1.4.2. CGRP and central sensitization 
 Central sensitization is described as an enhancement in the function of neurons and 
circuits in nociceptive pathways caused by increases in membrane excitability and synaptic 
efficacy within the spinal cord (Latremoliere and Woolf, 2009). Central sensitization can be 
initiated by damage to peripheral nerves or by repeated exposure to particularly intense noxious 
stimuli and coincides with spontaneous pain, pain elicited by normally innocuous stimuli 
(allodynia) or an exaggerated or prolonged response to a noxious stimulus (hyperalgesia) (Ji et 
al., 2003).   
 While glutamate has been indicated as the small molecule neurotransmitter responsible 
for rapid excitatory synaptic transmission between nociceptors and dorsal horn neurons, it has 
been noted that activation of C nociceptors, which contain a wide variety of neuropeptides, is 
necessary to induce central sensitization (Cook et al., 1987).  
 While CGRP on its own is incapable of directly increasing synaptic release from 
nociceptors or directly increasing excitation of dorsal horn neurons to cause central sensitization 
(Gamse and Saria, 1986), it is thought to play an indirect role in the induction and maintenance 
of central sensitization (Seybold, 2009).  
 During induction of central sensitization activation of CGRP receptors in dorsal horn 
neurons has been shown to increase the excitability of spinal neurons (Bird et al., 2006), likely 
through phosphorylation of AMPA receptor subunits, increasing their insertion into the 
postsynaptic plasma membrane (Esteban et al., 2003).  CGRP is also thought to contribute to the 
induction of central sensitization by competing with substance P for catabolism by 
endopeptidases (Le Greves et al., 1985). Substance P is another neuropeptide that is commonly 
co-expressed and released with CGRP in small diameter nociceptors (Lundberg et al., 1985). 
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Substance P binds to neurokinin 1 (NK1) receptors, another G-protein coupled receptor, on the 
secondary spinal neurons resulting in the phosphorylation of NMDA and AMPA receptors 
leading to increased ion conductance also necessary for the induction of central sensitization 
(Latremoliere and Woolf, 2009).    
 Intrathecal administration of a CGRP receptor antagonist blocks mechanically-evoked 
nociceptive responses in animals after the development of hyperalgesia indicating that activation 
of CGRP receptors is also necessary in the maintenance of central sensitization (Sun et al., 
2004). 
1.4.3. CGRP and neurogenic inflammation 
 The process of inflammation is classically defined as involving four cardinal signs: dolor 
(pain), calor (heat), rubor (redness) and tumor (swelling) (Scott et al., 2004) with pain previously 
being thought simply as a symptom of inflammation and not actively taking part in the process. 
More recently it has been discovered that nociceptors, specifically peptidergic nociceptors, 
actively take part in the process of inflammation. Nociceptors are thought to not only provide 
orthodromic signaling to the CNS, but action potentials also signal antidromically at branch 
points back down to the periphery, a process referred to as the axon reflex (Figure 1.4) (Chiu et 
al., 2012). The action potentials traveling back to the periphery are believed to lead to a local and 
rapid release of neural mediators from both peripheral axons and terminals contributing to the 
calor, rubor and tumor of inflammation, a process now referred to as neurogenic inflammation. 
 Neurogenic inflammation is primarily initiated by the release of CGRP and substance P 
(Richardson and Vasko, 2002), which act directly on the endothelial and smooth muscle cells of 
the vasculature with CGRP causing vasodilation (McCormack et al., 1989) and substance P 
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increasing the permeability of capillaries leading to plasma extravasation (leakage) and edema 
(Saria, 1984). 
 The release of CGRP and substance P along with other peptides further contribute to 
neurogenic inflammation by attracting and activating neutrophils, macrophages and lymphocytes 
at the site of injury, causing the degranulation of mast cells as well as dendritic and T-cell 
priming (Ansel et al., 1993; Ding et al., 2008; Rochlitzer et al., 2011).  Recent findings support 
the idea that peptidergic nociceptors not only play a passive role in host defense by detecting 
noxious stimuli and initiating avoidance behaviour, but also play an active role via the immune 
system to modulate the responses to and combat of harmful stimuli (Chiu et al., 2012).   
During this inflammatory process the variety of mediators released from other cell types 
cause a peripheral sensitization of the nociceptors lowering the excitation threshold leading to 
peripherally-mediated hyperalgesia and/or allodynia (Schaible, 2007). 
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Figure 1.4. CGRP and neurogenic inflammation. 
The release of CGRP and other neuropeptides from efferent signaling in nociceptors leads to 
neurogenic inflammation through: 1) attracting and activating neutrophils, macrophages and 
lymphocytes at the site of injury, and causing the degranulation of mast cells.  2) Vasodilation, 
plasma extravasation and edema. 3) dendritic and T-cell priming.   Adapted from (Chiu et al., 
2012) 
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1.4.4. CGRP and Migraine 
 Migraine is considered a neurovascular disorder characterized by a severe, debilitating 
and throbbing unilateral headache associated with anorexia, nausea, vomiting, photophobia, 
phonophobia and/or diarrhea (Goadsby et al., 2002). While the initial trigger for a migraine 
attack remains unknown, it is largely accepted that activation of the nociceptors innervating the 
meninges is necessary (Ebersberger, 2001; Pietrobon and Striessnig, 2003). It has been 
previously hypothesized that migraine pain was due to vasodilation of blood vessels of the 
cerebrum and that CGRP released from trigeminal peptidergic nociceptors causes this dilation 
(Jansen-Olesen et al., 1996).  
The vasodilation that occurs during migraine is no longer believed to be the cause but 
rather a secondary affect that may contribute to the painful state of migraine (Burgos-Vega et al., 
2015). Despite this, CGRP is still thought to play an important role in the pathophysiology of 
migraine for several reasons: CGRP levels are elevated during a migraine attack (Goadsby et al., 
1990), migraine patients that are infused with CGRP develop a delayed headache, fulfilling the 
criteria of a migraine (Lassen et al., 2002), the administration of medications during a migraine 
attack reduce CGRP levels that correspond with relief (Stepien et al., 2003) and finally the 
success of CGRP receptor antagonists in ameliorating a migraine attack all point towards the 
involvement of CGRP in migraine (Villalon and Olesen, 2009). 
 The two possible sites of action CGRP may take in the contribution to migraine are at the 
level of the meninges where it is released by the peripheral terminals of nociceptors or at the 
central terminals within the spinal trigeminal nucleus (Burgos-Vega et al., 2015). In the 
meninges it is possible that CGRP release results in a state of neurogenic inflammation, 
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peripheral sensitization and allodynia causing meningeal nociceptors to react to normally non-
painful vascular stimuli (Olesen et al., 2009). 
 Centrally, it is thought that the high frequency of action potential firing from the 
peripheral nociceptors to the trigeminal nucleus caudalis as a result of peripheral sensitization 
can lead to increased CGRP release centrally and the development of central sensitization as 
described above, contributing to the painful phase of the migraine attack (Dodick and Silberstein, 
2006).  
The development of a preparation to study peripheral CGRP fibres may help identify the 
possible underlying mechanisms of activation and peripheral sensitization and may have 
important implications for understanding and mitigating the pathogenesis of migraine headaches. 
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1.5 Triptans and Migraine 
While the etiology of migraine headache is poorly understood, sumatriptan and the 
triptan class of serotonin receptor subtype-selective drugs have an established efficacy in treating 
the pain associated with migraine. Triptans are a class of tryptamine-based drugs that activate 
serotonin type 1B and D (5-HT1B/D)  G-protein coupled receptors.  It has been long debated 
whether the anti-migraine actions of triptans occurs via activation of 5-HT1 receptors on arterial 
smooth muscle, the peripheral terminals of nociceptors, or within the nociceptive system of the 
CNS (Hoskin and Goadsby, 1998; Humphrey and Goadsby, 1994) 
1.5.1 Vasculature 
 Classically the effectiveness of triptans in the treatment of migraine pain has been 
attributed to their vasoconstrictive properties, which have been shown to occur exclusively 
through activation of 5-HT1B receptors on cranial arterial smooth muscle (Razzaque et al., 1999). 
But because vascular changes seen with triptan usage have not temporally coincided with pain 
relief (Limmroth et al., 1996) it is not known if vasculature 5-HT1B receptor activation is 
necessary for migraine relief.  
1.5.2 Central nociceptive system 
 Activation of dural afferents can result in central sensitization within the trigeminal 
nucleus caudalis (TNC) that may play a role in the pathogenesis of migraine (Dodick and 
Silberstein, 2006). While sumatriptan had been proposed to result in migraine relief through 
central mechanisms, this seems unlikely due to its hydrophilic nature, resulting in poor 
penetration of the blood brain barrier (Kaube et al., 1993; Sleight et al., 1990). More lipophilic 
triptans have been shown to have central effects, blocking dura-evoked activation of TNC 
neurons in both electrophysiological and c-fos studies (Cumberbatch et al., 1997; Hoskin and 
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Goadsby, 1998) indicating that triptans may possibly act centrally, particularly if there is a 
disruption in the blood brain barrier during migraine, which has been proposed to occur 
(Moskowitz and Cutrer, 1993). 
1.5.3 Peripheral nociceptors 
It is widely recognized that activation of dural nociceptive afferents is responsible for the 
development of migraine headache (Ebersberger, 2001; Pietrobon and Striessnig, 2003) and 
these dural afferents seem a likely target for triptans in the relief of migraine. 5-HT1D receptors 
have been found to be localized on peptidergic nociceptors (Potrebic et al., 2003) and it is 
proposed that triptans mediate their anti-migraine effects through inhibition of peptidergic dural 
afferents (Ahn and Basbaum, 2005).  Activation of nociceptors in the dura mater triggers 
neurogenic inflammation as described above and it has been proposed (in the somata of 
nociceptors), that sumatriptan inhibits CGRP and presumably substance P release through the 
inhibition of a variety of Ca2+ channels (P/Q, L and N-type) (Xiao et al., 2008). The inhibition of 
Ca2+ influx and subsequent decrease in neuropeptide release is thought to likely result in the 
resolution of neurogenic inflammation. While mechanisms of sumatriptan’s actions have been 
proposed in the cell bodies of nociceptors as well as the central terminals (Arvieu et al., 1996), a 
study has yet to look at the effect sumatriptan has in the peripheral terminals of nociceptors. 
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1.6 Peripheral µ-opioid receptors 
Opioids have been used for hundreds of years for the treatment of pain and are still 
considered to be the gold standard for the treatment of severe pain and inflammation (Stein and 
Kuchler, 2012). The analgesic effects of opioids occur via activation of opioid receptors (µ, δ, or 
κ) which are G-protein coupled receptors (mainly Gi/Go) that have been found to reduce neuronal 
activity by inhibiting adenylyl cyclase, decreasing the conductance of voltage gated Ca2+ 
channels and/or opening rectifying K+ channels in many neuronal systems (Stein and Zollner, 
2009). 
 Although opioids are very effective analgesics, their use is hampered by side effects such 
as depression of breathing, nausea, clouding of consciousness, constipation, addiction and 
tolerance (Kieffer and Gaveriaux-Ruff, 2002).  
Traditionally the analgesia experienced with the use of opioids was believed to occur 
mainly via inhibition of the CNS and although peripheral anti-nociceptive effects were believed 
to exist with opioid use more than a century ago (Stein, 1993), it wasn’t until the 1980’s that 
evidence began to surface that opioid receptors did indeed exist outside the CNS in peripheral 
sensory neurons (Stein, 1995; Stein et al., 1990).   
All three of the main types of opioid receptors have been found to exist within small-, 
medium-, and large-diameter DRG neurons (Buzas and Cox, 1997; Chen et al., 1997) and have 
been shown to be intra-axonally transported into the neuronal processes (Fields et al., 1980; 
Young et al., 1980) of the peripheral nerve terminals of rodents (Stein et al., 1990) and humans 
(Stein et al., 1996).  
Of the three types of opioid receptors, agonists of the µ-opioid receptor remain the most 
effective analgesics and in the cell bodies of sensory neurons their main inhibitory effect is 
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believed to occur via inhibition of various Ca2+ channels (Stein and Zollner, 2009) and not 
through the modulation of K+ channels (Akins and McCleskey, 1993). Although µ-opioid 
receptor activation in the cell bodies has also been shown to inhibit TRPV1 channels (Endres-
Becker et al., 2007) as well as activate one subtype of G-protein coupled inward-rectifying 
potassium channel (GIRK2) (Nockemann et al., 2013). 
While inhibitory mechanisms of µ-opioid receptor activation identified in the cell bodies 
of nociceptors provides valuable insight, the possibility exists that ion channel prevalence and 
density differ in the peripheral terminals and therefore the mechanisms by which µ-opioid 
agonists cause analgesic and/or anti-inflammatory effects in the pain-sensing terminals remain to 
be established. Identification of mechanisms by which µ-opioid receptor activation leads to 
analgesia in the peripheral terminals of nociceptors will aid in the targeting and development of 
peripherally restricted opioids resulting in analgesia with greatly improved side effect profiles 
(Sehgal et al., 2011).    
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1.7 General hypothesis 
The general hypothesis of this thesis is that the intracranial meninges of mice can be 
used to create a novel ex vivo preparation that allows the study of nociceptive signaling within 
the peripheral terminals of selectively identified dural nociceptors and that this preparation 
will generate novel insights into the mechanisms of peripheral analgesia.  
 
1.8 Thesis objectives   
1) Create an ex vivo preparation that allows for the study of nociceptive signaling within the 
peripheral terminals of nociceptors (Chapter 2). 
2) Provide direct evidence of the axon reflex in an individual branching nociceptor  (Chapter 2). 
3) Study the effect 5-HT1B/D receptor activation has on action potential-evoked Ca2+ transients in 
peripheral CGRP nociceptive terminals (Chapter 3). 
4) Identify the anti-nociceptive mechanism(s) of µ-opioid receptor activation in peripheral CGRP 
nociceptive terminals (Chapter 4). 
5) Extend ex vivo findings from aim (4) in vivo using a behavioural model of nociception and a 
novel peripherally restricted µ-opioid agonist (Chapter 4).  
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CHAPTER 2 
Functional imaging within individual pain fibres ex vivo with optical microscopy 
 
2.1 ABSTRACT 
Here I introduce a simple experimental approach for studying afferent pain fibre 
physiology. I have developed a mouse en bloc dural–skull preparation for optical 
microfluorometric imaging to directly study the physiological functioning in selectively 
identified, individual nociceptive fibre free nerve endings.  Functional optical imaging using 
widefield epifluorescence microscopy was combined with electrophysiological stimulations, 
pharmacological manipulations, and the UV photolysis of caged compounds.  For the first time, I 
show high–resolution functional imaging of single action potential–evoked fluorescent 
transients, as well as sub– and supra–threshold calcium signaling events within individual 
nociceptive fibre terminations.  This novel experimental approach opens up a new window for 
studying nociceptive fibre physiology and pathophysiology. 
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2.2 INTRODUCTION 
Our current understanding of peripheral pain fibre physiology has been almost 
exclusively derived from research in which electrophysiological recordings were made in the 
somata of cultured or acutely dissociated cell preparations taken from sensory ganglion cells –
not from the afferent fibre terminations themselves (Kostyuk and Kostyuk, 2009; Woolf and Ma, 
2007).  Investigating afferent signaling selectively within pain fibres is challenging because the 
majority of nociceptors are thin unmyelinated axon fibres that are inaccessible with conventional 
electrophysiological techniques such as intracellular recording with patch-clamp pipettes.  As 
well, the unmyelinated nociceptive fibres are characteristically located in highly light scattering 
tissues that are not compatible with functional optical imaging. 
Pain sensitivity within the skull is restricted to the intracranial meninges, the system of 
membranes that envelops the brain.  Afferent thinly myelinated Aδ-fibres and unmyelinated C-
fibres of the trigeminal nerve that originate primarily from neurons in the ophthalmic division of 
the trigeminal ganglion densely innervate the meninges, in particular the cranial dura mater 
(Fricke et al., 2001).  Trigeminal innervation of the dura mater serves an exclusive nociceptive 
function (Strassman and Levy, 2006) and despite species differences in brain size and 
organizational complexity, appears remarkably similar across mammals from mice and rat to cat 
and human (Feindel et al., 1960; Leiser and Moxon, 2007; Recober et al., 2009).  I have 
developed a mouse en bloc dural–skull preparation that maintains individual nociceptive fibre 
integrity intact for millimeters and offers unprecedented tissue properties for optical imaging in 
an intact preparation.  Here I introduce a simple imaging approach for studying afferent pain 
fibre physiology using widefield epifluorescence microscopy employing standard optical 
equipment that is widely available to most laboratories. 
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2.3 MATERIALS AND METHODS 
2.3.1 Dissection.   
This work was approved by the University of Saskatchewan’s Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal use.  
Mice (25 wild type; 20 Transgenic Tg [Calca–EGFP] (GENSAT Project at Rockefeller 
University) (1 month – adult) were anaesthetized by intraperitoneal injection of urethane and 
intracardially perfused with ice – cold physiological solution consisting of (in mM): 125 NaCl, 
2.5 KCl, 25 NaHCO3, 10 Glucose, 2 MgCl2, 1.25 NaH2PO4, and 2 CaCl2.  The head was 
removed from the body at the atlanto–occipital joint.  The skin was cut along the skull sagittally 
and gently moved laterally on both sides.  Dissection scissors were then inserted into the foramen 
magnum and the skull with brain was cut laterally below the occipital and parietal bones on both 
sides.  The two lateral cuts were joined sagitally at the ventral section of the frontal bone.  The 
remaining skull and brain was placed in a bath of physiological solution and the brain carefully 
removed from the skull leaving intact dura mater and arachnoid mater layers attached to the 
skull.  The interparietal bone was removed by cutting along the lambdoidal suture and the frontal 
bone removed by cutting along the coronal suture.  Two separate complete parietal bone – dural 
layer preparations were obtained with a remaining cut along the sagittal suture.  Individual 
dural–skull preparations were placed dural layer up in a microscope chamber and perfused with 
physiological saline, gravity fed at a flow rate of 3 ml/min and maintained at either 25 ± 0.5 or 
35 ± 0.5 oC with an inline heater (Warner Instruments). 
2.3.2 Calcium indicator application.   
Afferent nociceptive fibres were selectively loaded with the membrane permeant high 
affinity Ca2+ indicator Rhod–2 AM (Invitrogen) by applying a small piece of indicator solution 
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soaked Surgifoam® to the rostral area of the preparation for 10 – 20 seconds.  The 1mM 
indicator solution was made up fresh each day in physiological solution containing 5% Pluronic 
F–127/DMSO. 
2.3.3 Widefield epifluorescence microscopy.   
 I used the X–Cite 120PC system (EXFO Electro–Optical Engineering Inc.) light source 
(12% intensity) directly coupled to an Olympus BX51WIF upright research microscope by a 3 m 
liquid light guide. The light intensity was attenuated with two neutral density filters in series 
(Olympus N.D.25 and N.D.6) and shutter controlled with a ProScan II Controller (Prior 
Scientific).  The illumination and fluorescence light was filtered using either a TRITC filter set 
(41002 Olympus BX2 mounted -HQ535/50x HQ610/75m Q565LP), a FITC filter set (41001 
Olympus BX2 mounted -HQ480/40x HQ535/50m Q505LP), or a Cy5™ filter set (41024 
Olympus BX2 mounted -HQ620/60x HQ665lp Q660lp).  Epifluorescence was detected with two 
high sensitivity cooled CCD cameras - the 16-bit, 512x512 ImagEM EM CCD Camera (C9100-
13, Hamamatsu) cooled to -65°C and the 16-bit, 1344 x 1024 ORCA-R2 CCD camera (C10600-
10B, Hamamatsu) cooled to -35°C.  Images were acquired using variable frame rates, binning, 
and defined regions of interst. 
2.3.4 UV photolysis.   
Photorelease of caged compounds was achieved using a 355 nm wavelength, diode 
pumped solid–state laser (DPSL-355-30, Rapp Optoelectronic GMBH) capable of 30 mW output 
power and 10 kHz (3 µJ/pulse) repetition rate.  UV light was coupled to the microscope using a 
homemade optical alignment system.  The UV beam from a 100 µm core quartz light guide was 
directed through focusing optics and a 5x beam expander BXUV-4.0-5X-355 (CVI Laser) to a 
custom built beamsplitter (zt355/650rpc 25.5x36x1.5 mm sputtered laser polychroic, Chroma 
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Technology Corp.) that was seated at the back aperture of the objective. With this set up I 
achieved focal uncaging by diffraction limited spot illumination. 
2.3.5 Morphological two–photon laser imaging.   
I performed two–photon imaging using a custom modified Olympus BX51WIF upright 
research microscope interfaced with an Ultima–X-Y laser–scanning module (Prairie 
Technologies Inc.) directly coupled to a Mai Tai XF (Spectra Physics) mode–locked Ti: sapphire 
laser source.  EGFP and Alexa Fluor 594 fluorophores were excited at 920 nm and 780 nm 
respectively.  Images were acquired using high numerical aperture, long working distance, water 
immersion Olympus objective lenses (either a LUMPLFL 40XW/IR-2 40X or a UMPLFLN 
10X) and the epifluorescence detected with two top–mounted low dark current (<10 nA) high 
sensitivity (>8500 A/lumen) external PMT detectors (Hamamatsu).  Emission of the relevant 
wavelengths was simultaneously acquired with the use of selective emission bandpass 510 nm 
(40 nm bandpass) and 605 nm (55 nm bandpass) filters. 
2.3.6 Electrical stimulation.   
A Master 8-CP, software controlled 8-channel pulse stimulator and ISO–Flex stimulus 
isolator unit  (A.M.P.I.) were used to deliver electrical stimulations via 1µm bipolar tungsten 
electrodes (WPI).  Stimulation intensity was kept just above threshold to elicit action potentials 
(140–180 µA for a duration of 100 µs) and was not adjusted throughout the course of an 
experiment. 
2.3.7 Immunohistochemistry.   
En bloc dural–skull preparations were dissected as described above and placed in 2% 
paraformaldehyde for 15 minutes.  Preparations were then rinsed with 1X phosphate buffered 
saline (PBS) 4 times for 5 minutes each before being placed in a blocking solution consisting of 
	   39	  
10% goat serum, 1% bovine serum albumin (BSA), and 1xPBS containing 0.3% triton for 60 
minutes.  The primary antibody, rabbit anti–α–CGRP (Penninsula Laboratories), was then 
diluted 1:10000 with 10% goat serum, 1% BSA, and 1xPBS containing 0.3% triton and the 
preparations incubated at 4oC overnight.  The following day the preparations were then rinsed 
with 1xPBS 4 times for 5 minutes each.  The secondary antibody, Alexa Fluor 594 goat anti–
rabbit IgG (Invitrogen), was diluted to 1:100 with 1×PBS containing 0.3% triton and the 
preparations incubated at 4oC for 1 hour.  The preparations were then rinsed 4 times for 5 
minutes each and then viewed with epifluorescence and two–photon microscopy. 
2.3.8 Drugs.   
Tetrodotoxin (1µM) (Alomone Labs), capsazepine (10µM) (Sigma) and the selective 
TRPV1 custom caged molecule BCMACMOC–caged capsaicin (1µM) were bath applied.  For 
Ca2+ photolysis experiments, dural–skull preparations were incubated for 10 minutes in 
physiological solution containing the cell permeant form of the Ca2+ cage o–nitrophenyl EGTA, 
AM (NP–EGTA, AM) (Invitrogen) at 30µM and 0.5% DMSO.  The myelin stain FluoroMyelin 
Red® (Invitrogen) was bath applied (10 ml), diluted from the stock solution 100×.  Isolectin GS-
IB4 from Griffonia simplicifolia, AlexaFluor™ 647 conjugate (Invitrogen) was diluted to 1.5 
µg/25 ml and bath applied. 
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2.4. RESULTS 
2.4.1 En bloc dural–skull preparation 
The cranial dura mater consists of two layers: an outer periosteal layer that lines the 
internal surface of the cranial cavity and an inner meningeal layer adjacent to the arachnoid 
membrane that borders the cerebrospinal fluid-filled subarachnoid space.  I find that careful 
removal of the brain leaves behind intact dura and arachnoid mater layers attached to the skull 
along with nociceptive fibres embedded in the periosteal layer of the dura that run adjacent to the 
calvaria (Figure 2.1).  Periosteal nociceptive fibres were selected for experimentation by 
removing complete parietal bones with intact dural layers from the mice and placing the en bloc 
dural–skull preparations dural layer up in an upright research microscope perfusion chamber 
(Figure 2.2A–D).  Individual nociceptive fibre integrity is preserved intact for millimeters, well 
protected on one side by the calvaria and by the dural layers on the other.  The thinness of the 
mouse dural layer (~10 µm) that is maintained over the expanse of the parietal skull bone (~5 × 5 
millimeters) offers unprecedented tissue properties for optical imaging in an intact preparation 
and offers a unique opportunity for studying the physiology of afferent pain fibres (Figure 2.3A 
and B).   
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Figure 2.1 Nociceptive innervation in the cerebral dura mater. 
Boxed area in the coronal image of a mouse brain and skull marks the zoomed up area below 
showing the structural organization of the meninges and highlights the nociceptive fibres (green 
circles) protected by the calvaria above and the dural layers below. The brain is removed at the 
level of the subarachnoid space, with broken arachnoid trabeculae shown. CA; calvaria, DM(p); 
periosteal dura mater, DM(m); meningeal dura mater, AM; arachnoid mater, SAS; subarachnoid 
space, PM; pia mater, CO; cortex. 
 
 
 
	   42	  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. En bloc dural–skull preparation for imaging nociceptive fibre free endings. 
A) The complete parietal skull bone used in the dural–skull preparation is highlighted in white in 
this mouse skull image.  The arrow marks the anatomical location of the coronal section (B).  
C) The ventral aspect of the dural layers allows for optical imaging of the nociceptive fibres as 
well as simultaneous micropipette access during experiments that may involve electrical 
stimulation as well the pressure injection of drugs. D) The boxed area taken from (C) shows the 
structural organization of the dural layers and highlights the nociceptive fibres for imaging 
(green circles); CA; calvaria, DM(p); periosteal dura mater, DM(m); meningeal dura mater, AM; 
arachnoid mater. 
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Figure 2.3. CGRP innervation of the dura. 
A) Sequential images taken across a portion of the preparation highlight the dense network of 
CGRP nociceptive fibres.  The asterisk highlights the location of the terminal fibre shown in (B) 
at higher magnification. Scale bars; A) 300 µm; B) 50 µm 
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2.4.2 Selective nociceptive fibre identification 
It is common practice to classify nociceptive neurons depending on whether they contain 
peptides such as calcitonin gene-related peptide (CGRP).  Peptidergic and non-peptidergic 
neurons express different repertoires of ion channels and receptors involved in signal 
transduction and innervate distinct peripheral and central targets (Woolf and Ma, 2007).  The 
neuropeptide calcitonin gene–related peptide (CGRP) is conspicuously enriched in the trigeminal 
ganglion, the region that contains the highest concentration of CGRP–expressing neurons (–50% 
of the neurons store CGRP) (Uddman et al., 1986) and the cranial dura is well innervated by a 
dense network of CGRP fibres (Strassman et al., 2004).  To study CGRP nociceptive signaling 
mechanisms I selectively identify CGRP fibres using a fluorescent transgenic CGRP-EGFP 
mouse (Figure 2.3A and B; Figure 2.4 and 2.5).  Non-peptidergic nociceptors possess 
membrane-associated glycoconjugates that bind the plant lectin Isolectin B4 from Griffonia 
simplicifolia and have been shown in the dura to constitute a fibre population distinct from those 
containing CGRP (Soyguder, 1999).  For the selective identification of non-peptidergic dural 
nociceptive fibres I briefly perfuse a 25 ml solution containing fluorescently tagged IB4 that 
brightly labels the membranes of the fibres (Figure 2.6A-C).  I combined IB4 labeling with the 
Ca2+ indicator Rhod-2 (Figure 2.6B) for functional imaging studies (see below).  All functional 
imaging experiments (below) were performed on unmyelinated nociceptive fibres.  Myelinated 
fibres were easily identified in the IR–transmitted image (Figure 2.7A) and confirmed with a 
brief perfusion of a 10 ml solution containing the myelin stain FluoroMyelin Red® (Figure 2.7A 
– C). 
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Figure 2.5. Immunohistochemical confirmation of dural α-CGRP-EGFP in the α-CGRP-
EGFP transgenic mouse. 
A) α-CGRP-EGFP expressing fibres in the dura mater from the transgenic mouse. B) The anti α-
CGRP antibody (Alexa Fluor 594) confirms the pattern of expression of the α-CGRP-EGRP 
fibres in the dura mater; merged image (C). 
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Figure 2.6. Identification of nonpeptidergic fibres in the dura with conjugated IB4. 
A) Image of an isolectin B4-positive nonpeptidergic labeled fibre taken with widefield 
epifluorescence imaging at high magnification highlights the membrane patterned labeling 
(arrows) and contrasts the cytosolic labeling of the calcium indicator Rhod-2 (B) and merged 
images (C). 
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Figure 2.7. Identification of myelinated A-delta fibres in the dura. 
A) Myelinated fibres are easily identified with widefield IR–transmitted imaging.  FluoroMyelin 
Red ™ labeled myelin fibres seen using standard epifluorescence and CCD camera detection (B) 
confirms the identical fibres seen with transmitted imaging; merged image (C).  Scale bar 50 µm. 
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2.4.3 Functional imaging in pain fibres 
Here I demonstrate that high–resolution functional imaging can be performed on 
individual pain fibres in the dural–skull preparation.  In neurons, action potentials trigger large 
and rapid changes in cytosolic free Ca2+ and imaging with fluorescent Ca2+ indicators has been 
widely used to monitor neuronal spiking across populations of CNS neurons.  I find that very 
brief (10 – 20 sec) application of the Ca2+ indicator Rhod–2 loads peripheral pain fibres and that 
single action potential-evoked Ca2+ transients with large signal–to–noise ratios may be imaged 
within individual fibres (ΔF/F = 19.8 ± 1.2%, 72 fibres in n = 60 preparations) over long 
experimental periods without decrement (ΔF/F % control = 100 ± 3.2% at the 80 minute 
experimental time point, n = 4) (Figure 2.8A and B).  We performed a series of experiments to 
verify that the Ca2+ transients were the result of action potentials evoked from the electrical 
stimulation.  Stimulation within 10 µm of the afferent termination sites of the pain fibres evoked 
‘all–or–none’ Ca2+ transient responses during experiments of: 1) variable stimulus intensity; 140 
µA: (ΔF/F = 100 ± 4.9%) vs no transient observed at 110 µA stimulation: (ΔF/F = -0.2 ± 0.2%, 
n = 5), 2) TTX added; physiological solution: (ΔF/F = 100 ± 8.5%) vs no transient observed 
once TTX was added to the solution, +TTX: (ΔF/F = -1.1 ± 0.1%, n = 5), and 3) zero Ca2+: 2 
mM Ca2+: (ΔF/F = 100 ± 2.5%), vs no transient observed once Ca2+ was removed from the 
solution, 0 mM Ca2+: (ΔF/F = -1.6 ± 0.2%, n = 5) (Figure 2.9A and B).   
Next I show that UV photolysis experiments may be performed both in and at individual 
pain fibres.  Ca2+ transients from the photolysis of the Ca2+ cage NP–EGTA imaged at the site of 
photolysis in the fibre (ΔF/F = 135 ± 21.2%, n = 9), 30 µm away (ΔF/F = 50.1 ± 8.2%, n = 9), 
and 60 µm away (ΔF/F = 4.2 ± 0.8%, n = 9) are shown in (Figure 2.10A above; B left).  The 
transient receptor potential vanilloid 1 (TRPV1) receptor/channel is a polymodal sensor and 
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molecular integrator of a wide range of painful stimuli that is activated directly by capsaicin, the 
natural compound responsible for the sharpness of hot chili peppers (Clapham, 2003; Szallasi et 
al., 2007).  TRPV1 sensitivity to capsaicin is considered a principal pharmacological trait of 
lightly myelinated Aδ– and unmyelinated C–fibre nociceptors and is a hallmark for identifying 
primary afferent fibres as nociceptors (Kostyuk and Kostyuk, 2009).  Ca2+ transients from the 
photolysis of the novel and selective TRPV1 custom caged molecule BCMACMOC–caged 
capsaicin (Gilbert et al., 2007) at the pain fibre (ΔF/F = 108 ± 48%) as well as the block by the 
TRPV1 antagonist capsazepine (ΔF/F = -0.9 ± 0.2%, n = 8) is shown in (Figure 2.10A below; B 
right). 
Finally, I show an example of the ‘axon reflex’ in a CGRP peptidergic pain fibre.  The 
‘axon reflex’ theory posits a mechanism whereby both afferent and efferent impulse activity may 
occur in the same primary afferent sensory neuron at a point of bifurcation: “…a stimulus 
applied to one branch of a nerve, which sets up an impulse that moves centrally to the point of 
division of the nerve, where it is reflected down the other branch…” (Dorland, 2003).  This 
concept was originally proposed by Bruce 100 years ago (Bruce, 1913) and remains in current 
textbooks of physiology essentially unchanged from its original description.  Figure 2.11 shows 
an example of the axon reflex in a CGRP peptidergic pain fibre.  Stimulation (A) of the fibre 
termination at location (1) initiated afferent impulse activity that could be seen proximally as a 
Ca2+ transient at location (3), while at the same time efferent impulse activity caused a Ca2+ 
transient in the distal fibre termination at location (2).  Similarly, stimulation (B) of the fibre 
termination at location (2) initiated afferent impulse activity seen proximal as a Ca2+ transient at 
location (3), while at the same time, efferent impulse activity caused a Ca2+ transient in the distal 
fibre termination at location (1).  Importantly, both afferent and efferent action potential-evoked 
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Ca2+ transients are of equal amplitude at both distal fibre locations (1 + 2), as indicated by the 
ratio of transients resulting from stimulations (A + B)  
Location 1 ΔF/F(A)/ ΔF/F(B) = 102 ± 9% (n = 5)  
Location 2 ΔF/F(A)/ ΔF/F(B) = 98 ± 4% (n = 5) 
This physiological phenomenon seems to be well conserved as I found that the axon reflex 
occurred in all CGRP dural nociceptive fibres I tested for it in (n = 13 preparations). 
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Figure 2.9. Confirmation of action potential-induced Ca2+ transients. 
A) Electrical stimulation at afferent termination sites of the pain fibres (≤10µm) evoked ‘all–or–
none’ Ca2+ transient responses during experiments of; variable stimulus intensity (140 µA or 110 
µA) (upper), TTX (middle), and zero Ca2+ (bottom) conditions.  B) Bar graph summaries (ΔF/F; 
% control) of the experimental conditions seen in (A); (n = 5 for all conditions). Scale bars: 2 s, 
10% ΔF/F. 
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Figure 2.10. Molecular uncaging in and around nociceptive terminals. 
A) (above) Ca2+ transients showing the photolysis of the Ca2+ cage NP–EGTA imaged at the site 
of photolysis on the fibre (1), 30µm away (2), and 60µm away (3).  (below) Photolysis of the 
selective TRPV1 custom caged molecule BCMACMOC–caged capsaicin (4) is blocked with the 
TRPV1 antagonist capsazepine (5).  B) Bar graph summaries (ΔF/F) of the caged NP–EGTA (n 
= 9) and BCMACMOC–caged capsaicin (n = 8) photolysis experiments (numbers below bar 
summaries mark the experimental conditions under which the individual transients seen in (A) 
were acquired). Scale bars: above 3 s, 30% ΔF/F; below 2 s, 40% ΔF/F 
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Figure 2.11. The “axon reflex” in dural CGRP fibres. 
Image montage shows the peripheral region (>1500µm) of a CGRP–EGFP pain fibre.  Two 
distal terminations (1 + 2) after a bifurcation point as well as a more proximal region (3) are 
highlighted (white boxes) and at higher magnification to show the locations of the imaged Ca2+ 
transients (A + B).  Ca2+ transients (A or B) imaged at each location resulted from stimulation of 
either distal termination location (1 or 2) displayed here as stimulation pipettes marked  (A or B) 
respectively.  Evoked Ca2+ transients are shown to be of equal amplitude at both distal fibre 
locations (1 + 2), displayed as the ratio of transients resulting from stimulations (A + B).  Ca2+ 
transients were imaged at 25oC. Scale bars: all transients 2 s, 10% ΔF/F; 25 µm and 200 µm. 
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2.5 DISCUSSION 
I have introduced an experimental imaging approach to directly study physiological 
functioning within selectively identified nociceptive fibre free nerve endings that terminate in the 
cranial dura mater.  I have developed an en bloc mouse dural–skull preparation that preserves 
individual nociceptive fibre integrity for millimeters.  The thinness of the mouse dural layer that 
is maintained over the expanse of the parietal skull bone offers unprecedented tissue properties 
for optical microfluorometric imaging in an intact preparation.  To my knowledge, this is the first 
study to show high–resolution functional imaging selectively within individual nociceptive fibre 
terminations.   
Unmyelinated nociceptive fibre terminations have been shown to outnumber myelinated 
fibres in the parietal dura mater by a ratio of 10:1 (Fricke et al., 2001).  Because the small size of 
the unmyelinated nerve endings makes them inaccessible with conventional electrophysiological 
techniques I applied widefield epifluorescence microscopy to image action potential–evoked 
Ca2+ signaling as a means for measuring neuronal spiking.  I found that single action potential-
evoked ‘all–or–none’ Ca2+ transients with large signal–to–noise ratios could be imaged 
selectively within unmyelinated nociceptive fibre free nerve endings (~1 µm diameter).  High–
resolution functional imaging could be performed over long experimental periods without 
decrement, demonstrating the stability of the preparation for examining terminal afferent 
physiology and pathophysiology. 
The nature of the afferent signal depends on a complex interaction between the 
distribution, density, and biophysical properties of ion channels and molecular transducers 
present in the afferent terminals, as well as the morphological features of the terminal arbor 
(Kostyuk and Kostyuk, 2009; Woolf and Ma, 2007).  Significant quantitative differences may 
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exist between the patterns of expression of ion channels and signaling systems in the somata and 
peripheral processes of the afferent neuron.  Yet, the active membrane properties of the afferent 
neuron soma and its peripheral terminal endings are most commonly considered identical, and 
the very real possibility of significant quantitative differences has usually been neglected 
(Kostyuk and Kostyuk, 2009).  High–resolution functional optical imaging in the en bloc dural–
skull preparation now provides an opportunity to begin to study the fundamental physiological 
processes of activation, transduction, sensitization, and propagation of the nociceptive signal in 
peripheral pain fibre terminations.  This opens up a new window for examining physiological 
functioning in peripheral nociceptive fibres and to advance our understanding of the peripheral 
processes involved in pain pathophysiology. 
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Chapter 3 
 
Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP 
terminal fibres 
 
3.1 ABSTRACT 
The selective 5-HT1 receptor agonist sumatriptan is an effective therapeutic for migraine 
pain yet the antimigraine mechanisms of action remain controversial.  Pain-responsive fibres 
containing calcitonin gene-related peptide (CGRP) densely innervating the cranial dura mater are 
widely believed to be an essential anatomical substrate for the development of migraine pain.  
5HT1 receptors in the dura colocalize with CGRP fibres and thus provide a possible peripheral 
site of action for sumatriptan.  In the present study, I used high-resolution optical imaging within 
individual mouse dural CGRP nociceptive fibre terminations and found that application of 
sumatriptan caused a rapid, reversible concentration-dependent inhibition in the amplitude of 
single action potential-evoked Ca2+ transients.  Pre-application of the non-selective 5-HT1 
antagonist GR127935 or the selective 5-HT1D antagonist BRL 15572 prevented inhibition while 
the selective 5-HT1B antagonist SB 224289 did not, suggesting this effect was mediated 
selectively through the 5-HT1D receptor subtype.  Sumatriptan inhibition of the action potential- 
evoked Ca2+ signaling was mediated selectively through N-type Ca2+ channels.  Although the T-
type Ca2+ channel accounted for a greater proportion of the Ca2+ signal, it was not affected by the 
sumatriptan inhibition.  My findings support a peripheral site of action for sumatriptan in 
inhibiting the activity of dural pain fibres selectively through modulation of a single Ca2+ 
channel subtype.  This finding adds to our understanding of the mechanisms that underlie the 
clinical effectiveness of 5HT1 receptor agonists such as sumatriptan and may provide insight for 
the development of novel peripherally targeted therapeutics for mitigating the pain of migraine. 
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3.2 INTRODUCTION 
 The serotonin 5-HT1 receptor agonist sumatriptan and the other triptans are selective and 
effective therapies for the acute treatment of migraine pain (Bigal et al., 2009; Moskowitz and 
Cutrer, 1993; Sprenger and Goadsby, 2009; Tfelt-Hansen et al., 2000; Tfelt-Hansen and Koehler, 
2011).  However, despite the success of the triptans in the clinical setting, the anatomical locus 
of their antimigraine activity remains unresolved, and both peripheral and central nervous system 
sites of action are likely (Ahn and Basbaum, 2005; Akerman et al., 2011; Bartsch et al., 2004; 
Durham and Russo, 2002; Humphrey and Feniuk, 1991; Lambert, 2010; Levy et al., 2004; 
Mehrotra et al., 2008; Tfelt-Hansen, 2010).  Beyond providing insight into migraine 
neuropathology, understanding the anatomical locus of their action may lead to the development 
of novel therapeutics to better manage the disorder, and so continues to be an area of intense 
investigation. 
 The neuropeptide calcitonin gene-related peptide (CGRP) is hypothesized to play an 
important role in migraine pathology (Durham, 2008; Ho et al., 2010).  Serum levels of CGRP 
have been shown to be increased during migraine attack (Goadsby et al., 1990), although, this 
observation has been questioned (Tvedskov et al., 2005), migraine patients infused with CGRP 
develop a delayed headache, that meets the criteria of a migraine (Lassen et al., 2002), and 
infusion of CGRP receptor antagonists has been shown to effectively treat migraine pain 
(Durham and Vause, 2010; Fischer, 2010; Hoffmann and Goadsby, 2011).  Importantly, 
treatment of migraine headache pain with sumatriptan has been shown to correlate with 
normalization of CGRP levels –an effect that paralleled migraine resolution (Edvinsson and Ho, 
2010; Goadsby and Edvinsson, 1993; Sarchielli et al., 2006; Stepien et al., 2003). 
 CGRP fibres that originate from the trigeminal ganglion densely innervate the 
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intracranial meninges, in particular the cranial dura mater (Messlinger et al., 1993; Strassman et 
al., 2004) and this innervation is hypothesized to be the essential anatomical substrate for the 
development of migraine pain (Messlinger, 2009; Olesen et al., 2009; Pietrobon and Striessnig, 
2003).  5-HT1 receptors colocalize with CGRP immunoreactive fibres in the cranial dura and the 
antimigraine actions of sumatriptan may involve the inhibition of CGRP release from these 
terminals (Hargreaves, 2007; Harriott and Gold, 2008; Ho et al., 2010; Longmore et al., 1997).  
Consistent with this proposal, elevated CGRP levels after stimulation of the trigeminal ganglion 
are normalized with sumatriptan treatment both in animal models and in humans (Buzzi et al., 
1991; Goadsby and Edvinsson, 1993; Limmroth et al., 2001) and in primary cultures from rat 
trigeminal ganglia, CGRP secretion under conditions simulating migraine pathology is inhibited 
by sumatriptan (Durham and Russo, 1999). 
 I have recently introduced a new experimental approach that, for the first time, allows 
examination of the peripheral signaling processes selectively within individual CGRP terminal 
pain fibres in the dura (Baillie et al., 2011).  In the present study, I use high-resolution optical 
imaging to directly test the hypothesis that 5-HT1 receptor activation by sumatriptan has a 
peripheral site of action by inhibiting action potential mediated Ca2+ signaling in terminals of 
CGRP pain fibres.  
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3.3 MATERIALS AND METHODS  
3.3.1 Dissection  
This work was approved by the University of Saskatchewan's Animal Research Ethics 
Board, and adhered to the Canadian Council on Animal Care guidelines for humane animal use.  
41 Transgenic mice Tg (Calca-EGFP) (GENSAT Project at Rockefeller University) (1 month-
adult) were dissected as previously described (Baillie et al., 2011).  Briefly, the head from an 
anaesthetized animal was removed from the body at the atlanto–occipital joint.  The skin was cut 
along the skull sagittally and gently moved laterally on both sides.  Dissection scissors were then 
inserted into the foramen magnum and the skull with brain was cut laterally below the occipital 
and parietal bones on both sides.  The two lateral cuts were joined sagitally at the ventral section 
of the frontal bone.  The remaining skull and brain was placed in a bath of physiological solution 
and the brain carefully removed from the skull leaving intact dura mater and arachnoid mater 
layers attached to the skull.  The interparietal bone was removed by cutting along the lambdoidal 
suture and the frontal bone removed by cutting along the coronal suture.  Two separate and 
complete parietal bone-dural layer preparations were obtained with a remaining cut along the 
sagittal suture.  Individual dural-skull preparations were placed dural layer up in a microscope 
chamber and continuously perfused with physiological saline consisting of (in mM): 125 NaCl, 
2.5 KCl, 25 NaHCO3, 10 Glucose, 2 MgCl2, 1.25 NaH2PO4, and 2 CaCl2. 
3.3.2 Calcium indicator application 
  All functional imaging experiments were performed on unmyelinated nociceptive fibres 
(Baillie et al., 2011).  Afferent nociceptive fibres were selectively loaded with the membrane 
permeant high affinity Ca2+ indicator Rhod-2 AM (Biotium) by applying a small piece of 
indicator solution soaked Surgifoam® to the rostral area of the preparation for 10 - 20 s.  The 
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220 µM indicator solution was made up fresh each day in physiological solution containing 5% 
Pluronic F-127/DMSO. 
3.3.3 Immunohistochemistry  
Dural skull preparations were dissected as above and placed in 10% formalin for 15 
minutes.  Preparations were then rinsed in 0.01 M phosphate buffered saline (PBS) 3 times for 10 
minutes each before being placed in a blocking solution consisting of 10% goat serum, 1% 
bovine serum albumin (BSA) and 0.01 M PBS containing 0.3% triton for 60 minutes.  A custom 
primary antibody for the 5-HT1D receptor (Potrebic et al., 2003) was diluted to 1:60000 with 5% 
goat serum, 1% BSA, and 0.01 M PBS containing 0.3% triton and preparations added to this 
mixture and incubated at room temperature for 48 hours.  Preparations were then rinsed in 0.01 
M PBS containing 1% goat serum 3 times for 10 minutes each.  The secondary antibody, Alexa 
Fluor 594 goat anti-rabbit IgG (Invitrogen) was diluted to 1:500 with 0.01 M PBS containing 1% 
goat serum and the preparations incubated at room temperature for 1 h.  The preparations were 
then rinsed 3 times for 10 minutes each before imaging. 
3.3.4 Widefield epifluorescence microscopy  
I used the X-Cite 120PC system (EXFO Electro-Optical Engineering Inc.) light source 
(12% intensity) directly coupled to an Olympus BX51WIF upright research microscope by a 3 m 
liquid light guide. The light intensity was attenuated with two neutral density filters in series 
(Olympus N.D.25 and N.D.6) and shutter controlled with a ProScan II Controller (Prior 
Scientific). The illumination and fluorescence light was filtered using a TRITC filter set, a FITC 
filter set, or a Texas Red filter set.  Epifluorescence was detected with two high sensitivity 
cooled CCD cameras.  The 16-bit, 512 × 512 ImagEM EM CCD Camera (C9100-13, 
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Hamamatsu) cooled to -65 °C and the 16-bit, 1344 × 1024 ORCA-R2 CCD camera (C10600-
10B, Hamamatsu) cooled to -35 °C. 
3.3.5 Analysis of calcium signals  
Images were acquired at 20 frames/s using 2 × 2 binning and a minimum number of total 
images taken to reduce photodynamic damage.  Increasing fluorescence baseline, steadily 
diminishing transients, and/or changes in fibre morphology were considered indicative of 
photodynamic damage, and fibres showing these changes were discarded.  Fluorescence signals 
were converted to relative fluorescence changes over time and expressed in percentages, defined 
as ΔF/F = ((F1 - B1) - (F0 - B0))/(F0 - B0), where F1 and F0 are fluorescence in the terminal fibre 
at any given time point and at the beginning of the experiment, respectively, and B1 and B0 are 
the background fluorescence at any given time point and at the beginning of the experiment, 
respectively.  Background values were taken from an adjacent area located at least 10 µm from 
imaged areas.  To quantify the magnitude of fluorescence change, the peak amplitude of the 
transient was measured.  During drug application, responses were considered stable if < 5% 
variability was observed over the ~ 10 min control period and baseline fluorescence did not 
change.  The average magnitude of the Ca2+ transients before drug application was set as 100%, 
and the average of four Ca2+ transients in stable drug and wash conditions normalized to predrug 
conditions was taken as the magnitude of drug effect and drug recovery, respectively.  Results 
are shown as means ± s.e.m.  Statistical analysis was done using an independent group t - test 
(two-tailed); significance was achieved when P < 0.05. 
3.3.6 Electrical stimulation  
A Master 8 - CP, software controlled 8-channel pulse stimulator and ISO-Flex stimulus 
isolator unit (A.M.P.I.) were used to deliver electrical stimulations via 1 µm bipolar tungsten 
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electrodes (WPI).  Stimulation intensity was kept just above threshold to elicit action potentials 
(140 - 180 µA for a duration of 100 µs) and was not adjusted throughout the course of an 
experiment. 
3.3.7 Drugs  
Sumatriptan (500 nM - 40 µM) (Sigma), GR 127935 (300 nM) (Tocris), BRL 15572 (10 
nM) (Tocris), SB 224289 (10 nM) (Tocris), nifedipine (10 µM) (Sigma), ω-conotoxin GVIA (1 
µM) (Alomone labs), ω-agatoxin IVA (200 nM) (Alomone labs), and NNC 55-0396 
dihydrochloride (20 µM) (Tocris) were all bath applied.  
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3.4 RESULTS 
3.4.1 Sumatriptan inhibition of action potential evoked Ca2+ transient amplitude. 
 To study Ca2+ signaling in the terminals of CGRP-containing nociceptive fibres I 
selectively identified individual fibres using a fluorescent transgenic CGRP-EGFP mouse 
(Baillie et al., 2011).  Single action potential mediated Ca2+ transients were evoked by electrical 
stimulation (single pulse, 140 - 180 µA; 100 µs) at distances greater than 500 µm proximal to the 
distal fibre terminations (Figure. 3.1).  I found that bath application of sumatriptan caused a 
concentration-dependent inhibition in the amplitude of the evoked Ca2+ transient (500 nM – 40 
µM; n=5 for each concentration) (Figure. 3.2).  The lowest concentration of sumatriptan to 
achieve maximal inhibition (20 µM) was used in all subsequent experiments.  I used a custom 
primary antibody for the 5-HT1D receptor (Potrebic et al., 2003) because the serotonin 5-HT1D 
receptor subtype has been shown to be selectively expressed in primary afferent neurons and not 
in peripheral tissues (as the 5-HT1B receptor) (Longmore et al., 1997), and found punctate 5HT1D 
immunoreactive labeling in the CGRP terminating nociceptive fibres (Figure. 3.3).  I performed 
Ca2+ transient amplitude timecourse experiments and found that bath application of sumatriptan 
caused a rapid reversible inhibition in the amplitude of the Ca2+ transient (40.8 ± 1.4%; n=7) 
(Figures. 3.4 + 3.5).  Below the time course traces are examples of action potential-evoked Ca2+ 
transients before, during and after washout of sumatriptan.  Sumatriptan-mediated inhibition in 
the amplitude of the Ca2+ transient was prevented by pre-application of the 5-HT1 antagonist 
GR127935 (300 nM) or the selective 5-HT1D antagonist BRL 15572 (10 nM); Ca2+ transients 
remained at 102.7 ± 3.3%; n=5 and 99.7 ± 1.4%; n=5 of control conditions respectively (Figure. 
3.4+3.5).  Pre-application of the selective 5-HT1B antagonist SB 224289 (10 nM) did not block 
the sumatriptan-mediated inhibition in the amplitude of the Ca2+ transient; Ca2+ transients 
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decreased to 63.7 ± 1.0%; n=5 of control conditions (Figures. 3.4 + 3.5).  It should be noted that 
sumatriptan does not affect the baseline (un-evoked) Ca2+ signal in terminal CGRP fibres (98.9 ± 
0.5% of control; n=6) in contrast to studies performed in primary cultures of trigeminal neurons, 
where a large sustained Ca2+ influx was noted (Durham and Russo, 1999, 2003). 
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Figure 3.1. A typical imaging region and action potential-evoked fluorescent Ca2+ response 
in a CGRP-EGFP terminating nociceptive fibre. 
A CGRP-EGFP terminating nociceptive fibre showing a typical region from which fluorescent 
transients were acquired and quantified, along with a pseudocolour inset of baseline Rhod-2 
fluorescence (F0), and a single action potential-evoked signal (F1) with the corresponding 
transient displayed above. Scale bar: 20 µm. 
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Figure 3.2.  Sumatriptan causes a dose-dependent decrease in action potential-evoked Ca2+ 
transient amplitude. 
The sumatriptan dose-response curve shows that the amplitude of the Ca2+ transient is inhibited 
with increasing concentrations of sumatriptan. 
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Figure 3.3. Immunohistochemical confirmation of 5HT1D receptor expression in dural 
CGRP fibres. 
5-HT1D receptors are co-localized with terminating CGRP nociceptors.  (Left) CGRP-EGFP 
terminating nociceptive fibre shows punctate terminal immunoreactive labeling with a 5-HT1D 
antibody (middle and merge). Scale bar: 20 µm. 
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Figure 3.4.  Sumatriptan causes a rapid, reversible decrease in action potential-evoked Ca2+ 
transient amplitude via activation of 5HT1D receptors. 
Graph of Ca2+ transient amplitude timecourse experiments showing the effect of sumatriptan 
application in control conditions (solid circles), in the presence of the selective 5-HT1 receptor 
antagonist GR127935 (hollow circles), the selective 5-HT1D antagonist BRL 15572 (solid 
squares), and the selective 5-HT1B antagonist SB 224289 (hollow squares).  Individual example 
transients during control, sumatriptan, and wash conditions taken at the relative timepoints on the 
graph are shown below. 
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Figure 3.5. Sumatriptan-mediated reduction in Ca2+ transient amplitude occurs via 5HT1D 
receptors. 
Bar graph summary showing that the sumatriptan reduction in the amplitude of Ca2+ transients 
was completely reversible with wash, blocked by the 5-HT1B/D antagonist GR 127935 and the 5-
HT1D antagonist BRL 15572, and was not by the 5-HT1B antagonist SB 224289.  
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3.4.2 Sumatriptan inhibition of N-type Ca2+ channel mediated signaling 
 I have previously shown that action potential-evoked Ca2+ signaling in the terminals of 
CGRP-containing nociceptive fibres was dependent on extracellular Ca2+ suggesting that it 
depends on an influx through Ca2+channels (Baillie et al., 2011).  To examine the inhibitory Ca2+ 
signaling action of 5HT1 receptor activation by sumatriptan I first performed a series of selective 
Ca2+ channel block experiments to determine which Ca2+ channels mediate the action potential 
evoked Ca2+ signaling.  I found that block of P/Q-type Ca2+ channels by ω-agatoxin IVA (200 
nM) and block of L-type Ca2+ channels by nifedipine (10 µM) had no effect on action potential 
evoked Ca2+ transients (101.1 ± 1.5%; n=7 and 100.5 ± 1.4%; n=7 respectively; Figure 3.6A, B + 
3.9).  The low voltage activated T-type Ca2+ channel is known to exist in high density in 
nociceptors and is likely involved in central and peripheral nociceptive processing (Todorovic 
and Jevtovic-Todorovic, 2006, 2011).  I found that application of the selective T-type Ca2+ 
channel antagonist NNC 55-0396 (20 µM) caused a large irreversible decrease in the amplitude 
of the Ca2+ transient (48.8 ± 1.2%; n=6, Figures. 3.7 + 3.9).  Application of sumatriptan in the 
presence of the T-type Ca2+ channel antagonist caused a further decrease in amplitude (40.1 ± 
0.9%; n=6, Figures. 3.7 + 3.9), similar to the reduction with sumatriptan in control conditions 
(40.8 ± 1.4; n=7; Figures. 3.4 + 3.5), suggesting that the T-type Ca2+ channel does not mediate 
sumatriptan inhibition (Figures. 3.7 + 3.9).  A large body of work suggests that the N-type Ca2+ 
channel controls neurotransmitter release from peripheral sensory neurons (Altier et al., 2007; 
Snutch, 2005).  I found that brief application of the selective N-type Ca2+ channel antagonist ω-
conotoxin GVIA (1 µM) caused a large irreversible reduction in Ca2+ transient amplitude (40.7 ± 
1.0%; n=6; Figures 3.8 + 3.9).  Application of sumatriptan in the presence of the N-type Ca2+ 
channel antagonist did not cause a further decrease in the amplitude of the Ca2+ transient.  This 
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suggests that sumatriptan inhibition of Ca2+ signaling in the terminals of CGRP-containing 
nociceptive fibres occurs through inhibition of N-type Ca2+ channels.  
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Figure 3.6. Action potential-evoked Ca2+ transients do not activate P/Q or L-type voltage 
gated Ca2+ channels in dural CGRP fibres. 
Graphs of timecourse experiments showing the effects of Ca2+ channel blockers on the single 
action potential evoked Ca2+ transient amplitudes. (A + B) Neither the P/Q Ca2+channel blocker 
agatoxin-IVA (200 nm) nor the L-type Ca2+ channel blocker nifedipine (10 µM) decreased the 
amplitude of the Ca2+ transient.   
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Figure 3.7. The T-type Ca2+ channel makes up a significant portion of action potential-
evoked Ca2+ transients. 
The T-type Ca2+ channel blocker NNC 55-0936 (20 µM) significantly inhibited the Ca2+ transient 
amplitude. The amplitude of the T-type Ca2+ channel mediated inhibition was further reduced by 
the application of sumatriptan implying that sumatriptan inhibition of Ca2+ transient amplitude is 
not through T-type Ca2+ channels. 
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Figure 3.8. N-type Ca2+ channels mediate Sumatriptan inhibition of Ca2+ signaling. 
The N-type Ca2+ channel blocker conotoxin-GVIA (1µM) significantly inhibited the Ca2+ 
transient amplitude and the amplitude of the N-type Ca2+ channel mediated inhibition remained 
unaffected with sumatriptan application implying sumatriptan inhibition of Ca2+ transient 
amplitude occurs through N-type Ca2+ channels. 
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Figure 3.9. Bar graph summaries showing Ca2+ transient inhibition by various Ca2+ 
channel blockers and sumatriptan. 
Bar graph summaries under the experimental conditions seen in (Figs. 3.6-3.8) showing the 
inhibition of Ca2+ transient amplitudes (ΔF/F; % reduction) at the timepoints shown on the 
graphs (a1 - d1).  The magnitude of the sumatriptan-mediated inhibition alone was found to be 
equal to the magnitude of the sumatriptan mediated inhibition in the presence of the T-type Ca2+ 
channel blocker (c2), while in the presence of the N-type Ca2+ channel blocker, the sumatriptan 
mediated inhibition was completely occluded (d2). 
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3.5 DISCUSSION 
 In the present study I performed high-resolution functional imaging of Ca2+ selectively 
within individual dural CGRP nociceptive fibre terminations and found that sumatriptan has a 
peripheral site of action mediated through N-type Ca2+ channels to inhibit action potential- 
evoked Ca2+ signaling.  CGRP is hypothesized to play an important role in migraine pathology 
(Ho et al., 2010).  My finding that sumatriptan causes selective inhibition of N-type Ca2+ 
channel-mediated Ca2+ signaling in dural CGRP fibres is consistent with this hypothesis.  
Though I do not have a measure of CGRP release from the terminals, it can be inferred that 
given the significant contribution of the N-type Ca2+ channel to the Ca2+ signal (~40%), selective 
inhibition through 5-HT1 receptor activation should dramatically inhibit neurotransmitter release, 
since release shows a non-linear dependence on Ca2+ influx through voltage dependent Ca2+ 
channels (Bollmann and Sakmann, 2005; Dodge and Rahamimoff, 1967; Katz and Miledi, 1965; 
Schneggenburger and Neher, 2005).  N-type Ca2+ channels are also heavily clustered at synaptic 
sites associated with exocytotic proteins and a large body of work suggests that this channel 
controls functional coupling between action potentials and evoked neurotransmitter release from 
nociceptive terminals (Altier et al., 2007; Altier and Zamponi, 2004; Snutch, 2005; Zamponi et 
al., 2009).  It is also well established that N-type Ca2+ channels are strongly regulated by G-
protein coupled receptors that allow precise control of neurotransmitter release through 
inhibition of the N-type channel (Currie, 2010; Weiss, 2009). 
 To the best of my knowledge, this is the first study to show that the activation of 5-HT1 
receptors in trigeminal neurons causes inhibition of Ca2+ signaling selectively through a single 
Ca2+ channel subtype, the N-type.  The N-type Ca2+ channel subtype in particular over other 
subtypes has been shown to be an attractive target for therapeutic intervention concerning 
	   79	  
chronic and neuropathic pain conditions (Snutch, 2005; Zamponi et al., 2009).  Indeed, the 
highly selective N-type Ca2+ channel peptide antagonist ziconotide (Prialt®) is a non-opioid 
analgesic that has recently been used clinically for the amelioration of severe and chronic pain 
even in morphine-unresponsive situations and without the serious opioid-related side effects such 
as respiratory depression, addiction, and tolerance (Snutch, 2005).  The results presented in the 
current study suggest that the development of novel N-type Ca2+ channel-selective therapeutics 
may have implications for the treatment of migraine pain.  A major advantage for developing 
compounds that selectively target the dural N-type Ca2+ channel and regulate neurotransmitter 
release is that the medication would not have to cross the blood brain barrier for therapeutic 
action, thus eliminating serious central nervous system side effects. 
 I found in dural CGRP fibre terminations that the T-type Ca2+ channel accounted for a 
greater proportion of the Ca2+ signal (~50%) than the N-type channel but remained unaffected by 
the sumatriptan inhibition.  Application of sumatriptan in the presence of the T-type Ca2+ 
channel antagonist caused a decrease in the amplitude of the Ca2+ signal to the same extent as the 
reduction seen with sumatriptan in control conditions (~40%).  Although T-type Ca2+ channels 
are thought to play a central role in peripheral pain processing, where they are believed to 
regulate subthreshold excitability in the peripheral nociceptive fibres, they are not thought to 
control neurotransmitter release (Iftinca and Zamponi, 2009; Jevtovic-Todorovic and Todorovic, 
2006; Todorovic and Jevtovic-Todorovic, 2006, 2007, 2011).  Consistent with this, it was 
recently shown that T-type Ca2+ channels did not contribute to high potassium-induced CGRP 
release measured by an enzyme-linked immunoassay in an ex vivo rat dural-skull preparation 
similar to the mouse preparation used in my study (Amrutkar et al., 2011).  It is again interesting 
to speculate on the development of novel antimigraine therapeutics.  Compounds that selectively 
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target the T-type Ca2+ channel could be specific enough to ameliorate the pathophysiological 
activation and/or sensitization mechanisms of the dural nociceptive fibres that are thought to 
occur during migraine, without modifying neurotransmitter release mechanisms that may have 
remained unimpaired during the migraine event. 
 I found that block of P/Q- and L-type Ca2+ channels had no effect on action potential 
evoked Ca2+ transients in dural CGRP nociceptive fibre terminations.  These findings contrast 
with those of Amrutkar et al. (2011), who found that block of P/Q- and L-type Ca2+ channel 
subtypes each decreased 60 mM potassium-induced CGRP release (Amrutkar et al., 2011).  The 
differences between the two studies may be due to the different stimulation protocols and/or to 
the different concentrations of the Ca2+ channel antagonists used (Sidach and Mintz, 2000). 
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3.6 CONCLUSION 
 The antimigraine activity of the 5-HT1 receptor agonist sumatriptan is well established, 
yet the anatomical locus and mechanisms of action remain unresolved.  In the present study I 
have shown that sumatriptan acts peripherally at individual dural CGRP nociceptive fibre 
terminations to inhibit action potential-evoked Ca2+ signaling selectively through N-type Ca2+ 
channels.  This finding provides insight for the development of novel peripherally targeted 
therapeutics for mitigating the pain of migraine. 
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Chapter 4 
 
Peripheral µ-opioid receptor-mediated inhibition of calcium signaling and action potential-
evoked calcium transients in primary afferent CGRP nociceptive terminals 
 
4.1 ABSTRACT 
While µ-opioid receptor (MOR) agonists remain the most powerful analgesics for the 
treatment of severe pain, serious adverse side effects that are secondary to their central nervous 
system actions pose substantial barriers to therapeutic use.  Preclinical and clinical evidence 
suggest that peripheral MORs play an important role in opioid analgesia, particularly under 
inflammatory conditions.  However, the mechanisms of peripheral MOR signaling in primary 
afferent pain fibres remain to be established.  I have recently introduced a novel ex vivo optical 
imaging approach that, for the first time, allows the study of physiological functioning within 
individual peripheral nociceptive fibre free nerve endings in mice.  In the present study, I found 
that MOR activation in selectively identified, primary afferent CGRP nociceptive terminals 
caused inhibition of N-type Ca2+ channel signaling and suppression of action potential-evoked 
Ca2+ transients through activation of ‘big conductance’ Ca2+-activated K+ channels (BKCa).  In 
the live animal, I showed that the peripherally acting MOR agonist HS-731 produced analgesia 
and that BKCa channels were the major effectors of the peripheral MOR signaling.  I have 
identified two key molecular transducers of MOR activation that mediate significant inhibition of 
nociceptive signaling in primary afferent terminals.  Understanding the mechanisms of peripheral 
MOR signaling may promote the development of pathway-selective µ-opioid drugs that offer 
improved therapeutic profiles for achieving potent analgesia while avoiding serious adverse 
central side effects. 
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4.2 INTRODUCTION 
µ-Opioid agonists remain the most effective analgesics for the treatment of both acute 
and chronic forms of severe pain.  Unfortunately, serious centrally-mediated adverse effects such 
as sedation, respiratory depression, addiction, and tolerance limit their clinical use.  µ-Opioid 
receptors (MORs) are expressed on primary afferent nociceptive fibres located in the periphery 
and their activation has been shown to produce clinically measurable analgesia and anti-
inflammatory effects (Iwaszkiewicz et al., 2013; Stein, 2013).  However, the mechanisms by 
which MOR signaling within the peripheral terminals of primary nociceptive neurons causes 
analgesia and/or anti-inflammatory effects remain to be established. 
 Because the small size of unmyelinated nociceptive fibres makes them inaccessible to 
electrophysiologcial recording with patch-clamp pipettes, I have recently introduced a novel 
optical imaging approach to investigate physiological functioning within peripheral nociceptive 
fibre free nerve endings in mice (Baillie et al., 2011; Baillie et al., 2012).  My approach has 
opened up a new window for examining fundamental processes of pain signaling selectively 
within the peripheral terminals of individual unmyelinated nociceptive fibres in an intact tissue 
preparation.  In the present study, I examine MOR activation in peripheral nociceptive terminals 
and describe mechanisms of Ca2+ signaling inhibition, suppression of action potential (AP)-
evoked Ca2+ transients, and analgesia produced by a peripherally acting MOR agonist, HS 731 
(6β-glycine substituted 14-O-methyloxymorphone) (Al-Khrasani et al., 2007; Furst et al., 2005; 
Spetea et al., 2004).  My findings support the hypothesis that attacking pain at its source with 
opioids acting selectively in the periphery may achieve potent analgesia while avoiding adverse 
central side effects (Brower, 2000; Stein and Machelska, 2011; Stein et al., 2003).
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4.3 MATERIALS AND METHODS 
 This work was approved by the University of Saskatchewan's Animal Research Ethics 
Board and adhered to the Canadian Council on Animal Care guidelines for humane animal use.  
A total of 105 (both male and female) transgenic mice Tg [Calca-EGFP] (GENSAT Project at 
Rockefeller University) were used in this study.  Methods have been previously described in 
detail (Baillie et al., 2012; Baillie et al., 2011) and are briefly outlined below. 
4.3.1 Dural-skull preparation  
 The heads were removed from anaesthetized mice (1-4 month) and the brains carefully 
separated from the skulls leaving intact dura mater and arachnoid mater layers attached.  
Complete parietal bone dural-skull preparations were dissected and placed dural layer up in a 
microscope chamber and continuously perfused with oxygenated physiological saline consisting 
of (in mM): 125 NaCl, 2.5 KCl, 25 NaHCO3, 10 Glucose, 2 MgCl2, 1.25 NaH2PO4, and 2 CaCl2.  
In this preparation, individual nociceptive fibre integrity is preserved for millimeters, well 
protected on one side by the calvaria and by the dural layers on the other (Baillie et al., 2011). 
4.3.2 Functional imaging 
 All functional imaging experiments were performed on unmyelinated calcitonin gene-
related peptide (CGRP) nociceptive fibres identified using transgenic mice Tg [Calca-EGFP] and 
only a single fibre was imaged per preparation (Baillie et al., 2011).  The fibres were selectively 
loaded with the membrane permeant high affinity Ca2+ indicator Rhod-2 AM (Biotium).  
Electrical stimulations were delivered within 10 µm of the CGRP nociceptive fibres via 1 µm 
bipolar tungsten electrodes (WPI).  Stimulation intensity was kept just above threshold to elicit 
action potentials in physiological saline (140 - 180 µA for a duration of 100 µs).  A single pulse 
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was applied once every 90 seconds for the timecourse experiments and once every 6 seconds for 
the continuous stimulation protocols (defined as stimulation periods > 5 minutes).  During 
continuous fibre stimulation protocols, a series of 5 imaging acquisitions, each following a 60 
second interval, were taken in order to ‘snapshot’ 2 action potential-evoked Ca2+ transient (or 
failure) events for quantification.  Images were acquired at 20 frames/s using a high sensitivity 
16-bit, 512 × 512 ImagEM EM CCD Camera (C9100-13, Hamamatsu) cooled to -65 °C and a 
minimum number of total images taken to reduce photodynamic damage.  Increasing 
fluorescence baseline, steadily diminishing transients, and/or changes in fibre morphology were 
considered indicative of photodynamic damage, and fibres showing these changes were 
discarded.  Fluorescence signals were converted to relative fluorescence changes over time and 
expressed in percentages, defined as ΔF/F = ((F1 - B1) - (F0 - B0))/(F0 - B0), where F1 and F0 are 
fluorescence in the terminal fibre at any given time point and at the beginning of the experiment, 
respectively, and B1 and B0 are the background fluorescence at any given time point and at the 
beginning of the experiment, respectively.  Background values were taken from an adjacent area 
located at least 10 µm from imaged areas.  To quantify the magnitude of fluorescence change, 
the peak amplitude of the transient was measured.  During drug application experiments, 
responses were considered stable if < 5% variability was observed over an ~ 10 min control 
period without changes in baseline fluorescence.  The average magnitude of the Ca2+ transients 
before drug application was set as 100%.  Results are shown as means ± s.e.m.  Statistical 
analysis was performed using an independent group t-test (two-tailed) for the comparison of two 
means and a one-way ANOVA with a Tukey's post-hoc test for three or more.  Differences were 
considered to be significant when *p < 0.05 or greater; **p < 0.01 and  # p < 0.001. 
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4.3.3 Eye-wiping trigeminal nociceptive behavioural test 
 The mouse eye wiping behavioural test for trigeminal nociception (Farazifard et al., 
2005) was used in this study.  Each mouse was given an intraperitoneal injection of (1) 
phosphate buffer saline (PBS) alone (n=7), (2) PBS + 18% dimethyl sulfoxide (DMSO) (n=7), 
(3) HS-731 (50 µg/kg) (ChironWells GmbH) (n=8), (4) paxilline (1 mg/kg) (Tocris) (n=8), (5) 
NS-1619 (10 mg/kg) (Tocris) (n=9), or (6) naloxone methiodide (20 mg/kg) (Sigma) (n=8).  For 
experiments in which two drugs were administered, the first drug was injected 10 minutes prior 
to the second drug.  Ten minutes post injection, mice were placed in a 6" × 6" × 6" (L × W × H) 
open-top clear container.  Following a 10 minute habituation period, a 50 µl drop of 5 M NaCl 
was placed in one eye and the number of eye wipes with the ipsilateral paw was counted for 30 
seconds from video recordings.  Results are shown as means ± s.e.m.  Statistical analysis was 
performed using an independent group t-test (two-tailed) for the comparison of two means and a 
one-way ANOVA with a Tukey's post-hoc test for three or more.  The differences were 
considered to be significant when *p < 0.05 or greater. 
4.3.4 Immunohistochemistry 
Dural skull preparations were placed in 10% formalin for 15 minutes.  Preparations were 
then rinsed in 0.01 M phosphate buffered saline (PBS) 3 times for 10 minutes each before being 
placed in a blocking solution consisting of 10% goat serum, 1% bovine serum albumin (BSA) 
and 0.01 M PBS containing 0.3% triton for 60 minutes.  A MOR primary antibody (Millipore 
AB5511) was diluted to 1:2000 with 5% goat serum, 1% BSA, and 0.01 M PBS containing 0.3% 
triton and the preparations were added to this mixture and incubated at 4oC for 24 h.  
Preparations were then rinsed in 0.01 M PBS containing 1% goat serum 3 times for 10 minutes 
each.  The secondary antibody, Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen) was diluted to 
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1:500 with 0.01 M PBS containing 1% goat serum and the preparations incubated at room 
temperature for 1 h.  The preparations were then rinsed 3 times for 10 minutes each before 
imaging.  In a series of control experiments (n=4), preparations incubated in the same solutions 
without the primary antibody and subsequently processed as above showed no labeling. 
4.3.5 Drugs 
 The following drugs were added directly to the perfusate at the time points and for the 
durations indicated by the black bars in the figures for the timecourse experiments: HS-731 
(ChironWells GmbH), [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin (DAMGO) (Tocris), NS-1619 
(Tocris), charybdotoxin (Tocris), and ω-conotoxin GVIA (Alomone labs).  Naloxonazine 
dihydrochloride (Tocris) was added immediately after establishing a stable Ca2+ transient control 
period (naloxonazine dihydrochloride was present throughout the timecourses shown in the 
figures).  
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4.4 RESULTS 
4.4.1 µ-Opioid receptor inhibition of Ca2+ signaling 
MORs expressed on peripheral nociceptive fibres control afferent pain signaling and the 
local release of proinflammatory neuropeptides (Stein, 1995).  CGRP is the most prevalent 
neuropeptide found in nociceptive primary afferents and plays an important role in pain 
transmission and neurogenic inflammation (Basbaum et al., 2009; McCoy et al., 2013).  The 
trigeminal ganglion contains the highest concentration of CGRP-expressing neurons (Uddman et 
al., 1986), which extend long peripheral axons to densely innervate the cranial dura (Strassman 
et al., 2004).  I used a primary antibody for the MOR and found punctate MOR immunoreactive 
co-localized labeling in peripheral CGRP nociceptive fibres terminating in the dura (Figure 
4.1A-C).  All terminal CGRP fibres examined showed MOR labeling (35 fibres from 5 animals).  
Functional imaging experiments showed that single AP-mediated Ca2+ transients were reliably 
evoked by a single pulse electrical stimulation delivered at distances greater than 500 µm 
proximal to the distal fibre terminations (Figure 4.2).  Application of the selective MOR agonist 
DAMGO (1 µM) caused a rapid reversible inhibition in the amplitude of the AP-evoked Ca2+ 
transient (42.1 ± 3.1%; n=12) that was prevented by pre-application of the MOR antagonist 
naloxonazine (1 µM); Ca2+ transients remained at 101 ± 2.3%; n=9 under control conditions 
(Figure 4.3A+B).  I have previously shown through a series of selective Ca2+ channel block 
experiments, that only the T- and N-type Ca2+ channels mediate the AP-evoked Ca2+ signaling in 
dural CGRP nociceptive fibre terminations and that G protein-coupled receptor activation caused 
inhibition of Ca2+ signaling selectively through the single N-type channel subtype (Baillie et al., 
2012).  Here I found that brief application of the selective N-type Ca2+ channel antagonist ω-
conotoxin GVIA (1 µM) caused a large irreversible reduction in Ca2+ transient amplitude (42.6 ± 
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3.6%; n=6) (Figure 4.4A+B).  Application of DAMGO (1 µM) in the presence of the N-type 
Ca2+ channel antagonist did not cause a further decrease (42.9 ± 4.1%; n=6) indicating that MOR 
inhibition of Ca2+ signaling in the terminals of CGRP containing nociceptive fibres occurs 
through inhibition of N-type Ca2+ channels  (Figure 4.4A+B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   90	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Immunohistochemical confirmation of µ-Opioid receptor expression in CGRP 
fibres. 
A) A CGRP-EGFP terminating nociceptive fibre shows co-localized punctate labeling with a 
MOR antibody (B + C). Scale bar:10 µm 
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Figure 4.2. A typical peripheral CGRP fibre and corresponding action potential-evoked 
Ca2+ transient.  
A CGRP-EGFP fibre showing a typical region from which fluorescent transients were acquired 
and quantified, along with a pseudocolour inset of baseline Rhod-2 fluorescence (F0), and a 
single action potential evoked signal  (F1) with the corresponding transient above displayed. 
Scale bar = 20 µm, 2 s, 10% ΔF/F. 
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Figure 4.3. The µ-opioid receptor agonist DAMGO causes a reversible reduction in action 
potential-evoked Ca2+ transient amplitude that is blocked by the µ-opioid receptor 
antagonist naloxonazine. 
A) Graph of Ca2+ transient amplitude timecourse experiments showing the effect of DAMGO.  
Individual example transients taken at the relative timepoints on the graph are shown below.   
B) Bar graph summary of (A).   
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Figure 4.4. µ-Opioid receptor activation on peripheral CGRP fibres causes a decrease in 
action potential-evoked N-type channel mediated Ca2+ signaling. 
A) Timecourse experiments showing the effect of the N-type Ca2+ channel blocker ω conotoxin-
GVIA on the Ca2+ transient amplitudes remained unaffected with DAMGO application.  
Individual example transients taken at the relative timepoints on the graphs are shown below.   
B) Bar graph summary. 
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4.4.2 µ-Opioid receptor inhibition of action potential-evoked Ca2+ transient firing 
 I next determined whether peripheral MOR activation would modulate the firing 
properties of the CGRP terminating nociceptive fibres.  Because the small size of the 
unmyelinated nerve endings makes them inaccessible to conventional electrophysiological 
techniques, I imaged the AP-evoked Ca2+ transients as a means for measuring neuronal spiking 
(Baillie et al., 2012; Baillie et al., 2011).  I consistently observed that localized DAMGO 
application (1 µM) to the middle region of a fibre – but not a localized puff of physiological 
saline to the same region – would cause AP-evoked Ca2+ transients to fail in an ‘all-or-none’ 
manner at locations distal to the site of drug application (Figure 4.5).  I have previously shown 
that functional imaging could be performed over long experimental periods and that robust AP-
evoked Ca2+ transients could be evoked without decrement, which demonstrated the stability of 
the preparation for examining terminal afferent physiology (Baillie et al., 2012; Baillie et al., 
2011).  Here I found that continuous fibre stimulation (0.167 Hz) in physiological saline elicited 
consistent AP-evoked Ca2+ transients in CGRP nociceptive fibres (AP/stimulus applied = 
(110/110), 100 ± 0%; n=11) (Figure 4.6A+B).  However, I observed that AP-evoked Ca2+ 
transients failed frequently following application of DAMGO (1 µM).  Pursuing this further, I 
observed that this MOR-mediated failure of AP-evoked Ca2+ transients persisted after the 
inhibition to the Ca2+ transient amplitude had fully recovered and this allowed us to quantify the 
AP-evoked Ca2+ transient failure rate independent of any MOR-mediated inhibition of Ca2+ 
signaling.  I applied the continuous fibre stimulation protocol following DAMGO wash, (once 
the Ca2+ transients had returned to baseline control amplitudes observed prior to the DAMGO 
application), and found significant AP-evoked Ca2+ transient failures (AP/stimulus applied = 
(15/71), 21.1 ± 9.0%; n=6) (Figure 4.6A+B).  Two fibres remained unaffected (AP/stimulus 
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applied = (20/20), 100 ± 0%; n=2).  Pre-application of the MOR antagonist naloxonazine (1 µM) 
or the selective N-type Ca2+ channel antagonist ω-conotoxin GVIA (1 µM) prevented the MOR 
mediated inhibition of AP-evoked Ca2+ fluorescent transients (AP/stimulus applied = (76/76), 
100 ± 0%; n=6 and (66/66), 100 ± 0%; n=6 respectively) (Figure 4.6A+B). 
 Ca2+-activated K+ channels (KCa) activate in response to both membrane depolarization 
and an elevation of cytosolic Ca2+ (Fakler and Adelman, 2008).  They play key roles in the 
control of AP duration, firing frequency, and the generation of spike-frequency adaptation.  Their 
modulation by a range of transmitters is a key determinant in the regulation of neuronal 
membrane excitability (Sah, 1996).  Based on biophysical as well as pharmacological properties 
KCa are separated into two families: small (SKCa) and big (BKCa) conductance channels 
(Berkefeld et al., 2010).  I found that the specific inhibitor of BKCa channels charybdotoxin (50 
nM) caused an increase in the amplitude of the AP-evoked Ca2+ transient (126 ± 8.6%; n=6) 
(Figure 4.7A).  Application of DAMGO (1 µM) in the presence of Charybdotoxin caused a rapid 
inhibition in the amplitude of the AP evoked Ca2+ transient by 41.6 ± 7.4% (n=6) that was fully 
reversible with washing (128 ± 14.5%, n=6) (Figure 4.7A+B).  Two fibres did not show an initial 
increase in the amplitude of the AP-evoked Ca2+ transient in charybdotoxin and therefore 
DAMGO application was not pursued.  The selective inhibitor of SKCa apamin showed no effect 
(data not shown).  I then applied continuous fibre stimulation in the presence of charybdotoxin 
and following DAMGO wash out and found consistent AP-evoked Ca2+ fluorescent transients 
(AP/stimulus applied = (87/88), 98.8 ± 1.9%; n=6) (Figure 4.8A+B).  Apamin showed no effect 
(data not shown).  The selective BKCa channel activator NS-1619 (10 µM) caused frequent 
failure of the continuous fibre stimulation-evoked Ca2+ transients (AP/stimulus applied = 
(19/90), 21.1 ± 5.3%; n=6) (Figure 4.8A+B). 
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Figure 4.5. Localized DAMGO application causes action potential failure in an ‘all-or-
none’ manner.  
Image illustrating AP propagation failures observed after localized DAMGO application.  In 
control conditions, a train of five 1 Hz stimulations caused AP evoked facilitating Ca2+ transients 
at both distal (1) and proximal (2) imaging locations.  After a brief localized puff of DAMGO 
(centre circle), Ca2+ transients at the distal (3) imaging location fail in an ‘all-or-none’ manner 
but do not at the proximal (4) location (‘all-or-none’ AP failures seen at proximal locations when 
the fibre was stimulated at the distal location and were observed with a range of stimulation 
paradigms).  Scale bar = 50 µm.   
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Figure 4.6. The µ-opioid receptor agonist DAMGO causes action potential failure during 
continuous fibre stimulation that is prevented by preapplication of the µ-opioid receptor 
antagonist naloxonazine or the N-type Ca2+ channel blocker conotoxin-GVIA. 
A) In control conditions, continuous fibre stimulation elicits consistent AP firing observed as 
non-failing Ca2+ transients.  APs fail often during continuous fibre stimulation experiments when 
DAMGO had been previously applied to a fibre and after which the Ca2+ transients had returned 
to baseline control amplitudes (asterisk used to distinguish this condition from in the presence of 
DAMGO).  Non-failing Ca2+ transients were observed when naloxonazine or ω conotoxin-GVIA 
was applied before DAMGO.  B) Bar graph summary quantifying the number of AP-evoked 
Ca2+ transients as a percentage of stimuli applied during the conditions shown in (A).   
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Figure 4.7. The BKCa channel antagonist charybdotoxin causes an increase in action 
potential-evoked Ca2+ transient amplitude that is reduced by DAMGO. 
A) Graph of Ca2+ transient amplitude timecourse experiments showing the effect of DAMGO 
application in the presence of the specific inhibitor of BKCa channels charybdotoxin.  Individual 
example transients taken at the relative timepoints on the graph are shown below. B) Bar graph 
summary of (A).   
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Figure 4.8. The BKCa channel antagonist charybdotoxin prevents DAMGO-mediated 
action potential failure and the BKCa channel agonist NS 1619 mimics the action potential 
failure observed with DAMGO application. 
A) Sustained AP firing was observed when charybdotoxin was applied before DAMGO, but APs 
fail often in experiments with the BKCa channel activator NS-1619 applied alone.  B) Bar graph 
summary of (A). 
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4.4.3 Peripheral µ-opioid receptor mediated antinociception 
I	  examined	  whether	  MOR	  activation	  by	  a	  peripherally	  acting	  MOR	  agonist	  would	  cause	  inhibition	  of	  Ca2+	  signaling	  and	  AP-­‐evoked	  Ca2+	  transients	  in	  the	  CGRP	  terminating	  nociceptive	  fibres.	  	  The	  6	  β-­‐glycine	  substituted	  derivative	  of	  14-­‐O-­‐methyloxymorphone	  (HS-­‐731)	  has	  been	  described	  as	  a	  potent	  MOR	  agonist	  that	  does	  not	  readily	  cross	  the	  blood	  brain	  barrier,	  and	  induces	  peripherally-­‐mediated	  antinociceptive	  actions	  in	  various	  pain	  models	  (Al-­‐Khrasani	  et	  al.,	  2007;	  Bileviciute-­‐Ljungar	  et	  al.,	  2006;	  Furst	  et	  al.,	  2005).	  	  Application	  of	  HS-­‐731	  (1	  μM)	  caused	  a	  rapid	  reversible	  inhibition	  in	  the	  amplitude	  of	  the	  AP	  evoked	  Ca2+	  transient	  (40.0	  ±	  3.6%;	  n=5)	  that	  was	  prevented	  by	  pre-­‐application	  of	  the	  MOR	  antagonist	  naloxonazine	  (1	  μM)	  (103	  ±	  2.1%;	  n=5)	  (Figure	  4.9+4.10A).	  	  I	  then	  applied	  the	  continuous	  fibre	  stimulation	  protocol	  following	  a	  HS-­‐731	  wash	  out	  period,	  after	  which	  the	  Ca2+	  transients	  had	  returned	  to	  the	  baseline	  control	  amplitudes	  before	  HS-­‐731	  application,	  and	  found	  that	  AP-­‐evoked	  Ca2+	  transients	  failed	  frequently	  (AP/stimulus	  applied	  =	  (17/85),	  20.0	  ±	  6.7%;	  n=7)	  (Figure	  4.10B).	  	  Pre-­‐application	  of	  the	  MOR	  antagonist	  naloxonazine	  (1	  μM)	  prevented	  the	  MOR	  mediated	  inhibition	  of	  AP-­‐evoked	  Ca2+	  transients	  (AP/stimulus	  applied	  =	  (63/63),	  100	  ±	  0%;	  n=5)	  (Figure	  4.10B). 
 To determine whether HS-731 produced antinociception I used the mouse eye wipe in 
response to NaCl application behavioural test for trigeminal nociception (Farazifard et al., 2005).  
Animals given control vehicle intraperitoneal injections exhibited 16.2 ± 1.0 (n=14) eye wipes 
with the ipsilateral paw in 30 seconds.  Intraperitoneal injection of HS-731 (50 µg/kg) caused a 
significant decrease in the number of mouse eye-wipes (9.9 ± 2.1; n=8) that was prevented by a 
prior injection of the peripherally acting MOR antagonist naloxone methiodide (20 mg/kg) (16.0 
± 1.9; n=8) (Figure 4.11).  Intraperitoneal injection of the potent blocker of BKCa channels 
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paxilline (1 mg/kg) did not change the number of eye wipes (17.7 ± 1.0; n=8) compared to 
control conditions, but prevented the HS-731 induced reduction (15.6 ± 1.9; n=8).  Injection of 
the BKCa channel activator NS-1619 (10 mg/kg) alone mimicked the decrease in the number of 
eye wiping seen with HS-731 (12.0 ± 1.9; n=9) (Figure 4.11). 
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Figure 4.9. The peripherally restricted MOR agonist HS-731 produces a reduction in action 
potential-evoked Ca2+ transient amplitude similar to DAMGO. 
Graph of Ca2+ transient amplitude timecourse experiments showing the effect of HS-731.  
Individual example transients taken at the relative timepoints on the graph are shown below. 
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Figure 4.10. The peripherally restricted MOR agonist HS-731 causes a reduction in action 
potential-evoked Ca2+ transient amplitude and action potential failure similar to DAMGO. 
A) Bar graph summary showing that the HS-731 reduction in the amplitude of the Ca2+ transient 
was completely blocked by naloxonazine.  B) Bar graph summary quantifying the number of AP 
evoked Ca2+ transients during continuous fibre stimulation as a percentage of stimuli applied for 
experiments with previous application of HS-731 (asterisk used to distinguish this condition 
from in the presence of HS-731) and MOR block with naloxonazine. 
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Figure 4.11 The peripherally restricted MOR agonist HS-731 caused antinociception in the 
mouse eye-wiping behavioural test of trigeminal nociception. 
Bar graph summary quantifying the eye-wiping behavioural experiments.  The peripherally 
acting MOR agonist HS-731 caused a significant decrease in the number of eye-wiping that was 
normalized from a preceding injection of the peripheral MOR antagonist naloxone methiodide 
(NalMeth).  The potent blocker of BKCa channels paxilline prevented the HS-731 induced 
reduction, while injection of the BKCa channel activator NS-1619 alone mimicked the decrease 
in the number of eye-wipes seen with HS-731.  *p < 0.05. 
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4.5 DISCUSSION 
 In the present study I discovered that peripheral MOR activation in individual nociceptive 
CGRP terminals has a dual modulatory effect, that is, inhibition of N-type Ca2+ channel signaling 
and BKCa channel-mediated suppression of AP-evoked Ca2+ transients.  I extended these 
observations to the whole animal and showed that the peripherally acting MOR agonist HS-731 
produced analgesia that was prevented by a potent antagonist of BKCa channels and mimicked by 
an activator of BKCa channels administered alone. 
 The terminals of CGRP-containing primary afferent nociceptors respond to noxious 
stimuli not only by transmitting APs toward the central nervous system, but by releasing CGRP 
locally in the periphery to promote inflammation (Gold and Gebhart, 2010; Jancsó, 2009; 
Richardson and Vasko, 2002).  CGRP is among the most potent vasodilators (Brain et al., 1985) 
and its peripheral release plays a major role in inflammatory pain by mediating neurogenic 
vasodilation (Meyer et al., 2005).  N-type Ca2+ channels control neurotransmitter release from 
peripheral sensory neurons (Snutch, 2005).  Given the significant contribution of the N-type Ca2+ 
channels to the Ca2+ signal in dural nociceptive CGRP fibres (~40%), their selective inhibition 
through MOR activation should dramatically inhibit CGRP release, since neurotransmitter 
release shows a non-linear dependence on Ca2+ influx through voltage dependent Ca2+ (Zucker, 
1993).  My present findings suggest that MORs located on CGRP fibres in the periphery may be 
an attractive target for therapeutic intervention to reduce neurogenic vasodilation and 
inflammatory pain states. 
 BKCa channels are expressed in peripheral CGRP nociceptive neurons (Lu et al., 2014) 
and are thought to be important regulators of pain signaling in afferent nociceptive fibres 
(Tsantoulas and McMahon, 2014; Waxman and Zamponi, 2014).  A substantial reduction in both 
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the mRNA and protein levels of BKCa channels in primary afferent neurons has been seen in a 
model of neuropathic pain (Chen et al., 2009).  BKCa channel block has been shown to prolong 
the duration of APs and increase firing frequency, while their activation suppressed AP firing 
(Zhang et al., 2003).  In this study I found that the profound MOR mediated suppression of AP-
evoked Ca2+ transients (~80%) was completely blocked with BKCa channel antagonism and 
mimicked by BKCa channel activation alone.  Thus I have identified BKCa channels as mediators 
of peripheral MOR activation that causes suppression of AP firing in CGRP nociceptive fibres.  
My findings suggest that peripheral MORs located on CGRP fibres acting through BKCa 
channels, may represent a new therapeutic target to effectively quell the increased excitability 
and ectopic AP firing seen in primary afferent nociceptive fibres in neuropathic pain states 
(Cohen and Mao, 2014).  Considering the efferent functioning of the nociceptive fibres, the 
dramatic suppression of AP firing from peripheral MOR activation would be expected to 
considerably reduce the release of CGRP.  Indeed, it has recently been shown that NS1619 dose 
dependently inhibited neurogenic dural vasodilation in a model of trigeminovascular nociception 
(Akerman et al., 2010). 
 I found that the peripherally acting MOR agonist HS-731 caused inhibition of Ca2+ 
signaling (~40%) and suppression of AP-evoked Ca2+ fluorescent transients (~80%) in CGRP 
fibres to the same extent as the prototypical MOR agonist DAMGO.  To evaluate the analgesic 
potential of HS-731 I used the mouse eye wiping behavioural test for trigeminal nociception.  I 
chose this model for the current study because the cornea is extremely densely innervated by a 
network of CGRP nociceptive fibres that are derived from the same ophthalmic branch of the 
trigeminal nerve that innervates the dura (Muller et al., 2003).  HS-731 produced significant 
antinociception by suppressing the pain evoked eye wiping behaviour by ~40%.  Support for my 
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proposal that BKCa channels are peripheral MOR effectors, analgesia was prevented with BKCa 
channel antagonism and mimicked by BKCa channel activation.  These findings suggest that 
potent analgesia may be achieved with peripherally selective therapeutics targeting MORs 
located outside the central nervous system, thus eliminating the serious side effects that 
accompany conventional opioid interventions. 
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Chapter 5 
 
General discussion 
 
 The work in this dissertation outlined the development of a novel preparation for the 
study of nociceptive signaling within the peripheral terminals of individual nociceptors and 
highlighted the utility of this preparation by determining the effects two analgesics had on 
signaling in the peripheral terminals of CGRP containing nociceptive fibres.  
5.1 Major thesis findings 
1. The development of the dural-skull preparation allows, for the first time, the study of 
nociceptive signaling within the peripheral terminals of nociceptors while they reside in the 
parietal dura mater, undisturbed, protected by the meningeal dura mater on one side and the 
calvaria on the other. 
2. The commonly used anti-migraine drug, sumatriptan, which via activation of 5-HT1D 
receptors, inhibited N-type Ca2+ channels resulting in a reduction in the amount of Ca2+ entering 
the nociceptive terminal during an action potential. 
3. In the peripheral terminals of CGRP-containing nociceptive fibres µ-opioid receptor activation 
resulted in a reduction in Ca2+ signaling through inhibition of N-type Ca2+ channels similar to the 
sumatriptan study as well as caused a frequency-dependent suppression of action potential firing 
that occurred through activation of the BK Ca2+-activated K+ channel. 
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5.2 Functional imaging within individual pain fibres ex vivo with optical microscopy. 
I have introduced an experimental imaging approach to directly study physiological 
functioning within selectively identified nociceptive fibre free nerve endings that terminate in the 
cranial dura mater. While the peripheral nociceptors innvervating the dura mater are far too small 
to study using conventional electrophysiological technqiues such as intracellular recording with 
patch clamp pipettes, the relatively thin, translucent cellular constituents of the intracranial 
meninges makes it ideal for experiments involving high-resolution optical imaging (Figure 5.1). 
This en bloc dural skull preparation can be performed in rats and mice, preserves the integrity of 
nociceptive processes for millimeters and offers ideal tissue conditions for optical 
microfluorometric imaging.   
 The dural skull preparation introduced here allows for the identification of myelinated 
Aδ-fibre and unmyelinated C-fibre nociceptors. The optical properties of the dura mater allow 
for identification of myelin with simple transmitted light, which I confirmed was truly myelin 
with the selective myelin stain Fluoromyelin Red® (Invitrogen). The dural skull preparation also 
allows for the study of both main subpopulations of C-fibres; peptidergic with the use of a 
transgenic CGRP-EGFP mouse (Transgenic Tg [Calca-EGFP] (GENSAT Project at Rockefeller 
University)) and non-peptidergic with the application of a fluorescent conjugated isolectin B4 
that selectively bind to membrane-associated glycoconjugates that exist only in non-peptidergic 
nociceptors (Soyguder, 1999). 
 Using a brief application of the high affinity Ca2+ indicator Rhod2-AM and electrical 
stimulation I was able to show that single action potential-induced Ca2+ transients could be 
elicited with high signal-to-noise ratios in individual C-fibres with no decrement in size for 
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extended periods of time.  To my knowledge this is the first study to show high-resolution 
functional imaging selectively within individual nociceptive fibre terminations. 
 The cellular make up of the dural-skull preparation also makes it ideal for experiments 
using molecular uncaging. I was able to couple a 355 nm wavelength laser to a wide field 
epifluorescence microscope to allow focal uncaging in and near individual nociceptive terminals.  
The use of molecular uncaging allows localized and precise control of molecule application 
(Amatrudo et al., 2014; Pettit et al., 1997).   
 Finally I was able to provide direct evidence of the axon reflex in a single CGRP 
peptidergic nociceptor. The axon reflex, first proposed by (Bruce, 1913) suggests that both 
afferent and efferent activity can occur in the same primary sensory neuron at a point of 
bifurcation.  Activation of one branch of a nociceptor results in action potentials that travel 
afferently back to the CNS but also efferently down other branches at points of bifurcation. The 
efferent signaling that occurs at a point of bifurcation results in the release of neuropeptides such 
as CGRP and substance P (Richardson and Vasko, 2002), which leads to neurogenic 
inflammation and peripheral sensitization (Foreman, 1987).   
 Although the axon reflex was first proposed over 100 years ago, this is the first study to 
my knowledge that provides direct evidence of its existence in a single branching nociceptor as 
opposed to bundles of axons where phenomena such as ephaptic transmission could account for 
previous observations.  
 Signaling in the afferent terminals of nociceptors depends on the distribution, density and 
biophysical properties of molecular transducers and ion channels that exist within them (Woolf 
and Ma, 2007), which likely differ from the cell bodies of nociceptors in which much of our 
current understanding of nociception has been obtained (Kostyuk and Kostyuk, 2009).  
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High-resolution functional optical imaging in the en bloc dural-skull preparation now 
provides an opportunity to begin to study the fundamental physiological processes of activation, 
transduction, sensitization, and propagation of the nociceptive signal in peripheral pain fibre 
terminations. This opens up a new window for examining physiological functioning in peripheral 
nociceptive fibres and to advance our understanding of the peripheral processes involved in pain 
pathophysiology. 
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Figure 5.1. High-resolution image of terminating CGRP nociceptive fibre in the cerebral 
meninges. 
A) Two-photon IR-transmitted image of the relatively translucent meninges in the dural-skull 
preparation. B) Two-photon image of a terminating CGRP nociceptive fibre from CGRP-EGFP 
transgenic mouse. C) Merge of (A+B). 
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5.3 Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP 
terminal fibres. 
 Since the anatomical locus of the triptan’s anti-migraine effects have been long debated 
(Hoskin and Goadsby, 1998; Humphrey and Goadsby, 1994) I wished to test its effect on 
nociceptive signaling within the CGRP nociceptive terminals, which are believed to play a large 
role in the pathophysiological mechanisms of migraine headache (Durham, 2006).  
 I found a concentration-dependent decrease in the amplitude of action potential-evoked 
Ca2+ transients during bath application of the 5-HT1B/D agonist sumatriptan. Through the use of 
separate 5-HT1B and 5-HT1D antagonists I determined that sumatriptan’s effect on Ca2+ transient 
amplitude was mediated through activation of the 5-HT1D receptors specifically. 
 Next I performed a series of Ca2+ channel blocking experiments to determine which Ca2+ 
channel(s) are being inhibited by the activation of the 5-HT1D receptor and found interesting 
results, the first being the types of voltage gated Ca2+ channels present in the peripheral terminals 
of CGRP nociceptive fibres.  Studies of cultured nociceptors have found the presence of a 
multitude of voltage gated Ca2+ channels including, P/Q, L, N, R and T (Yusaf et al., 2001) and a 
study of sumatripan’s effect on CGRP release from cultured TRG neurons found that P/Q, L and 
N-type Ca2+ channels are all inhibited during 5-HT1B/D activation resulting in a decrease in 
CGRP release (Amrutkar et al., 2011). Through Ca2+ channel blocking experiments in the 
peripheral terminals of CGRP nociceptive fibres I found that only T-type and N-type Ca2+ 
channels are activated during an electrically-evoked action potential and that sumatriptan’s 
reduction in Ca2+ transient amplitude was due solely to inhibition of the N-type Ca2+ channel.  
 To my knowledge this is the first study to show that triptans inhibit Ca2+ signaling 
selectively through a single Ca2+ channel subtype, the N-type Ca2+ channel. Although I did not 
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have a measurement for the release of neuropeptides from the CGRP nociceptive fibres that I 
was studying, it can be inferred that the (~40%) reduction in Ca2+ signal through the activation of 
5-HT1D receptors should dramatically inhibit neurotransmitter release, since release shows a non-
linear dependence on Ca2+ influx through voltage dependent Ca2+ channels (Bollmann and 
Sakmann, 2005; Dodge and Rahamimoff, 1967; Schneggenburger and Neher, 2005). N-type 
Ca2+ channels have also been proposed to control neurotransmitter release from peripheral 
sensory neurons (Snutch, 2005) lending more evidence that neuropeptide release would be 
reduced through N-type Ca2+ channel inhibition.  
 When a migraine is initiated and peripheral CGRP nociceptive fibres become activated it 
is possible that through the efferent signaling component of the axon reflex that CGRP release 
from activated terminals results in a state of neurogenic inflammation, peripheral sensitization 
and allodynia causing the meningeal nociceptors to then react to normally non-painful vascular 
stimuli and result in the long-lasting painful phase of migraine (Olesen et al., 2009). Thus 
triptans may relieve the painful state of migraine by inhibiting N-type Ca2+ channels leading to a 
reduction in CGRP or substance P release, resolving neurogenic inflammation, peripheral 
sensitization and the corresponding allodynia allowing nociceptive thresholds to return to 
baseline and the cessation of their activation. 
Aside from acting on the peripheral terminals of nociceptors it has also been proposed 
that triptans may cause migraine relief though arterial vasoconstriction (Ahn and Basbaum, 
2005). It is worth noting, in experiments not included in the chapter publication, I tested the 
effect bath applied sumatriptan had on dural arteriole diameter in the dural-skull preparation and 
found no vascular changes with a concentration of sumatriptan that caused the maximal change 
in transient amplitude (~20 µM). To confirm vasculature was still viable in the dural skull 
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preparation, 1 µM norepinephrine was applied in a similar manner and resulted in repeatable 
vasoconstriction of dural arterioles. These results favour the idea that the peripheral terminals of 
nociceptors are an anatomical locus of triptans in relieving migraine pain.   
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5.4 Peripheral µ-opioid receptor mediated inhibition of calcium signaling and action 
potential- evoked calcium transients in primary afferent CGRP nociceptive terminals. 
 In this study I wished to determine the effect µ-opioid receptor activation had on 
nociceptive signaling in the peripheral terminals of CGRP fibres. First I found nearly identical 
results to the sumatriptan study in that activation of µ-opioid receptors by a selective µ-agonist 
DAMGO or novel peripherally-restricted, selective µ-opioid agonist, HS-731 (Furst et al., 2005) 
caused an approximately 40% reduction in the amplitude of AP-evoked Ca2+ transients and that 
this reduction was mediated through the inhibition of N-type Ca2+ channels only. The reduction 
in Ca2+ entry through µ-opioid receptor activation would likely play a role in the reduction of 
inflammatory pain. During nociceptor activation signals travel not only afferently to the CNS but 
also efferently at points of bifurcation leading to release of neuropeptides at the peripheral 
terminals. It can be inferred that the large reduction in Ca2+ entry through µ-opioid receptor 
activation would result in a reduction in CGRP release from the peripheral terminals thus 
relieving the neurogenic inflammation and reducing inflammatory pain that occurs as a result of 
CGRP release (Richardson and Vasko, 2002). 
 A novel finding in this study was the observation of frequency-dependent AP-evoked 
Ca2+ transient failure after the application of µ-opioid receptor agonists. Following µ-opioid 
receptor activation I observed that AP-evoked Ca2+ transients fail in an ‘all-or-none’ manner 
when an increase in frequency of stimulation was applied. This failure in AP firing was 
attributed to activation of the large conductance Ca2+-activated K+ channel (BKCa).  BKCa 
channels have been shown to be expressed on CGRP-containing primary afferents (Lu et al., 
2014) and are believed to be important in pain signaling within afferent nociceptive fibres 
(Tsantoulas and McMahon, 2014; Waxman and Zamponi, 2014).  
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 BKCa channel block has been shown to prolong the duration of APs and increase firing 
frequency, while their activation suppressed AP firing (Zhang et al., 2003).  These findings were 
both observed in this study with an increase in amplitude and width of AP-evoked Ca2+ 
transients observed after BKCa antagonism by charybdotoxin indicating an increase in AP 
duration and with a suppression in AP-evoked Ca2+ transients in an all-or-none manner via 
activation of the µ-opioid receptor or by direct activation of the BKCa channel by the agonist NS-
1619, indicating AP failure. Antagonism of the BKCa channel by charybdotoxin also prevented 
the µ-opioid receptor mediated frequency-induced failure of AP-evoked Ca2+ transients lending 
more evidence to BKCa being responsible for the failure of AP firing.  
 Interestingly I was able to extend results observed ex vivo in the dural skull preparation, 
to in vivo using the mouse eye wiping behavioural test for trigeminal nociception. µ-opioid 
receptor activation resulted in a ~40% reduction in pain-evoked eye wiping.  This analgesia 
through µ-opioid receptor activation was prevented by blocking BKCa channels and mimicked by 
direct activation of BKCa channels lending evidence to the proposal that BKCa are modulated by 
µ-opioid receptor activation. 
 To my knowledge this is the first study to identify BKCa channels as mediators of 
peripheral µ-opioid receptor activation and that µ-opioid receptor mediated BKCa activation leads 
to suppression of AP firing in CGRP nociceptive fibres. These findings suggest a new 
therapeutic pathway through which µ-opioid receptor activation acts in relieving pain and a 
potential therapeutic target in the development of more specific, peripherally acting analgesics 
that avoid the unwanted central side effects that are commonly associated with current 
analgesics.  
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5.5 Limitations 
 Like all current methods for studying cellular nociception, the ex vivo dural skull 
preparation has some limitations, one being the use of chemical Ca2+ indicators. While day-to-
day loading of dural CGRP nociceptors with the cell permeable high affinity Ca2+ indicator 
Rhod-2 AM, consistently resulted in a healthy preparation in which single afferents could be 
stimulated for hours. Occasionally, particularly when a new lot of Ca2+ indicator was purchased, 
loading times had to be slightly adjusted to prevent both excess loading of background cells 
(resident macrophages and dendritic cells) reducing signal-to-noise and over-loading of the 
nociceptors themselves leading to cell death.  
 This limitation, while minor, will hopefully be extinguished with the use of the newly 
developed genetically encoded Ca2+ indicator GCAMP6 (Chen et al., 2013). This newly 
developed genetically encoded indicator has a 10-fold improvement in Ca2+ sensitivity over the 
previous version, GCAMP3 and surprisingly was shown to exceed one of the commonly used 
chemical indicators, Oregon Green Bapta-1 AM in dissociated rat hippocampal neurons (Figure 
5.2).     
 The cross of two transgenic mice, one that expresses cre-recombinase in TRPV1 
containing neurons (Cavanaugh et al., 2011) and another which is a cre-dependent GCAMP6 
reporter mouse (B6;129S6-Gt(ROSA)26Sortm96(CAG-GCaMP6s)Hze/J; Jackson Laboratory) 
that is currently underway in the Mulligan Lab will result in offspring that express the 
ultrasensitive genetically encoded Ca2+ indicator GCAMP6 in TRPV1 containing neurons 
negating the need for the use of chemical indicators in the dural skull preparation.  
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Figure 5.2.  Signal- to-noise ratio of the newly developed genetically encoded Ca2+ indicator 
GCAMP6. 
The genetically encoded Ca2+ indicator GCAMP6 greatly exceeds both the previous version 
GCAMP3 and one of the most commonly used chemical Ca2+ indicators Oregon Green Bapta1 
(OGB1). Adapted from (Chen et al., 2013). 
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One question of the dural skull preparation is whether nociceptive processes such as 
transduction, propagation and sensitization studied in this preparation can be extrapolated to 
cutaneous nociceptors. While it has been demonstrated that most properties in TRG cells are 
similar to those in DRG cells, the chemical responsiveness of some cell types differ slightly 
between the TRG and DRG (Xu et al., 2010). Also the surrounding tissue in cutaneous and dural 
nociceptors differs with the peripheral terminals of cutaneous nociceptors residing mainly in the 
epidermis and dermis (Dubin and Patapoutian, 2010) with the epidermis consisting primarily of 
keratinocytes and dermis, collagen and elastin fibres (Chong et al., 2013; Lulevich et al., 2010). 
The cranial nociceptive terminals mainly reside in the dura mater which is primarily made up of 
fibroblasts and an extracellular matrix consisting of collagen fibrils, microfibrils and elastic 
fibres (Adeeb et al., 2012). Despite the differences in composition, both tissues appear to be 
exposed to a similar array of immune cells that are believed to take part in nociceptive processes 
including mast cells, macrophages, dendritic cells, neutrophils and lymphocytes (Chong et al., 
2013; Kipnis et al., 2012; Levy et al., 2007) indicating that nociceptive processes such as 
neurogenic inflammation and peripheral sensitization may be very similar in both the skin and 
dura mater. 
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5.6 Future directions 
 There are a number of future directions in which the dural skull preparation could go 
potentially, including the study of specific nociceptive processes, screening of novel analgesic 
compounds, and finally, with the development of new genetically encoded Ca2+ indicators, the 
dural skull preparation could be extended to in vivo studies. 
5.6.1 Study of nociceptive processes 
 Much of our understanding on nociceptive transduction is based on experiments using the 
isolated cell bodies of nociceptors and it is very possible that differences in the expression of 
transduction channels exist between the somata and terminals. The dural skull preparation 
provides the opportunity to test transduction mechanisms identified in the somata, in the 
peripheral terminals of nociceptors and also allows for the identification of new transduction 
channels. Although the activation of nociceptors in experiments within this dissertation was 
restricted to electrical and chemical stimulation, all forms of noxious stimuli including 
mechanical and thermal stimuli could potentially be used in the dural-skull preparation, which 
allows for the identification and testing of numerous different types of transduction channels.  
For example the recently identified mechanical piezo channels (Kim et al., 2012) or two-pore 
potassium channels (Honore, 2007) which have been implicated in nociception could be tested.  
 The neuropeptide CGRP is a very potent vasodilator and it is thought that the release of 
this neuropeptide from nociceptors may contribute to neurogenic inflammation and migraine 
through vascular mechanisms (Durham, 2008; Kilo et al., 1997). The extent to which CGRP- 
containing nociceptors need to be activated to cause vasodilation and the exact mechanism 
through which it occurs could potentially be resolved using the dural skull preparation.  Initial 
data I gathered indicates vasodilation caused by CGRP containing nociceptor activation could be 
	   122	  
induced by brief trains of action potentials (20 seconds at 5Hz) in individual CGRP-fibres and 
this activations results in reliable, repeatable, localized arteriole dilation (Figure 5.3).  
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Figure 5.3  CGRP-fibre stimulation causes repeated, localized arteriole dilation.  
A) EGFP-CGRP fibre and Alexa-594 IB4 stained (intracardial perfusion) arteriole overlay image 
shows the close CGRP-fibre-vessel relationship common to these terminating fibres in the 
meninges (Fricke et al. 2001). B) IR-transmitted image of the same arteriole shown in (A) and 
the IR- transmitted and fluorescence image overlay (C). D) Luminal diameter changes over time 
from fibre stimulation (20 seconds at 5Hz).  
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 Not only can the process of CGRP-induced vasodilation be observed in the dural-skull 
preparation, but I have also developed a novel experimental approach to assay the actual release 
of CGRP from the terminals. CGRP in nociceptors is packaged in large dense core vesicles 
(Matteoli et al., 1988) and I found that incubation with the acidotropic fluorescent probe DND-
99 selectively labels the CGRP large dense core vesicles in a manner similar to LDCVs labeled 
in chromaffin cells (Duncan et al., 2003). CGRP fibres maintain 1 – 3 LDCVs per terminal 
bouton (Fricke et al., 1997; Zhang et al., 1995). I have found that brief application of the TRPV1 
agonist capsaicin evokes stochastic loss of the DND-99 labeled LDCVs suggesting CGRP 
release (Figure 5.4) and have also found stochastic loss of labeled LDCVs with photolysis of 
caged capsaicin and electrical stimulation of the fibre. 
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Figure 5.4. TRPV1 channel evoked release of DND-99 labeled CGRP dense core vesicles.  
(A – D) series of schematic figures illustrating a primary afferent terminal in which the TRPV1 
channel mediates the release of CGRP dense core vesicles labeled with the acidotropic probe 
DND-99 (red). E) Image of a CGRP-EGFP terminal that shows two dense core vesicles loaded 
with DND-99 (two arrows). F) Brief application of the TRPV1 agonist capsaicin evoked the 
stochastic loss of one of the DND-99 labeled vesicles suggesting release of a dense core vesicle 
(single arrow shows remaining vesicle). 
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Because both nociceptors and a variety of immune cells including macrophages, dendritic 
cells and mast cells can be easily identified and also labeled with Ca2+ indicators in the dural 
skull preparation, it offers the only opportunity that I am aware of, besides in a culture dish, to 
directly study immune cell-nociceptor interaction.  In the dural skull preparation I have been able 
to easily identify mast cells with transmitted light or bath application of toluidine blue (Sridharan 
and Shankar, 2012), as well as to develop a novel method to label macrophages and dendritic 
cells in live tissue with a bath application of conjugated monoclonal antibodies (Figure 5.5). 
Since CGRP is considered a key neuropeptide in nociceptor-immune cell interaction (Assas et 
al., 2014), the dural skull preparation potentially allows for the study of immune cell recruitment, 
activation and mast cell degranulation through the activation of CGRP containing nociceptors.  
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Figure 5.5. Dual macrophage and dendritic cell labeling in live tissue. 
Dendritic cells and macrophages were labeled in live tissue with a bath application of fluorescent 
molecule conjugated monoclonal antibodies. Dendritic cells (purple) were labeled using a rat 
anti-mouse MHC Class II RT1B Alexa Fluor® 488 monoclonal antibody and macrophages 
(orange) labeled using a rat anti-mouse CD163 (ED2) Alexa Fluor® 647 antibody. 
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5.6.2 Testing of novel compounds for analgesia 
The ability to study the pain sensing peripheral terminals of nociceptors, in an 
environment that closely reflects in vivo conditions, offers the unique opportunity to identify new 
analgesics that have been proposed in behavioural models of nociception or somata in vitro 
models. There are a large number of recently developed pain related toxins (Klinger et al., 2012; 
Rowe et al., 2013; Yang et al., 2013), antibodies (Gearing et al., 2013; Lee et al., 2014) and 
chemicals that have been tested in in vitro somata or behaviourally that could be easily tested in 
the dural skull preparation to identify their effectiveness in the peripheral terminals of 
nociceptors. 
 The dural skull preparation also offers the opportunity to study the mechanisms by which 
currently used analgesics work in the peripheral terminals and to develop new peripherally 
restricted analgesics, such as peripherally restricted opioids. I had the opportunity of successfully 
testing a recently developed peripherally restricted µ-opioid agonist (Furst et al., 2005) in the 
dural skull preparation (Baillie et al., 2015), that may potentially lead to analgesia without the 
unwanted side effects (Stein, 2013).  
In experiments performed that are not included in this dissertation I had the opportunity 
to test several selective, small-molecule Na+ and Ca2+ channel blockers being developed for 
analgesic purpose by the lab of Dr. Terry Snutch at The University of British Columbia. 
Interestingly differences in the effectiveness of a few of the molecules were found to exist when 
results in the preparation were compared to previous results gathered in nociceptor somata 
indicating the utility of the dural-skull preparation in testing novel analgesic compounds. 
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5.6.3 In vivo study of dural nociceptors 
 It can be inferred by the title of numerous recent reviews (Dodick, 2008; Lambert, 2010; 
Levy, 2010; Messlinger, 2009) that much of the current understanding regarding the 
pathophysiological mechanisms of migraine remain speculative in nature and it has also been 
proposed that the pharmaceutical industry is losing interest in developing new drugs to treat 
migraine (Olesen and Jansen-Olesen, 2012). Both of these issues have been attributed to a lack 
of a reliable animal model of the disorder to understand the pathophysiological mechanisms and 
test novel compounds. 
 The creation of ultra-sensitive genetically encoded Ca2+ indicators as described above 
offers the ability to extend the dural skull preparation in vivo while leaving the cranium 
completely intact. I have been able to perform in vivo imaging of the mouse dura through a 
thinned-skull optical window, which leaves the skull intact and allows the dural nociceptive 
fibres, vasculature, and immune cells to remain completely undisturbed. The thinness of the skull 
at the location of the optical window, together with the proximity of the dural fibres beneath the 
skull allows for excellent optical resolution to be achieved while imaging through the skull in the 
anesthetized animal (Figure 5.6).  
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Figure 5.6 Thinned-skull optical window technique for imaging of sensory fibres in live 
mice.  
A) Mouse shown in the head-mounted position (to reduce movement artifacts during imaging). 
The highlighted circle marks the anatomical location of the thinned-skull optical window. B) A 
schematic diagram showing the imaging lens and cross section of the skull with relative sizes of 
the thinned imaging area (thinnest region is ~20 µm in thickness and ~200 µm in diameter). C) 
In vivo two- photon overlay image showing EGFP-CGRP fibres (green) and Alexa-594 
conjugated isolectin B4 stained arterioles (red) (tail vein injection). D) A terminating sensory 
fibre at higher magnification from boxed area in (C). 
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Two methods can be used to initiate activation of the dural nociceptors and are 
considered a “migraine model” in mice; the activation of a cortical speading depression (CSD) 
event (Eikermann-Haerter and Moskowitz, 2008) and the infusion of glyceryl trinitrite (GTN) 
(Olesen and Jansen-Olesen, 2012). 
5.6.3.1 Cortical spreading depression  
One key event that may be responsible for the initiation of migraine appears to be cortical 
spreading depression (CSD), a self-propagating wave of tissue depolarization that migrates 
without a loss in depolarization amplitude and is followed by a prolonged period of suppressed 
neural activity (Lauritzen, 1994; Leao, 1944; Olsen, 1995). In up to 30% of migraine sufferers 
there is a pre-headache experience termed ‘aura’; a transient disorder of cerebral cortical 
functioning that typically manifests as visual disturbances that drift across the visual field. 
Additional sensory and/or motor changes can also occur that are believed to be caused by CSD 
(Goadsby, 2007). For the ~70% of migraineurs that do not experience aura, it may be that CSD is 
in clinically less conspicuous brain regions compared with the visual cortex and may be the 
trigger of migraine pain ostensibly without a ‘perceived’ aura (Ayata, 2010). 
 CSD can be experimentally provoked by topical application of chemicals like KCl, by 
mechanical stimulation of the cortex with a pin prick or by electrical stimulation of the cortex 
(Eikermann-Haerter and Moskowitz, 2008). The experimental process for studying activation of 
dural nociceptors caused by a CSD event involves making a very small hole away from the 
imaging region and mechanically, chemically or electrically stimulating the cortex to induce 
CSD followed by monitoring of the Ca2+ activity in the nociceptors. The in vivo thinned skull 
method also allows for observation of dural vasculature through a simple tail vein injection of 
Alexa-594 conjugated isolectin B4 (Figure 5.6).   
	   132	  
5.6.3.2 Nitric oxide donors 
Nitric oxide (NO) is a versatile gaseous signaling molecule that plays a key role in a 
variety of biological processes including inflammation and neurotransmission. NO is suggested 
to be a key constituent in the generation of nociceptive processes in migraine pain (Olesen, 2008; 
Olesen et al., 1993; Olesen et al., 1995). In migraineurs, the infusion of the NO donors, 
nitroglycerin and nitroprusside induced headaches that were reported to be very similar to 
spontaneous migraine attacks (Christiansen et al., 1999). Nitrite, a stable product of NO 
degradation, has been found in high concentrations in the venous outflow from the head during 
migraine attacks (Sarchielli et al., 2000) and elevated venous nitrite levels exist even between 
attacks in migraineurs when compared with healthy controls (D'amico et al., 2002). Similarly, 
clinical trials suggest that blockade of endogenous NO generation can be successful in 
alleviating migraine pain (Lassen et al., 1997). 
 The infusion of nitric oxide donors has been extended to rodents to create an animal 
model of migraine (Bates et al., 2010; Iversen et al., 1989; Pardutz et al., 2000) and could 
potentially be used with the thinned skull preparation in transgenic mice expressing GCMP6 in 
TRPV1 containing neurons to monitor peripheral afferent activity during nitric oxide induced 
headache. The role the dural vasculature plays in nitric oxide induced headache could also be 
observed with a tail vein injection of Alexa-594 conjugated isolectin B4. 
 The development of the dural-skull preparation to study signaling in the peripheral 
terminals of nociceptors and the ability to extend the study of peripheral terminals in vivo will 
hopefully help unravel some of the poorly understood mechanisms of both peripheral nociceptive 
signaling and migraine headache.  
 
	   133	  
REFERENCES 
Abdel Samad, O., Liu, Y., Yang, F.C., Kramer, I., Arber, S., and Ma, Q. (2010). Characterization 
of two Runx1-dependent nociceptor differentiation programs necessary for inflammatory versus 
neuropathic pain. Molecular pain 6, 45. 
Adeeb, N., Mortazavi, M.M., Tubbs, R.S., and Cohen-Gadol, A.A. (2012). The cranial dura 
mater: a review of its history, embryology, and anatomy. Child's nervous system : ChNS : 
official journal of the International Society for Pediatric Neurosurgery 28, 827-837. 
Ahn, A.H., and Basbaum, A.I. (2005). Where do triptans act in the treatment of migraine? Pain 
115, 1-4. 
Akerman, S., Holland, P.R., and Goadsby, P.J. (2011). Diencephalic and brainstem mechanisms 
in migraine. Nat Rev Neurosci 12, 570-584. 
Akerman, S., Holland, P.R., Lasalandra, M.P., and Goadsby, P.J. (2010). Inhibition of 
trigeminovascular dural nociceptive afferents by Ca(2+)-activated K(+) (MaxiK/BK(Ca)) 
channel opening. Pain 151, 128-136. 
Akins, P.T., and McCleskey, E.W. (1993). Characterization of potassium currents in adult rat 
sensory neurons and modulation by opioids and cyclic AMP. Neuroscience 56, 759-769. 
Al-Aqaba, M.A., Fares, U., Suleman, H., Lowe, J., and Dua, H.S. (2010). Architecture and 
distribution of human corneal nerves. The British journal of ophthalmology 94, 784-789. 
Al-Khrasani, M., Spetea, M., Friedmann, T., Riba, P., Kiraly, K., Schmidhammer, H., and Furst, 
S. (2007). DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine 
show peripheral, preemptive antinociception after systemic administration in a mouse visceral 
pain model and high intrinsic efficacy in the isolated rat vas deferens. Brain research bulletin 74, 
369-375. 
Altier, C., Dale, C.S., Kisilevsky, A.E., Chapman, K., Castiglioni, A.J., Matthews, E.A., Evans, 
R.M., Dickenson, A.H., Lipscombe, D., Vergnolle, N., et al. (2007). Differential role of N-type 
calcium channel splice isoforms in pain. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 27, 6363-6373. 
Altier, C., and Zamponi, G.W. (2004). Targeting Ca2+ channels to treat pain: T-type versus N-
type. Trends Pharmacol Sci 25, 465-470. 
Amatrudo, J.M., Olson, J.P., Lur, G., Chiu, C.Q., Higley, M.J., and Ellis-Davies, G.C. (2014). 
Wavelength-selective one- and two-photon uncaging of GABA. ACS chemical neuroscience 5, 
64-70. 
Amrutkar, D.V., Ploug, K.B., Olesen, J., and Jansen-Olesen, I. (2011). Role for Voltage Gated 
Calcium Channels in Calcitonin Gene-Related Peptide Release in the Rat Trigeminovascular 
System. Neuroscience 172, 510-517. 
	   134	  
Ansel, J.C., Brown, J.R., Payan, D.G., and Brown, M.A. (1993). Substance P selectively 
activates TNF-alpha gene expression in murine mast cells. Journal of immunology 150, 4478-
4485. 
Arvieu, L., Mauborgne, A., Bourgoin, S., Oliver, C., Feltz, P., Hamon, M., and Cesselin, F. 
(1996). Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord. 
Neuroreport 7, 1973-1976. 
Assas, B.M., Pennock, J.I., and Miyan, J.A. (2014). Calcitonin gene-related peptide is a key 
neurotransmitter in the neuro-immune axis. Frontiers in neuroscience 8, 23. 
Ayata, C. (2010). Cortical spreading depression triggers migraine attack: pro. Headache 50, 725-
730. 
Babos, M.B., Grady, B., Wisnoff, W., and McGhee, C. (2013). Pathophysiology of pain. 
Disease-a-month : DM 59, 330-358. 
Baillie, L.D., Ahn, A.H., and Mulligan, S.J. (2012). Sumatriptan inhibition of N-type calcium 
channel mediated signaling in dural CGRP terminal fibres. Neuropharmacology 63, 362-367. 
Baillie, L.D., Hagen, V., Gardner, K.M., and Mulligan, S.J. (2011). Functional imaging within 
individual pain fibres ex vivo with optical microscopy. Journal of neuroscience methods 198, 
274-279. 
Baillie, L.D., Schmidhammer, H., and Mulligan, S.J. (2015). Peripheral mu-opioid receptor 
mediated inhibition of calcium signaling and action potential-evoked calcium fluorescent 
transients in primary afferent CGRP nociceptive terminals. Neuropharmacology 93, 267-273. 
Bartsch, T., Knight, Y.E., and Goadsby, P.J. (2004). Activation of 5-HT(1B/1D) receptor in the 
periaqueductal gray inhibits nociception. Ann Neurol 56, 371-381. 
Basbaum, A.I., Bautista, D.M., Scherrer, G., and Julius, D. (2009). Cellular and molecular 
mechanisms of pain. Cell 139, 267-284. 
Bates, E.A., Nikai, T., Brennan, K.C., Fu, Y.H., Charles, A.C., Basbaum, A.I., Ptacek, L.J., and 
Ahn, A.H. (2010). Sumatriptan alleviates nitroglycerin-induced mechanical and thermal 
allodynia in mice. Cephalalgia : an international journal of headache 30, 170-178. 
Benarroch, E.E. (2011). CGRP: sensory neuropeptide with multiple neurologic implications. 
Neurology 77, 281-287. 
Benemei, S., Nicoletti, P., Capone, J.G., and Geppetti, P. (2009). CGRP receptors in the control 
of pain and inflammation. Current opinion in pharmacology 9, 9-14. 
Bennett, G.J., and Xie, Y.K. (1988). A Peripheral Mononeuropathy in Rat That Produces 
Disorders of Pain Sensation Like Those Seen in Man. Pain 33, 87-107. 
	   135	  
Berkefeld, H., Fakler, B., and Schulte, U. (2010). Ca2+-activated K+ channels: from protein 
complexes to function. Physiological reviews 90, 1437-1459. 
Bigal, M.E., Krymchantowski, A.V., and Ho, T. (2009). Migraine in the triptan era: progresses 
achieved, lessons learned and future developments. Arq Neuropsiquiatr 67, 559-569. 
Bileviciute-Ljungar, I., Spetea, M., Guo, Y., Schutz, J., Windisch, P., and Schmidhammer, H. 
(2006). Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-
epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]ace tic acid (HS-731) 
after subcutaneous and oral administration in rats with carrageenan-induced hindpaw 
inflammation. The Journal of pharmacology and experimental therapeutics 317, 220-227. 
Bird, G.C., Han, J.S., Fu, Y., Adwanikar, H., Willis, W.D., and Neugebauer, V. (2006). Pain-
related synaptic plasticity in spinal dorsal horn neurons: role of CGRP. Molecular pain 2, 31. 
Blanchard, J.W., Eade, K.T., Szucs, A., Lo Sardo, V., Tsunemoto, R.K., Williams, D., Sanna, 
P.P., and Baldwin, K.K. (2015). Selective conversion of fibroblasts into peripheral sensory 
neurons. Nature neuroscience 18, 25-+. 
Bollmann, J.H., and Sakmann, B. (2005). Control of synaptic strength and timing by the release-
site Ca2+ signal. Nature neuroscience 8, 426-434. 
Boyce-Rustay, J.M., Honore, P., and Jarvis, M.F. (2010). Animal models of acute and chronic 
inflammatory and nociceptive pain. Methods in molecular biology 617, 41-55. 
Brain, S.D., and Grant, A.D. (2004). Vascular actions of calcitonin gene-related peptide and 
adrenomedullin. Physiological reviews 84, 903-934. 
Brain, S.D., Williams, T.J., Tippins, J.R., Morris, H.R., and MacIntyre, I. (1985). Calcitonin 
gene-related peptide is a potent vasodilator. Nature 313, 54-56. 
Brower, V. (2000). New paths to pain relief. Nature biotechnology 18, 387-391. 
Bruce, A.N. (1913). Vaso-dilator axon reflexes. Q J Exp Physiol 6, 339 - 354. 
Burgos-Vega, C., Moy, J., and Dussor, G. (2015). Meningeal afferent signaling and the 
pathophysiology of migraine. Progress in molecular biology and translational science 131, 537-
564. 
Burkey, T.H., Hingtgen, C.M., and Vasko, M.R. (2004). Isolation and culture of sensory neurons 
from the dorsal-root ganglia of embryonic or adult rats. Methods in molecular medicine 99, 189-
202. 
Buzas, B., and Cox, B.M. (1997). Quantitative analysis of MU and delta opioid receptor gene 
expression in rat brain and peripheral ganglia using competitive polymerase chain reaction. 
Neuroscience 76, 479-489. 
	   136	  
Buzzi, M.G., Carter, W.B., Shimizu, T., Heath, H., 3rd, and Moskowitz, M.A. (1991). 
Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal 
sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30, 1193-
1200. 
Carr, R.W., and Brock, J.A. (2002). Electrophysiology of corneal cold receptor nerve terminals. 
Advances in experimental medicine and biology 508, 19-23. 
Carr, R.W., Pianova, S., and Brock, J.A. (2002). The effects of polarizing current on nerve 
terminal impulses recorded from polymodal and cold receptors in the guinea-pig cornea. The 
Journal of general physiology 120, 395-405. 
Carr, R.W., Pianova, S., Fernandez, J., Fallon, J.B., Belmonte, C., and Brock, J.A. (2003). 
Effects of heating and cooling on nerve terminal impulses recorded from cold-sensitive receptors 
in the guinea-pig cornea. The Journal of general physiology 121, 427-439. 
Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., and Julius, D. 
(1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 
816-824. 
Cavanaugh, D.J., Chesler, A.T., Jackson, A.C., Sigal, Y.M., Yamanaka, H., Grant, R., 
O'Donnell, D., Nicoll, R.A., Shah, N.M., Julius, D., et al. (2011). Trpv1 reporter mice reveal 
highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. 
The Journal of neuroscience : the official journal of the Society for Neuroscience 31, 5067-5077. 
Cesare, P., and McNaughton, P. (1996). A novel heat-activated current in nociceptive neurons 
and its sensitization by bradykinin. Proceedings of the National Academy of Sciences of the 
United States of America 93, 15435-15439. 
Chambers, S.M., Qi, Y.C., Mica, Y., Lee, G., Zhang, X.J., Niu, L., Bilsland, J., Cao, L.S., 
Stevens, E., Whiting, P., et al. (2012). Combined small-molecule inhibition accelerates 
developmental timing and converts human pluripotent stem cells into nociceptors. Nat 
Biotechnol 30, 715-+. 
Chen, J.J., Dymshitz, J., and Vasko, M.R. (1997). Regulation of opioid receptors in rat sensory 
neurons in culture. Mol Pharmacol 51, 666-673. 
Chen, S.R., Cai, Y.Q., and Pan, H.L. (2009). Plasticity and emerging role of BKCa channels in 
nociceptive control in neuropathic pain. Journal of neurochemistry 110, 352-362. 
Chen, T.W., Wardill, T.J., Sun, Y., Pulver, S.R., Renninger, S.L., Baohan, A., Schreiter, E.R., 
Kerr, R.A., Orger, M.B., Jayaraman, V., et al. (2013). Ultrasensitive fluorescent proteins for 
imaging neuronal activity. Nature 499, 295-300. 
Chiu, I.M., von Hehn, C.A., and Woolf, C.J. (2012). Neurogenic inflammation and the peripheral 
nervous system in host defense and immunopathology. Nature neuroscience 15, 1063-1067. 
	   137	  
Chong, S.Z., Evrard, M., and Ng, L.G. (2013). Lights, camera, and action: vertebrate skin sets 
the stage for immune cell interaction with arthropod-vectored pathogens. Frontiers in 
immunology 4, 286. 
Christiansen, I., Thomsen, L.L., Daugaard, D., Ulrich, V., and Olesen, J. (1999). Glyceryl 
trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia 
: an international journal of headache 19, 660-667. 
Chung, M.K., Guler, A.D., and Caterina, M.J. (2008). TRPV1 shows dynamic ionic selectivity 
during agonist stimulation. Nature neuroscience 11, 555-564. 
Clapham, D.E. (2003). TRP channels as cellular sensors. Nature 426, 517-524. 
Cohen, S.P., and Mao, J. (2014). Neuropathic pain: mechanisms and their clinical implications. 
Bmj 348, f7656. 
Cook, A.J., Woolf, C.J., Wall, P.D., and McMahon, S.B. (1987). Dynamic receptive field 
plasticity in rat spinal cord dorsal horn following C-primary afferent input. Nature 325, 151-153. 
Cox, J.J., Reimann, F., Nicholas, A.K., Thornton, G., Roberts, E., Springell, K., Karbani, G., 
Jafri, H., Mannan, J., Raashid, Y., et al. (2006). An SCN9A channelopathy causes congenital 
inability to experience pain. Nature 444, 894-898. 
Cumberbatch, M.J., Hill, R.G., and Hargreaves, R.J. (1997). Rizatriptan has central 
antinociceptive effects against durally evoked responses. European journal of pharmacology 328, 
37-40. 
Cunha, T.M., Verri, W.A., Jr., Vivancos, G.G., Moreira, I.F., Reis, S., Parada, C.A., Cunha, 
F.Q., and Ferreira, S.H. (2004). An electronic pressure-meter nociception paw test for mice. 
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e 
biologicas / Sociedade Brasileira de Biofisica  [et al] 37, 401-407. 
Currie, K.P. (2010). G protein modulation of CaV2 voltage-gated calcium channels. Channels 
(Austin) 4, 497-509. 
D'amico, D., Ferraris, A., Leone, M., Catania, A., Carlin, A., Grazzi, L., and Bussone, G. (2002). 
Increased plasma nitrites in migraine and cluster headache patients in interictal period: basal 
hyperactivity of L-arginine-NO pathway? Cephalalgia : an international journal of headache 22, 
33-36. 
D'amour, F.E., and Smith, D.L. (1941). A method for determining loss of pain sensation. Journal 
of Pharmacology and Experimental Therapeutics 72, 74-79. 
Dib-Hajj, S.D., Yang, Y., Black, J.A., and Waxman, S.G. (2013). The Na(V)1.7 sodium channel: 
from molecule to man. Nature reviews Neuroscience 14, 49-62. 
Ding, W., Stohl, L.L., Wagner, J.A., and Granstein, R.D. (2008). Calcitonin gene-related peptide 
biases Langerhans cells toward Th2-type immunity. Journal of immunology 181, 6020-6026. 
	   138	  
Dodge, F.A., Jr., and Rahamimoff, R. (1967). Co-operative action a calcium ions in transmitter 
release at the neuromuscular junction. The Journal of physiology 193, 419-432. 
Dodick, D., and Silberstein, S. (2006). Central sensitization theory of migraine: clinical 
implications. Headache 46 Suppl 4, S182-191. 
Dodick, D.W. (2008). Examining the essence of migraine--is it the blood vessel or the brain? A 
debate. Headache 48, 661-667. 
Dorland, W.A.N. (2003). Dorland's Illustrated Medical Dictionary, 30th Edition, 30th edn 
(Philadelphia Saunders/Elsevier). 
Dubin, A.E., and Patapoutian, A. (2010). Nociceptors: the sensors of the pain pathway. The 
Journal of clinical investigation 120, 3760-3772. 
Duncan, R.R., Greaves, J., Wiegand, U.K., Matskevich, I., Bodammer, G., Apps, D.K., Shipston, 
M.J., and Chow, R.H. (2003). Functional and spatial segregation of secretory vesicle pools 
according to vesicle age. Nature 422, 176-180. 
Durham, P.L. (2006). Calcitonin gene-related peptide (CGRP) and migraine. Headache 46, S3-
S8. 
Durham, P.L. (2008). Inhibition of calcitonin gene-related peptide function: a promising strategy 
for treating migraine. Headache 48, 1269-1275. 
Durham, P.L., and Russo, A.F. (1999). Regulation of calcitonin gene-related peptide secretion by 
a serotonergic antimigraine drug. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 19, 3423-3429. 
Durham, P.L., and Russo, A.F. (2002). New insights into the molecular actions of serotonergic 
antimigraine drugs. Pharmacol Ther 94, 77-92. 
Durham, P.L., and Russo, A.F. (2003). Stimulation of the calcitonin gene-related peptide 
enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in 
trigeminal ganglia neurons. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 23, 807-815. 
Durham, P.L., and Vause, C.V. (2010). Calcitonin gene-related peptide (CGRP) receptor 
antagonists in the treatment of migraine. CNS drugs 24, 539-548. 
Ebersberger, A. (2001). Physiology of meningeal innervation: aspects and consequences of 
chemosensitivity of meningeal nociceptors. Microscopy research and technique 53, 138-146. 
Ebersberger, A., Charbel Issa, P., Vanegas, H., and Schaible, H.G. (2000). Differential effects of 
calcitonin gene-related peptide and calcitonin gene-related peptide 8-37 upon responses to N-
methyl-D-aspartate or (R, S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate in spinal 
nociceptive neurons with knee joint input in the rat. Neuroscience 99, 171-178. 
	   139	  
Edvinsson, L., and Ho, T.W. (2010). CGRP receptor antagonism and migraine. 
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 7, 
164-175. 
Eftekhari, S., and Edvinsson, L. (2010). Possible sites of action of the new calcitonin gene-
related peptide receptor antagonists. Therapeutic advances in neurological disorders 3, 369-378. 
Eftekhari, S., Salvatore, C.A., Calamari, A., Kane, S.A., Tajti, J., and Edvinsson, L. (2010). 
Differential distribution of calcitonin gene-related peptide and its receptor components in the 
human trigeminal ganglion. Neuroscience 169, 683-696. 
Eikermann-Haerter, K., and Moskowitz, M.A. (2008). Animal models of migraine headache and 
aura. Current opinion in neurology 21, 294-300. 
Endres-Becker, J., Heppenstall, P.A., Mousa, S.A., Labuz, D., Oksche, A., Schafer, M., Stein, C., 
and Zollner, C. (2007). Mu-opioid receptor activation modulates transient receptor potential 
vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol 
Pharmacol 71, 12-18. 
Esteban, J.A., Shi, S.H., Wilson, C., Nuriya, M., Huganir, R.L., and Malinow, R. (2003). PKA 
phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. 
Nature neuroscience 6, 136-143. 
Fakler, B., and Adelman, J.P. (2008). Control of K(Ca) channels by calcium nano/microdomains. 
Neuron 59, 873-881. 
Farazifard, R., Safarpour, F., Sheibani, V., and Javan, M. (2005). Eye-wiping test: a sensitive 
animal model for acute trigeminal pain studies. Brain research Brain research protocols 16, 44-
49. 
Feindel, W., Penfield, W., and Mc, N.F. (1960). The tentorial nerves and Iocalization of 
intracranial pain in man. Neurology 10, 555-563. 
Fertleman, C.R., Baker, M.D., Parker, K.A., Moffatt, S., Elmslie, F.V., Abrahamsen, B., Ostman, 
J., Klugbauer, N., Wood, J.N., Gardiner, R.M., et al. (2006). SCN9A mutations in paroxysmal 
extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 
52, 767-774. 
Fields, H.L., Emson, P.C., Leigh, B.K., Gilbert, R.F., and Iversen, L.L. (1980). Multiple opiate 
receptor sites on primary afferent fibres. Nature 284, 351-353. 
Fischer, M.J. (2010). Calcitonin gene-related peptide receptor antagonists for migraine. Expert 
opinion on investigational drugs 19, 815-823. 
Foreman, J.C. (1987). Peptides and Neurogenic Inflammation. Brit Med Bull 43, 386-400. 
	   140	  
Franck, M.C., Stenqvist, A., Li, L., Hao, J., Usoskin, D., Xu, X., Wiesenfeld-Hallin, Z., and 
Ernfors, P. (2011). Essential role of Ret for defining non-peptidergic nociceptor phenotypes and 
functions in the adult mouse. The European journal of neuroscience 33, 1385-1400. 
Fricke, B., Andres, K.H., and Von During, M. (2001). Nerve fibers innervating the cranial and 
spinal meninges: morphology of nerve fiber terminals and their structural integration. 
Microscopy research and technique 53, 96-105. 
Fricke, B., von During, M., and Andres, K.H. (1997). Topography and immunocytochemical 
characterization of nerve fibers in the leptomeningeal compartments of the rat. A light- and 
electron-microscopical study. Cell and tissue research 287, 11-22. 
Fruhstorfer, H., Gross, W., and Selbmann, O. (2001). von Frey hairs: new materials for a new 
design. European journal of pain 5, 341-342. 
Furst, S., Riba, P., Friedmann, T., Timar, J., Al-Khrasani, M., Obara, I., Makuch, W., Spetea, M., 
Schutz, J., Przewlocki, R., et al. (2005). Peripheral versus central antinociceptive actions of 6-
amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain 
in the rat. The Journal of pharmacology and experimental therapeutics 312, 609-618. 
Gamse, R., and Saria, A. (1986). Nociceptive behavior after intrathecal injections of substance P, 
neurokinin A and calcitonin gene-related peptide in mice. Neuroscience letters 70, 143-147. 
Gearing, D.P., Virtue, E.R., Gearing, R.P., and Drew, A.C. (2013). A fully caninised anti-NGF 
monoclonal antibody for pain relief in dogs. BMC veterinary research 9, 226. 
Gilbert, D., Funk, K., Dekowski, B., Lechler, R., Keller, S., Mohrlen, F., Frings, S., and Hagen, 
V. (2007). Caged capsaicins: New tools for the examination of TRPV1 channels in 
somatosensory neurons. Chembiochem 8, 89-97. 
Goadsby, P.J. (2007). Recent advances in understanding migraine mechanisms, molecules and 
therapeutics. Trends in molecular medicine 13, 39-44. 
Goadsby, P.J., and Edvinsson, L. (1993). The trigeminovascular system and migraine: studies 
characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 
33, 48-56. 
Goadsby, P.J., Edvinsson, L., and Ekman, R. (1990). Vasoactive peptide release in the 
extracerebral circulation of humans during migraine headache. Annals of neurology 28, 183-187. 
Goadsby, P.J., Lipton, R.B., and Ferrari, M.D. (2002). Migraine--current understanding and 
treatment. The New England journal of medicine 346, 257-270. 
Gold, M.S., and Gebhart, G.F. (2010). Nociceptor sensitization in pain pathogenesis. Nature 
medicine 16, 1248-1257. 
	   141	  
Gover, T.D., Kao, J.P., and Weinreich, D. (2003). Calcium signaling in single peripheral sensory 
nerve terminals. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 23, 4793-4797. 
Gover, T.D., Moreira, T.H., Kao, J.P., and Weinreich, D. (2007). Calcium regulation in 
individual peripheral sensory nerve terminals of the rat. The Journal of physiology 578, 481-490. 
Grace, P.M., Hutchinson, M.R., Maier, S.F., and Watkins, L.R. (2014). Pathological pain and the 
neuroimmune interface. Nature reviews Immunology 14, 217-231. 
Grandl, J., Kim, S.E., Uzzell, V., Bursulaya, B., Petrus, M., Bandell, M., and Patapoutian, A. 
(2010). Temperature-induced opening of TRPV1 ion channel is stabilized by the pore domain. 
Nature neuroscience 13, 708-714. 
Handwerker, H.O. (2010). Classification of nociceptors - To what purpose? Pain 148, 355-356. 
Hargreaves, K., Dubner, R., Brown, F., Flores, C., and Joris, J. (1988). A new and sensitive 
method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32, 77-88. 
Hargreaves, R. (2007). New migraine and pain research. Headache 47 Suppl 1, S26-43. 
Harriott, A.M., and Gold, M.S. (2008). Serotonin type 1D receptors (5HTR) are differentially 
distributed in nerve fibres innervating craniofacial tissues. Cephalalgia : an international journal 
of headache 28, 933-944. 
Harrison, R.G. (1907). Observations on the living developing nerve fiber. P Soc Exp Biol Med 4, 
140-143. 
Heinricher, M.M., Tavares, I., Leith, J.L., and Lumb, B.M. (2009). Descending control of 
nociception: Specificity, recruitment and plasticity. Brain research reviews 60, 214-225. 
Ho, T.W., Edvinsson, L., and Goadsby, P.J. (2010). CGRP and its receptors provide new insights 
into migraine pathophysiology. Nat Rev Neurol 6, 573-582. 
Hoffmann, J., and Goadsby, P.J. (2011). New Agents for Acute Treatment of Migraine: CGRP 
Receptor Antagonists, iNOS Inhibitors. Current treatment options in neurology. 
Honore, E. (2007). The neuronal background K2P channels: focus on TREK1. Nature reviews 
Neuroscience 8, 251-261. 
Honore, P., Wismer, C.T., Mikusa, J., Zhu, C.Z., Zhong, C., Gauvin, D.M., Gomtsyan, A., El 
Kouhen, R., Lee, C.H., Marsh, K., et al. (2005). A-425619 [1-isoquinolin-5-yl-3-(4-
trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, 
relieves pathophysiological pain associated with inflammation and tissue injury in rats. The 
Journal of pharmacology and experimental therapeutics 314, 410-421. 
	   142	  
Hoskin, K.L., and Goadsby, P.J. (1998). Comparison of more and less lipophilic serotonin 
(5HT(1B/1D)) agonists in a model of trigeminovascular nociception in cat. Exp Neurol 150, 45-
51. 
Huang, J., Han, C., Estacion, M., Vasylyev, D., Hoeijmakers, J.G., Gerrits, M.M., Tyrrell, L., 
Lauria, G., Faber, C.G., Dib-Hajj, S.D., et al. (2014). Gain-of-function mutations in sodium 
channel Na(v)1.9 in painful neuropathy. Brain : a journal of neurology 137, 1627-1642. 
Humphrey, P.P., and Feniuk, W. (1991). Mode of action of the anti-migraine drug sumatriptan. 
Trends Pharmacol Sci 12, 444-446. 
Humphrey, P.P.A., and Goadsby, P.J. (1994). The Mode of Action of Sumatriptan Is Vascular - a 
Debate. Cephalalgia : an international journal of headache 14, 401-410. 
Iftinca, M.C., and Zamponi, G.W. (2009). Regulation of neuronal T-type calcium channels. 
Trends Pharmacol Sci 30, 32-40. 
Iversen, H.K., Olesen, J., and Tfelthansen, P. (1989). Intravenous Nitroglycerin as an 
Experimental-Model of Vascular Headache - Basic Characteristics. Pain 38, 17-24. 
Iwaszkiewicz, K.S., Schneider, J.J., and Hua, S. (2013). Targeting peripheral opioid receptors to 
promote analgesic and anti-inflammatory actions. Frontiers in pharmacology 4, 132. 
Jancsó, G.b. (2009). Neurogenic inflammation in health and disease, 1st edn (Amsterdam: 
Elsevier). 
Jansen-Olesen, I., Mortensen, A., and Edvinsson, L. (1996). Calcitonin gene-related peptide is 
released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral 
arteries concomitant with activation of adenylyl cyclase. Cephalalgia : an international journal of 
headache 16, 310-316. 
Janssen, P.A., Niemegeers, C.J., and Dony, J.G. (1963). The inhibitory effect of fentanyl and 
other morphine-like analgesics on the warm water induced tail withdrawl reflex in rats. 
Arzneimittel-Forschung 13, 502-507. 
Jevtovic-Todorovic, V., and Todorovic, S.M. (2006). The role of peripheral T-type calcium 
channels in pain transmission. Cell calcium 40, 197-203. 
Ji, R.R., Kohno, T., Moore, K.A., and Woolf, C.J. (2003). Central sensitization and LTP: do pain 
and memory share similar mechanisms? Trends in neurosciences 26, 696-705. 
Jordt, S.E., and Julius, D. (2002). Molecular basis for species-specific sensitivity to "hot" chili 
peppers. Cell 108, 421-430. 
Jordt, S.E., Tominaga, M., and Julius, D. (2000). Acid potentiation of the capsaicin receptor 
determined by a key extracellular site. Proceedings of the National Academy of Sciences of the 
United States of America 97, 8134-8139. 
	   143	  
Julius, D., and Basbaum, A.I. (2001). Molecular mechanisms of nociception. Nature 413, 203-
210. 
Kandel, E.R. (2013). Principles of neural science, 5th edn (New York: McGraw-Hill). 
Kangrga, I., Larew, J.S., and Randic, M. (1990). The effects of substance P and calcitonin gene-
related peptide on the efflux of endogenous glutamate and aspartate from the rat spinal dorsal 
horn in vitro. Neuroscience letters 108, 155-160. 
Kangrga, I., and Randic, M. (1990). Tachykinins and calcitonin gene-related peptide enhance 
release of endogenous glutamate and aspartate from the rat spinal dorsal horn slice. The Journal 
of neuroscience : the official journal of the Society for Neuroscience 10, 2026-2038. 
Katz, B., and Miledi, R. (1965). The Effect of Calcium on Acetylcholine Release from Motor 
Nerve Terminals. Proc R Soc Lond B Biol Sci 161, 496-503. 
Kaube, H., Hoskin, K.L., and Goadsby, P.J. (1993). Inhibition by sumatriptan of central 
trigeminal neurones only after blood-brain barrier disruption. British journal of pharmacology 
109, 788-792. 
Kieffer, B.L., and Gaveriaux-Ruff, C. (2002). Exploring the opioid system by gene knockout. 
Progress in neurobiology 66, 285-306. 
Kilo, S., Harding-Rose, C., Hargreaves, K.M., and Flores, C.M. (1997). Peripheral CGRP release 
as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion 
in rat paw skin. Pain 73, 201-207. 
Kim, S.E., Coste, B., Chadha, A., Cook, B., and Patapoutian, A. (2012). The role of Drosophila 
Piezo in mechanical nociception. Nature 483, 209-212. 
Kipnis, J., Gadani, S., and Derecki, N.C. (2012). Pro-cognitive properties of T cells. Nature 
reviews Immunology 12, 663-669. 
Klinger, A.B., Eberhardt, M., Link, A.S., Namer, B., Kutsche, L.K., Schuy, E.T., Sittl, R., 
Hoffmann, T., Alzheimer, C., Huth, T., et al. (2012). Sea-anemone toxin ATX-II elicits A-fiber-
dependent pain and enhances resurgent and persistent sodium currents in large sensory neurons. 
Molecular pain 8, 69. 
Kostyuk, E.P., and Kostyuk, P.G. (2009). Peculiarities of Ion Channels and Modulation of Their 
Functions in Neurons Belonging to the Nociceptive System. Neurophysiology 41, 241-250. 
Kuner, R. (2010). Central mechanisms of pathological pain. Nature medicine 16, 1258-1266. 
Lambert, G.A. (2010). The lack of peripheral pathology in migraine headache. Headache 50, 
895-908. 
Lassen, L.H., Ashina, M., Christiansen, I., Ulrich, V., and Olesen, J. (1997). Nitric oxide 
synthase inhibition in migraine. Lancet 349, 401-402. 
	   144	  
Lassen, L.H., Haderslev, P.A., Jacobsen, V.B., Iversen, H.K., Sperling, B., and Olesen, J. (2002). 
CGRP may play a causative role in migraine. Cephalalgia : an international journal of headache 
22, 54-61. 
Latremoliere, A., and Woolf, C.J. (2009). Central sensitization: a generator of pain 
hypersensitivity by central neural plasticity. The journal of pain : official journal of the American 
Pain Society 10, 895-926. 
Lauritzen, M. (1994). Pathophysiology of the migraine aura. The spreading depression theory. 
Brain : a journal of neurology 117 ( Pt 1), 199-210. 
Le Bars, D., Gozariu, M., and Cadden, S.W. (2001). Animal models of nociception. 
Pharmacological reviews 53, 597-652. 
Le Greves, P., Nyberg, F., Terenius, L., and Hokfelt, T. (1985). Calcitonin gene-related peptide 
is a potent inhibitor of substance P degradation. European journal of pharmacology 115, 309-
311. 
Leao, A.A.P. (1944). Spreading depression of activity in the cerebral cortex. Journal of 
neurophysiology 7, 359-390. 
Lee, J.H., Park, C.K., Chen, G., Han, Q., Xie, R.G., Liu, T., Ji, R.R., and Lee, S.Y. (2014). A 
monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell 
157, 1393-1404. 
Leiser, S.C., and Moxon, K.A. (2007). Responses of trigeminal ganglion neurons during natural 
whisking behaviors in the awake rat. Neuron 53, 117-133. 
Lennerz, J.K., Ruhle, V., Ceppa, E.P., Neuhuber, W.L., Bunnett, N.W., Grady, E.F., and 
Messlinger, K. (2008). Calcitonin receptor-like receptor (CLR), receptor activity-modifying 
protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat 
trigeminovascular system: differences between peripheral and central CGRP receptor 
distribution. The Journal of comparative neurology 507, 1277-1299. 
Levy, D. (2010). Migraine pain and nociceptor activation--where do we stand? Headache 50, 
909-916. 
Levy, D., Burstein, R., Kainz, V., Jakubowski, M., and Strassman, A.M. (2007). Mast cell 
degranulation activates a pain pathway underlying migraine headache. Pain 130, 166-176. 
Levy, D., Jakubowski, M., and Burstein, R. (2004). Disruption of communication between 
peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D 
receptor agonists. Proc Natl Acad Sci U S A 101, 4274-4279. 
Limmroth, V., Katsarava, Z., Liedert, B., Guehring, H., Schmitz, K., Diener, H.C., and Michel, 
M.C. (2001). An in vivo rat model to study calcitonin gene related peptide release following 
activation of the trigeminal vascular system. Pain 92, 101-106. 
	   145	  
Limmroth, V., May, A., Auerbach, P., Wosnitza, G., Eppe, T., and Diener, H.C. (1996). Changes 
in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for 
the pathophysiology of migraine. Journal of the neurological sciences 138, 60-65. 
Longmore, J., Shaw, D., Smith, D., Hopkins, R., McAllister, G., Pickard, J.D., Sirinathsinghji, 
D.J., Butler, A.J., and Hill, R.G. (1997). Differential distribution of 5HT1D- and 5HT1B-
immunoreactivity within the human trigemino-cerebrovascular system: implications for the 
discovery of new antimigraine drugs. Cephalalgia : an international journal of headache 17, 833-
842. 
Lu, R., Lukowski, R., Sausbier, M., Zhang, D.D., Sisignano, M., Schuh, C.D., Kuner, R., Ruth, 
P., Geisslinger, G., and Schmidtko, A. (2014). BKCa channels expressed in sensory neurons 
modulate inflammatory pain in mice. Pain 155, 556-565. 
Lulevich, V., Yang, H.Y., Isseroff, R.R., and Liu, G.Y. (2010). Single cell mechanics of 
keratinocyte cells. Ultramicroscopy 110, 1435-1442. 
Lundberg, J.M., Franco-Cereceda, A., Hua, X., Hokfelt, T., and Fischer, J.A. (1985). Co-
existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory 
nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. European journal 
of pharmacology 108, 315-319. 
Madrid, R., Donovan-Rodriguez, T., Meseguer, V., Acosta, M.C., Belmonte, C., and Viana, F. 
(2006). Contribution of TRPM8 channels to cold transduction in primary sensory neurons and 
peripheral nerve terminals. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 26, 12512-12525. 
Marmigere, F., and Ernfors, P. (2007). Specification and connectivity of neuronal subtypes in the 
sensory lineage. Nature reviews Neuroscience 8, 114-127. 
Matteoli, M., Haimann, C., Torritarelli, F., Polak, J.M., Ceccarelli, B., and Decamilli, P. (1988). 
Differential Effect of Alpha-Latrotoxin on Exocytosis from Small Synaptic Vesicles and from 
Large Dense-Core Vesicles Containing Calcitonin Gene-Related Peptide at the Frog 
Neuromuscular-Junction. Proceedings of the National Academy of Sciences of the United States 
of America 85, 7366-7370. 
McCormack, D.G., Mak, J.C., Coupe, M.O., and Barnes, P.J. (1989). Calcitonin gene-related 
peptide vasodilation of human pulmonary vessels. Journal of applied physiology 67, 1265-1270. 
McCoy, E.S., Taylor-Blake, B., Street, S.E., Pribisko, A.L., Zheng, J., and Zylka, M.J. (2013). 
Peptidergic CGRPalpha primary sensory neurons encode heat and itch and tonically suppress 
sensitivity to cold. Neuron 78, 138-151. 
Mehrotra, S., Gupta, S., Chan, K.Y., Villalon, C.M., Centurion, D., Saxena, P.R., and 
MaassenVanDenBrink, A. (2008). Current and prospective pharmacological targets in relation to 
antimigraine action. Naunyn Schmiedebergs Arch Pharmacol 378, 371-394. 
	   146	  
Melli, G., and Hoke, A. (2009). Dorsal Root Ganglia Sensory Neuronal Cultures: a tool for drug 
discovery for peripheral neuropathies. Expert opinion on drug discovery 4, 1035-1045. 
Messlinger, K. (2009). Migraine: where and how does the pain originate? Experimental brain 
research 196, 179-193. 
Messlinger, K., Hanesch, U., Baumgartel, M., Trost, B., and Schmidt, R.F. (1993). Innervation 
of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like 
and substance P-like immunoreactivity. Anatomy and embryology 188, 219-237. 
Meyer, R.A., Ringkamp, R., Campbell, J.N., and and Raja, S.N. (2005). Peripheral Mechanisms 
of Cutaneous Nociception. In Wall and Melzack's Texbook of Pain, M.K.S. McMahon, ed. 
(Elsevier), pp. 3-34. 
Moskowitz, M.A., and Cutrer, F.M. (1993). SUMATRIPTAN: a receptor-targeted treatment for 
migraine. Annual review of medicine 44, 145-154. 
Muller, L.J., Marfurt, C.F., Kruse, F., and Tervo, T.M. (2003). Corneal nerves: structure, 
contents and function. Experimental eye research 76, 521-542. 
Natura, G., von Banchet, G.S., and Schaible, H.G. (2005). Calcitonin gene-related peptide 
enhances TTX-resistant sodium currents in cultured dorsal root ganglion neurons from adult rats. 
Pain 116, 194-204. 
Niederkorn, J.Y. (2005). Corneal immune privilege. The ocular surface 3, S158-160. 
Nockemann, D., Rouault, M., Labuz, D., Hublitz, P., McKnelly, K., Reis, F.C., Stein, C., and 
Heppenstall, P.A. (2013). The K+ channel GIRK2 is both necessary and sufficient for peripheral 
opioid-mediated analgesia. Embo Mol Med 5, 1263-1277. 
Oh, U. (2006). The nociceptive membrane (Amsterdam ; Boston: Elsevier). 
Oh, U., Hwang, S.W., and Kim, D. (1996). Capsaicin activates a nonselective cation channel in 
cultured neonatal rat dorsal root ganglion neurons. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 16, 1659-1667. 
Olesen, J. (2008). The role of nitric oxide (NO) in migraine, tension-type headache and cluster 
headache. Pharmacology & therapeutics 120, 157-171. 
Olesen, J., Burstein, R., Ashina, M., and Tfelt-Hansen, P. (2009). Origin of pain in migraine: 
evidence for peripheral sensitisation. The Lancet Neurology 8, 679-690. 
Olesen, J., Iversen, H.K., and Thomsen, L.L. (1993). Nitric oxide supersensitivity: a possible 
molecular mechanism of migraine pain. Neuroreport 4, 1027-1030. 
Olesen, J., and Jansen-Olesen, I. (2012). Towards a reliable animal model of migraine. 
Cephalalgia : an international journal of headache 32, 578-580. 
	   147	  
Olesen, J., Thomsen, L.L., Lassen, L.H., and Olesen, I.J. (1995). The nitric oxide hypothesis of 
migraine and other vascular headaches. Cephalalgia : an international journal of headache 15, 
94-100. 
Olsen, T.S. (1995). Pathophysiology of the migraine aura: the spreading depression theory. Brain 
: a journal of neurology 118 ( Pt 1), 307-308. 
Pardutz, A., Krizbai, I., Multon, S., Vecsei, L., and Schoenen, J. (2000). Systemic nitroglycerin 
increases nNOS levels in rat trigeminal nucleus caudalis. Neuroreport 11, 3071-3075. 
Pettit, D.L., Wang, S.S., Gee, K.R., and Augustine, G.J. (1997). Chemical two-photon uncaging: 
a novel approach to mapping glutamate receptors. Neuron 19, 465-471. 
Pietrobon, D., and Striessnig, J. (2003). Neurobiology of migraine. Nature reviews Neuroscience 
4, 386-398. 
Potrebic, S., Ahn, A.H., Skinner, K., Fields, H.L., and Basbaum, A.I. (2003). Peptidergic 
nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: 
Implications for the selective antimigraine action of triptans. Journal of Neuroscience 23, 10988-
10997. 
Randall, L.O., and Selitto, J.J. (1957). A method for measurement of analgesic activity on 
inflamed tissue. Archives internationales de pharmacodynamie et de therapie 111, 409-419. 
Razzaque, Z., Heald, M.A., Pickard, J.D., Maskell, L., Beer, M.S., Hill, R.G., and Longmore, J. 
(1999). Vasoconstriction in human isolated middle meningeal arteries: determining the 
contribution of 5-HT1B- and 5-HT1F-receptor activation. British journal of clinical 
pharmacology 47, 75-82. 
Recober, A., Kuburas, A., Zhang, Z., Wemmie, J.A., Anderson, M.G., and Russo, A.F. (2009). 
Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 29, 8798-8804. 
Reeh, P.W. (1986). Sensory receptors in mammalian skin in an in vitro preparation. 
Neuroscience letters 66, 141-146. 
Reichling, D.B., and Levine, J.D. (1997). Heat transduction in rat sensory neurons by calcium-
dependent activation of a cation channel. Proceedings of the National Academy of Sciences of 
the United States of America 94, 7006-7011. 
Renganathan, M., Cummins, T.R., and Waxman, S.G. (2001). Contribution of Na(v)1.8 sodium 
channels to action potential electrogenesis in DRG neurons. Journal of neurophysiology 86, 629-
640. 
Richardson, J.D., and Vasko, M.R. (2002). Cellular mechanisms of neurogenic inflammation. 
The Journal of pharmacology and experimental therapeutics 302, 839-845. 
	   148	  
Rochlitzer, S., Veres, T.Z., Kuhne, K., Prenzler, F., Pilzner, C., Knothe, S., Winkler, C., 
Lauenstein, H.D., Willart, M., Hammad, H., et al. (2011). The neuropeptide calcitonin gene-
related peptide affects allergic airway inflammation by modulating dendritic cell function. 
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical 
Immunology 41, 1609-1621. 
Rowe, A.H., Xiao, Y., Rowe, M.P., Cummins, T.R., and Zakon, H.H. (2013). Voltage-gated 
sodium channel in grasshopper mice defends against bark scorpion toxin. Science 342, 441-446. 
Sah, P. (1996). Ca(2+)-activated K+ currents in neurones: types, physiological roles and 
modulation. Trends in neurosciences 19, 150-154. 
Sarchielli, P., Alberti, A., Codini, M., Floridi, A., and Gallai, V. (2000). Nitric oxide metabolites, 
prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during 
spontaneous migraine attacks. Cephalalgia : an international journal of headache 20, 907-918. 
Sarchielli, P., Pini, L.A., Zanchin, G., Alberti, A., Maggioni, F., Rossi, C., Floridi, A., and 
Calabresi, P. (2006). Clinical-biochemical correlates of migraine attacks in rizatriptan responders 
and non-responders. Cephalalgia : an international journal of headache 26, 257-265. 
Saria, A. (1984). Substance P in sensory nerve fibres contributes to the development of oedema 
in the rat hind paw after thermal injury. British journal of pharmacology 82, 217-222. 
Schaible, H.G. (2007). Peripheral and central mechanisms of pain generation. Handbook of 
experimental pharmacology, 3-28. 
Schneggenburger, R., and Neher, E. (2005). Presynaptic calcium and control of vesicle fusion. 
Current opinion in neurobiology 15, 266-274. 
Scott, A., Khan, K.M., Cook, J.L., and Duronio, V. (2004). What is "inflammation"? Are we 
ready to move beyond Celsus? British journal of sports medicine 38, 248-249. 
Sehgal, N., Smith, H.S., and Manchikanti, L. (2011). Peripherally acting opioids and clinical 
implications for pain control. Pain physician 14, 249-258. 
Seybold, V.S. (2009). The role of peptides in central sensitization. Handbook of experimental 
pharmacology, 451-491. 
Sidach, S.S., and Mintz, I.M. (2000). Low-affinity blockade of neuronal N-type Ca channels by 
the spider toxin omega-agatoxin-IVA. J Neurosci 20, 7174-7182. 
Sleight, A.J., Cervenka, A., and Peroutka, S.J. (1990). In vivo effects of sumatriptan (GR 43175) 
on extracellular levels of 5-HT in the guinea pig. Neuropharmacology 29, 511-513. 
Snider, W.D., and McMahon, S.B. (1998). Tackling Pain at the Source- New Ideas about 
Nociceptors. Neuron 20, 629-632. 
	   149	  
Snutch, T.P. (2005). Targeting chronic and neuropathic pain: the N-type calcium channel comes 
of age. NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics 2, 
662-670. 
Soyguder, Z. (1999). Lectin and neuropeptide labeling in whole-mount preparation of meninges 
in the rat. Turk J Vet Anim Sci 23, 495-498. 
Spetea, M., Friedmann, T., Riba, P., Schutz, J., Wunder, G., Langer, T., Schmidhammer, H., and 
Furst, S. (2004). In vitro opioid activity profiles of 6-amino acid substituted derivatives of 14-O-
methyloxymorphone. European journal of pharmacology 483, 301-308. 
Sprenger, T., and Goadsby, P.J. (2009). Migraine pathogenesis and state of pharmacological 
treatment options. BMC Med 7, 71. 
Sridharan, G., and Shankar, A.A. (2012). Toluidine blue: A review of its chemistry and clinical 
utility. Journal of oral and maxillofacial pathology : JOMFP 16, 251-255. 
Stein, C. (1993). Peripheral mechanisms of opioid analgesia. Anesthesia and analgesia 76, 182-
191. 
Stein, C. (1995). The control of pain in peripheral tissue by opioids. The New England journal of 
medicine 332, 1685-1690. 
Stein, C. (2013). Targeting pain and inflammation by peripherally acting opioids. Frontiers in 
pharmacology 4, 123. 
Stein, C., Hassan, A.H., Przewlocki, R., Gramsch, C., Peter, K., and Herz, A. (1990). Opioids 
from immunocytes interact with receptors on sensory nerves to inhibit nociception in 
inflammation. Proceedings of the National Academy of Sciences of the United States of America 
87, 5935-5939. 
Stein, C., and Kuchler, S. (2012). Non-Analgesic Effects of Opioids: Peripheral Opioid Effects 
on Inflammation and Wound Healing. Curr Pharm Design 18, 6053-6069. 
Stein, C., and Machelska, H. (2011). Modulation of peripheral sensory neurons by the immune 
system: implications for pain therapy. Pharmacological reviews 63, 860-881. 
Stein, C., Pfluger, M., Yassouridis, A., Hoelzl, J., Lehrberger, K., Welte, C., and Hassan, A.H.S. 
(1996). No tolerance to peripheral morphine analgesia in presence of opioid expression in 
inflamed synovia. Journal of Clinical Investigation 98, 793-799. 
Stein, C., Schafer, M., and Machelska, H. (2003). Attacking pain at its source: new perspectives 
on opioids. Nature medicine 9, 1003-1008. 
Stein, C., and Zollner, C. (2009). Opioids and sensory nerves. Handbook of experimental 
pharmacology, 495-518. 
	   150	  
Stepien, A., Jagustyn, P., Trafny, E.A., and Widerkiewicz, K. (2003). Suppressing effect of the 
serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) 
concentration in migraine attacks. Neurologia i neurochirurgia polska 37, 1013-1023. 
Strassman, A.M., and Levy, D. (2006). Response properties of dural nociceptors in relation to 
headache. Journal of neurophysiology 95, 1298-1306. 
Strassman, A.M., Weissner, W., Williams, M., Ali, S., and Levy, D. (2004). Axon diameters and 
intradural trajectories of the dural innervation in the rat. The Journal of comparative neurology 
473, 364-376. 
Sun, R.Q., Tu, Y.J., Lawand, N.B., Yan, J.Y., Lin, Q., and Willis, W.D. (2004). Calcitonin gene-
related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia 
and central sensitization. Journal of neurophysiology 92, 2859-2866. 
Szallasi, A., Cortright, D.N., Blum, C.A., and Eid, S.R. (2007). The vanilloid receptor TRPV1: 
10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6, 357-372. 
Takayama, Y., Uta, D., Furue, H., and Tominaga, M. (2015). Pain-enhancing mechanism 
through interaction between TRPV1 and anoctamin 1 in sensory neurons. Proceedings of the 
National Academy of Sciences of the United States of America. 
Takazawa, T., and MacDermott, A.B. (2010). Synaptic pathways and inhibitory gates in the 
spinal cord dorsal horn. Annals of the New York Academy of Sciences 1198, 153-158. 
Tfelt-Hansen, P., De Vries, P., and Saxena, P.R. (2000). Triptans in migraine: a comparative 
review of pharmacology, pharmacokinetics and efficacy. Drugs 60, 1259-1287. 
Tfelt-Hansen, P.C. (2010). Does sumatriptan cross the blood-brain barrier in animals and man? J 
Headache Pain 11, 5-12. 
Tfelt-Hansen, P.C., and Koehler, P.J. (2011). One hundred years of migraine research: major 
clinical and scientific observations from 1910 to 2010. Headache 51, 752-778. 
Todorovic, S.M., and Jevtovic-Todorovic, V. (2006). The role of T-type calcium channels in 
peripheral and central pain processing. CNS & neurological disorders drug targets 5, 639-653. 
Todorovic, S.M., and Jevtovic-Todorovic, V. (2007). Regulation of T-type calcium channels in 
the peripheral pain pathway. Channels (Austin) 1, 238-245. 
Todorovic, S.M., and Jevtovic-Todorovic, V. (2011). T-type voltage-gated calcium channels as 
targets for the development of novel pain therapies. British journal of pharmacology 163, 484-
495. 
Tsantoulas, C., and McMahon, S.B. (2014). Opening paths to novel analgesics: the role of 
potassium channels in chronic pain. Trends in neurosciences 37, 146-158. 
	   151	  
Tvedskov, J.F., Lipka, K., Ashina, M., Iversen, H.K., Schifter, S., and Olesen, J. (2005). No 
increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58, 
561-568. 
Uddman, R., Edvinsson, L., Ekblad, E., Hakanson, R., and Sundler, F. (1986). Calcitonin gene-
related peptide (CGRP): perivascular distribution and vasodilatory effects. Regulatory peptides 
15, 1-23. 
Venkatachalam, K., and Montell, C. (2007). TRP channels. Annual review of biochemistry 76, 
387-417. 
Villalon, C.M., and Olesen, J. (2009). The role of CGRP in the pathophysiology of migraine and 
efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacology & 
therapeutics 124, 309-323. 
Wainger, B.J., Buttermore, E.D., Oliveira, J.T., Mellin, C., Lee, S., Saber, W.A., Wang, A.J., 
Ichida, J.K., Chiu, I.M., Barrett, L., et al. (2015). Modeling pain in vitro using nociceptor 
neurons reprogrammed from fibroblasts. Nature neuroscience 18, 17-+. 
Wang, H., and Woolf, C.J. (2005). Pain TRPs. Neuron 46, 9-12. 
Waxman, S.G., and Zamponi, G.W. (2014). Regulating excitability of peripheral afferents: 
emerging ion channel targets. Nature neuroscience 17, 153-163. 
Weiss, N. (2009). Regulation of N-type calcium channels by G-proteins: multiple pathways to 
control calcium entry into neurons. Channels (Austin) 3, 219-220. 
Woolf, C.J., and Ma, Q. (2007). Nociceptors--noxious stimulus detectors. Neuron 55, 353-364. 
Woolfe, G., and Macdonald, A.D. (1944). The evaluation of the analgesic action of Pethidine 
hydrochloride (Demerol). Journal of Pharmacology and Experimental Therapeutics 80, 300-307. 
Xiao, Y., Richter, J.A., and Hurley, J.H. (2008). Release of glutamate and CGRP from trigeminal 
ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Molecular pain 4, 12. 
Xie, W.R. (2011). Assessment of Pain in Animals. Neuromethods 49, 1-+. 
Xu, S., Ono, K., and Inenaga, K. (2010). Electrophysiological and chemical properties in 
subclassified acutely dissociated cells of rat trigeminal ganglion by current signatures. Journal of 
neurophysiology 104, 3451-3461. 
Yang, S., Xiao, Y., Kang, D., Liu, J., Li, Y., Undheim, E.A., Klint, J.K., Rong, M., Lai, R., and 
King, G.F. (2013). Discovery of a selective NaV1.7 inhibitor from centipede venom with 
analgesic efficacy exceeding morphine in rodent pain models. Proceedings of the National 
Academy of Sciences of the United States of America 110, 17534-17539. 
Young, W.S., Wamsley, J.K., Zarbin, M.A., and Kuhar, M.J. (1980). Opioid Receptors Undergo 
Axonal Flow. Science 210, 76-78. 
	   152	  
Yusaf, S.P., Goodman, J., Pinnock, R.D., Dixon, A.K., and Lee, K. (2001). Expression of 
voltage-gated calcium channel subunits in rat dorsal root ganglion neurons. Neuroscience letters 
311, 137-141. 
Zamponi, G.W., Lewis, R.J., Todorovic, S.M., Arneric, S.P., and Snutch, T.P. (2009). Role of 
voltage-gated calcium channels in ascending pain pathways. Brain research reviews 60, 84-89. 
Zhang, X., Bean, A.J., Wiesenfeld-Hallin, Z., Xu, X.J., and Hokfelt, T. (1995). Ultrastructural 
studies on peptides in the dorsal horn of the rat spinal cord--III. Effects of peripheral axotomy 
with special reference to galanin. Neuroscience 64, 893-915. 
Zhang, X.F., Gopalakrishnan, M., and Shieh, C.C. (2003). Modulation of action potential firing 
by iberiotoxin and NS1619 in rat dorsal root ganglion neurons. Neuroscience 122, 1003-1011. 
Zimmermann, K., Hein, A., Hager, U., Kaczmarek, J.S., Turnquist, B.P., Clapham, D.E., and 
Reeh, P.W. (2009). Phenotyping sensory nerve endings in vitro in the mouse. Nature protocols 4, 
174-196. 
Zucker, R.S. (1993). Calcium and transmitter release. Journal of physiology, Paris 87, 25-36. 
 
